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Cervical cancer is the third most common female malignancy in the world with 
about 529,000 new cases occurring annually. More than 80% of these cases occur in 
developing countries where cervical cancer often ranks first place.1 It is the second 
largest cause of female cancer mortality worldwide with 274,000 deaths each 
year. The highest incidence rates are found in South America and Africa with 37.7 
per 100,000 in Brazil, 43.9 per 100,000 in Peru and 47.3 per 100,000 per year in 
Zimbabwe.2
In the Netherlands, mortality trends of cervical cancer have declined. In 2007 the 
incidence rate was 6.3 per 100,000 women years and mortality rate 1.4 per 100,000 
women years (age adjusted).3 In 2010, 718 new cases of cervical cancer were 
reported.4
1.1 etiology and carcinogenesis
Epidemiologic and clinical data show that the development of cervical cancer is a 
multifactorial process in which infection with HPV takes a central place.5 There are 
more than 150 types of HPV identified of which the mucosal types are associated 
predominantly with anogenital lesions. These can vary from benign warts (related to 
infection with HPV 6 and 11)6 to a persistent infection with one of the high-risk HPV 
leading to invasive cancer. There are about 15 types of HPV classified as high-risk 
types. Examples of high-risk HPV types are HPV 16 and HPV 18, together responsible 
for 70-75% of cervical cancer.7 Other high-risk types are types 31, 33, 35, 45, 52, 
56, 58, 59, 68, 73, and 82 with different type-specific prevalence in high-grade 
squamous epithelial lesions (HSIL, see further this chapter) and invasive cervical 
cancer worldwide.8 In 1999, Walboomers et al detected HPV in almost all cervical 
cancer biopsies, giving a prevalence of 99.7%.9 HPV is very common and estimated is 
that 75% – 80% of all sexually active people will be infected with HPV at some point. 
90% of these infections will be eliminated in two years.10
HPV is found in virtually all cervical cancers and is thought to be the causative factor 
in cervical cancer. Additional factors such as smoking, an early sexarche, lifetime 





HPV is a causative agent in (probably) all cases of dysplasia.12 The HPV genome 
consists of a double-stranded circular DNA molecule of approximately 8000 base pairs 
wrapped in a protein shell, called capsid. The DNA contains seven early (E) genes (E1, 
E2, E3, E4, E5, E6 and E7) and two late (L) genes (L1 and L2). After HPV-infection of 
the (basal layer of) epithelial cells of the cervix, the HPV genome is able to replicate 
episomally and this seems to be the situation in benign and preneoplastic lesions. 
In malignant lesions however, HPV DNA is frequently integrated into host DNA. This 
integration corresponds with the development of cervical intraepithelial neoplasia 
(CIN) lesions and coinciding expression level of early HPV oncogenes E5, E6, and 
E7.13 These genes are responsible for initiation and progression of cervical cancer 
as both E6 and E7 are known for inactivation of the major tumor suppressor genes 
p53 and retinoblastoma protein (pRb), respectively. The role of p53 is to control 
the integrity of the genome by inducing cell cycle arrest or apoptosis. pRb plays an 
important role in controlling the correct G1/S transition of the cell cycle, a transition 
after cell growth (G1-phase) and before DNA synthesis and replication (S-phase). 
E6, in combination with host E6 associated protein (E6AP), binds and marks p53 
tumor suppressor protein leading to degradation of p53 by proteasomes, genetic 
instability and progression to malignancy.14 E7 competes with pRb, binding and 
inactivating the retinoblastoma protein by proteasomal degradation. Consequently, 
the transcription factor E2F (retained by pRb) is freed, stimulating the expression 
of genes involved in the progression of cell cycle and DNA synthesis and pushing 
the cell cycle forwards. Under physiological conditions free E2F leads to induction 
of p16INK4, a tumor suppressor protein inhibiting cyclin-dependent kinase binding 
to cyclin D which regulates the G1 cycle checkpoints and causes cell cycle arrest in 
the G1 phase.15 In cells infected with HPV, however, E6 blocks the inhibitory effect 
of p16INK4, showing a synergistically interaction with E7 and resulting in altering cell 
differentiation by keeping the keratinocyte in a favorable state for viral genome 
replication, reactivation of DNA synthesis, stimulation of progression of the cell cycle 




1.3 Precursor lesions of cervical cancer
The cervix consists of an ectocervix covered with stratified squamous epithelium 
and an endocervix, covered with simple columnar epithelium. The border between 
ectocervix and endocervix is the part where columnar epithelium is replaced 
by squamous epithelium and is known as the transformation zone. Replacing 
of columnar epithelium by squamous epithelium is a continuous physiological 
process called metaplasia. Metaplasia can occur in response to chronic physical or 
chemical irritation. An abnormal development of the transformation zone is called 
dysplasia and is characterized by an expansion of immature cells. It is considered a 
precancerous condition.17 
Dysplasia, as well as cervical carcinoma, can be detected by using the Papanicolaou 
(Pap) test, taking a swab of the cervix (Pap smear) in a screening program or in 
case of complaints like irregular vaginal blood loss, discharge or vaginal bleeding 
after sexual intercourse. This test examines the presence of abnormal cervical cells 
resulting in a Pap smear classification. In 1988 an alternative reporting system has 
been developed for cervical cytology, called The Bethesda System, last revised in 
2001. Main differences with the originally Pap classification is combining Pap results 
into low-grade squamous intraepithelial lesion (LSIL) and HSIL and the inclusion of 
specimen adequacy in order to establish uniform terminology and adequacy for 
evaluation.18 
If the abnormal cells have a high chance of (becoming) cervical cancer, further 
investigation will be advised, leading to follow-up Pap smears after 6 months or a 
colposcopy with taking biopsies of abnormal areas. Biopsies can provide evidence 
for (pre)cancerous changes. Precancerous stages are called CIN. CIN lesions are 
categorized in CIN 1 (mild dysplasia), CIN 2 (moderate dysplasia), and CIN 3 (severe 
dysplasia and carcinoma in	situ), depending on the height of abnormal cells in the 
squamous epithelium.19 Most CIN-lesions are stable and do not develop into cervical 
cancer. CIN 1 is usually treated conservative with follow-up Pap smears. The risk of 
progression of untreated CIN 1 to CIN 3 or (micro invasive) cervical cancer is estimated 
at 2.1% in 2 years time whereas about 70% of CIN 1 lesions will regress within 2 years. 
CIN 2 and 3 are usually treated with a large loop excision of the transformation zone 
(LLETZ), since progression of untreated CIN 2 to CIN 3 or (micro) invasive cervical 
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cancer is much higher, namely 16% in 2 years time.20 Progression of untreated CIN 
3 to cervical cancer is estimated at 31% in 10 years.21 The transition from CIN 3 to 
(invasive) cervical cancer depends on whether or not the basement membrane of 
the epithelium is crossed and malignant cells invade the underlying stroma of the 
cervix.
1.4 cervical cancer, staging and therapy
Cervical cancer is staged according to the Fédération Internationale de Gynécologie 
et d’Obstétrique (FIGO) staging system (specific for gynecological malignancies). 
Besides the FIGO staging system there is also the tumor, node, metastases (TNM) 
staging system which is a surgical staging and can be used for all tumors. These two 
systems are not always comparable and can cause confusion since both systems are 
used, especially when recording lymph node involvement. Cervical cancer is the 
only gynecological malignancy that is staged clinically according to the FIGO staging 
system. In the United Kingdom a survey was carried out to determine which staging 
system is preferred and FIGO staging was recommended. TNM style recording of 
lymph node status was also recommended since lymph node status is not included 
in FIGO staging.22 Recently, both staging systems were revised, based on clinical and 
histomorphological studies.23 Cervical cancer spreads predominantly by local invasion 
to the vagina and parametrium and by lymphatic metastasis to pelvic lymph nodes. 
Pelvic lymph node metastases are found in 0% - 88% of the patients depending on 
FIGO stage.24 Para-aortic lymph nodes containing metastases are secondary stations 
and are detected in 15-30% of the patients with locally advanced cervical cancer.25 
Hematogenous spread is detected in combination with bulky disease, endometrial 
extension and lymph node metastasis. The most common sites are lungs (present in 
3% - 57% depending on FIGO stage)26 and bone (1.9% - 16%).27
Surgical treatment relies on FIGO stage and can vary from conization to a radical 
hysterectomy with removal of the tissue on both sides of the uterus (parametrium), 
the upper part of the vagina and pelvic lymph nodes (external iliac, common iliac 
and obturator fossa). In case of larger early tumors (stage IB2 and IIA2) radiotherapy 
(with or without chemotherapy) or an extended surgical procedure can be chosen 
(Wertheim Okabayashi). In case of advanced stage tumors (stage IIB to IVA) 




2 interAction between tHe iMMune systeM And cervicAl 
cAncer
2.1 inflammatory response
Most neoplastic tissues have an inflammatory component consisting of a diversity 
of inflammatory cells. This inflammatory component of the tumor can be initiated 
by predisposing conditions to cancer, but also by genetic events causing neoplastic 
transformation.28 Cells forming the cancer-related inflammation (CRI) are for 
instance leukocytes, dendritic cells (DC) and tumor associated macrophages (TAM), 
but also myofibroblasts, mast cells and to a lesser extend natural killer (NK) cells.29 
In this process, the tumor microenvironment (including fibroblasts and vessels) is 
the result of the interaction between tumor cells, stromal cells and inflammatory 
cells influencing tumor growth, tumor differentiation and tumor progression. Both 
tumor cells as well as cells of the tumor environment are capable of producing 
soluble mediators like cytokines, of which the balance can lead to antitumor activity 
or tumor progression.30 
Antitumor activity is mainly mediated by circulating effector cells, in particular cytotoxic 
T cells, NK cells and neutrophils.31 Also adaptive immunity (B- and T-lymphocytes) 
can be efficient as an antitumor response, generating memory cells and being more 
specific.32 Several studies show a positive correlation between poor outcome and 
composition of the tumor environment with a special role for angiogenesis and TAM 
with tumor hypoxia and secondary necrosis due to rapid tumor cell proliferation as 
a possible driving force for the production of growth factors and chemoattractive 
cytokines like chemokine C-C motif ligand (CCL)2.33 TAM are frequently present in 
the tumor environment and are thought to be important in cross-talk with other 
inflammatory cells and cancer cells. They are derived from monocytes circulating in 
the blood and attracted to the tumor by specific produced chemotactic factors like 
CCL2.34 Once in the tumor stroma, monocytes can differentiate into a M1 macrophage 
(an effector cell known for killing microorganisms and tumor cells and supplier of 
proinflammatory cytokines) or into a M2 macrophage (cells capable of tuning the 
inflammatory responses, scavenging debris, promoting wound healing, angiogenesis 
and tissue remodeling) (Figure 1).35 TAM are known for their diversity of released 




CSF-1, IL-10, IL-4 & IL-13
IFN-γ & LPS, TNF-α Immune complexes + IL-1/LPS
M1 
IL-6, IL-12 IL-1Ra, IL-10, TGF-β
IL-23, TNF-α fibronectin 1, CCL2
matrix remodelling
TH1 response Tumor resistance TH2 responseTumor promotion
figure 1. Selected functions of M1 and M2 macrophages. Monocytes are attracted to the tumor stroma 
by tumor derived signals. Once in the tumor stroma, monocytes are able to differentiate into M1 or 
M2 macrophages, depending on different microenvironmental signals. Abbreviations: CSF-1, colony 
stimulating factor-1; IFN-γ, interferon-γ; IL, interleukin; IL-1Ra, interleukin-1 receptor antagonist; LPS, 
lipopolysaccharide; TH, T helper; TGF-β1, transforming growth factor-β1; TNF, tumor necrosis factor.
They play a major role in this process by providing pro-angiogenic cytokines, tumor 
stroma remodeling factors (for instance matrix metalloproteinases (MMP)38 and 
growth factors thus providing an ideal basis for angiogenesis (Figure 2). Monocytes 
are also capable of differentiating into (inflammatory) DC.39 DC are one of the most 
potent antigen-presenting cells of the immune system and form a heterogeneous 
group of cells originating from different backgrounds. They can be classified into 
two major subsets: (1) the myeloid DC (mDC), containing three types of DC: the 
epithelial DC (Langerhans’ cells (LHC), almost exclusively found in epithelia), the 
interstitial DC (found in the interstitium and extravascular areas of most tissues) 
and the monocyte-derived DC (blood myeloid DC), and (2) the lymphoid DC (lDC) 
subset, cluster of differentiation (CD)11c- plasmacytoid DC precursors, present in 
blood, tonsils and thymus). Interstitial and monocyte-derived DC display phenotypic 
and functional similarities.40, 41 DC display different molecules and receptors on 




figure 2. Role of tumor associated macrophages in tumor progression. Abbreviations: CCL, chemokine 
(C-C motif) ligand; CSF-1, colony stimulating factor-1; EGF, epidermal growth factor; FGF, fibroblast 
growth factor; IL, interleukin; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; PGE-
2, prostaglandin E2; TGF-β1, transforming growth factor-β1; TNF, tumor necrosis factor; VEGF, vascular 
endothelial growth factor.
Adapted	from	Rogers	et	al.95
After maturation of the mDC, in response to stimuli like tumor necrosis factor (TNF)-α, 
these cells migrate from peripheral tissues via the lymph vessels to T and B cell areas 
of secondary lymphoid organs. Here, processed antigens, in major histocompatibility 
complex molecules (MHC) class I or II and co-stimulatory molecules like CD80 
and CD86, are presented to naive CD8+ and CD4+ T cells, subsequently triggering 
an adaptive immune response.42, 43 Within the lymph nodes, DC and LHC seem to 
migrate to distinctive locations: DC cluster nearer to the B cell follicles, probably 
more involved in regulation of the humoral responses, while the LHC move to the 
deep paracortex of the T cell zone, suggesting that LHC are more involved in a T-cell 
immune response.44 Previously it was assumed that the immune response depends 
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on the type of subset of DC in which the mDC induce a T helper lymphocyte 1 (TH1) 
and the lDC a T helper lymphocyte 2 (TH2) response. In general this still seems to 
be true, but some refinement has been made. Especially the mDC are capable of 
activating both a TH1 and/or a TH2 response dependent on the presence of various 
maturation stimuli.45 Normal DC are capable in inducing a TH2 response after contact 
with an allergen. In case of an infection, the combination of pathogen and allergen 
can differentiate DC either into a DC1 subtype, activating the TH1 system or into a 
regulatory DC (DCreg) subtype, inducing a regulatory T cell (Treg) response.46 TH1, 
TH2 and also T helper 17 (TH17) are all effector T-cell subsets with different functions 
and with a different profile of produced cytokines (Figure 3). In general TH1 cells are 
important for host defense against intracellular pathogens and involved in induction 
of delayed-type hypersensitivity responses. TH1 response is considered to be pro-
inflammatory. TH2 cells play an important role in eosinophilic inflammation, allergic 
reactions and clearing extracellular organisms and is linked to immunoregulatory 
or anti-inflammatory and promotes antibody-mediated immunity.47 TH17 cells 
are mainly involved in organ-specific autoimmunity, mediating host defenses and 
promoting tissue inflammation and recruitment of neutrophils. At present, their role 
in cancer is still unclear. Regulatory T cells (Treg) play an important role in controlling 
autoimmune pathogenesis.48 Furthermore, FoxP3 positive Treg seem to regulate the 




figure 3. Example of differentiation of T helper lymphocyte subsets by cytokines. Abbreviations: IFN, 
interferon; IL, interleukin; TGF-β1, transforming growth factor-β1; TH, T helper cell; TNF-α, tumor necrosis 
factor-α; Treg, regulatory T cell.
2.2 cytokines and chemokines
Cytokines are small proteins and peptides, secreted by different cell types in nano- 
to picomolar concentrations. Cytokines transmit signals between cells locally and at 
a distance in different ways: autocrine (produced cytokines acts on the cytokine-
producing cells), paracrine (produced cytokines acts on near-by cells), intracrine 
(after internalization of extracellular signaling proteins and peptides, these proteins 
and peptides interact with intracellular targets),50 juxtacrine (membrane-bound 
cytokines produced by an effector cell acts via a membrane-bound cytokine receptor 
on a adjacent target cell) or retrocrine (soluble forms of normally membrane-bound 
receptors are produced and reacts with distant target cells) (Figure 4). Recently, 
also the term necrocrine was introduced, aiming at the effect of cytokines released 
by necrotic cells.51 Cytokines are active in virtually every aspect of immunity and 
inflammation and determine whether an immune response will develop and how 






figure 4. Possible ways of transmitting signals between cells by cytokines: intracrine (produced cytokine 
acts inside the producing cell), autocrine (secreted cytokine binds to receptors on the same cell), paracrine 
(secreted cytokine binds to receptors on a cell nearby), endocrine (cytokine is secreted directly into the 
bloodstream), juxtacrine (intercellular communication between adjacent cells by both binding secreted 
cytokine) and suggested retrocrine factors (soluble parts of receptors interact with target cells by binding 
to cytokines which are membrane-bound on this target cell).
Adapted	from	Simpson	et	al.96
Cytokines can be divided into subcategories, depending on type or function, for 
example pro-inflammatory cytokines [TNF-α, Interleukin (IL)-12, IL-6], growth factors 
[granulocyte colony-stimulating factor (G-CSF), IL-2] or inhibitory cytokines [IL-10 
or transforming growth factor (TGF)-β1] (Table 1). Chemokines are a group of small 
molecules, structurally related to cytokines with chemotaxis (cellular directional 
movement on the basis of a concentration gradient of chemotactic factors) as most 
important effect. They regulate the activity by interacting with guanine nucleotide 
binding (G-) protein-coupled 7-transmembrane receptors. In humans they can be 
divided in α-chemokines, genes of this family map to human chromosome 4q12-
21 and share a separation of the first two cysteine residues by a single amino acid 
[CXC (motif) –chemokines]; β-chemokines, genes map to chromosome 17q11-




chemokines); γ-chemokines or XC (motif) -chemokines which lack a cysteine residue 
and δ-chemokine (CX3C-chemokine) which is a type 1 transmembrane glycoprotein 
(Table 2).53 
Cytokines act as part of a complex network in which redundancy (several produced 
cytokines display similar properties leading to additive effects, for example IL-2, IL-
4, IL-7, IL-9 and IL-15 which all can act as T-cell growth factors) and pleiotropism 
(many cytokines are able to have an effect on different cell types leading to different 
consequences). An example of pleiotropism is IL-2 which is able to induce proliferation 
of T cells, but also cytolytic activity of NK cells and immunoglobulin biosynthesis 
by B-cells.54 Cytokines can have dual roles depending on the cell type, for example 
interferon (IFN)-γ which promotes TH1 responses, also inhibits development of a TH2 
response. Cytokines act by binding to a receptor on the surface of an effector cell after 
which signal transduction molecules carry the signal from the receptor to the inside of 
the cell or nucleus leading to transcription of specific genes. Examples are IL-6 and IL-
12. Both are bound by specific receptors on the surface of the effector cell, activating 
Janus kinases (JAK) in the cytoplasm. Subsequently, signal transducer and activator 
of transcription (STAT) molecules are phosphorylated and migrate to the nucleus.55 
Chemokines are bound by a specific transmembrane G-protein-coupled receptor 
and after activation, an intracellular signaling cascade is started, causing migration 
of the target cell towards a high concentration of the chemokine. A good example 
of this process is reflected by the immunosurveillance of leukocytes. Normally these 
cells circulate in the blood vessels but under the influence of, for example, CCL2 they 
move to the interstitial compartment: first by tethering and rolling on the surface of 
the endothelial cells (a process mediated by selectins) followed by activation, arrest 
and transmigration to the interstitial compartment where the highest concentration 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































table 2. Characteristics of the different chemokine-families.
Chemokine
family
Characteristic Chromosome Example Function
α -CXC- 4q12-21 CXCL8 (IL-8) Primarily acting on 
neutrophils
β -CC- 17q11-32 CCL2 (MCP-1) Chemotactic for monocytes, 
role in antiviral host defense
γ -XC- 1q23-25 XCL1 (Lymphotactin) Chemotactic for lymphocytes 
and NK cells, active against 
bacteria
δ -CX3C- 16q13 CX3CL1 (Fractalkine) Chemotactic for neutrophils
2.3 cytokines, chemokines, inflammatory cells, and cervical cancer
Cytokines are known to be produced by a wide variety of cells, including epithelial 
cells, stromal cells as well as cells of the immune system.57-59 Also cancer cells and cells 
of the tumor environment are capable of producing cytokines with a wide variety 
of effects.53, 60 Several types of cancers develop after years of chronic inflammation. 
Examples are lung cancer (cigarette smoking), cancer of the esophagus (gastro 
esophageal reflux) and cervical cancer (HPV infection). A chronic inflammatory state, 
together with the permanent presence of HPV could increase epithelial cell turnover 
resulting in DNA changes and, finally, in malignant transformation.47 Persistent HPV 
infection also has its effect on the composition of cytokines.61 Cytokine levels can be 
affected by malignant transformation of the cervix, as in early stage cervical cancer 
LHC as well as mDC numbers are found in reduced numbers61, 62 Due to the inhibitory 
effect of E6 and E7 proteins, cytokines like granulocyte-monocyte colony-stimulating 
factor (GM-CSF), TNF-α,63 IL-8 (in vitro),64 and CCL265 are suppressed. In HPV-related 
VIN several cytokines and chemokines showed a different expression pattern when 
compared to control samples [e.g. up-regulation of CXCL8 (IL-8)] in combination with 
an increased number of mature dendritic cells in the dermis, suggesting most mature 
dendritic cells do not receive the appropriate (chemokine) signal to migrate.66 Since 
DC are one of the most potent antigen-presenting cells in draining lymph nodes, this 
process may be hampered by the low number of DC.67 The normal uterine cervix 
contains a limited number of different leukocytes (T lymphocytes, DC, macrophages). 




well as Treg cells, although the latter ones are more observed in early phase of tumor 
progression.68 Tumor-infiltrating immune cells are linked to prognosis and response 
to (conventional) therapy. High numbers of CD8+ T cells are frequently correlated with 
a better prognosis in solid tumors.69-71 Also a high CD4+/CD8+ T cells is of importance 
for a better outcome of patients suffering from cervical carcinoma.72 A known T-cell 
chemoattractant is the chemokine CXCL12 which binds selectively the receptor 
CXCR4. In a study of Jaafar et al it was shown that CXCL12 could attract T cells at low 
concentrations and shows the opposite effect at high concentration.73 Furthermore, 
balance of T cells seems to reflect tumor stage as found in both breast cancer as 
gastric cancer.74, 75 In an early stage both tumors show an increased ratio of TH17/
Treg cells whereas in advanced stage the number of TH17 cells gradually decreased 
while the number of Treg cells increased. In cervical carcinoma numbers of both 
TH17 cells and Treg cells increase gradually with disease progression, resulting in an 
increased TH17/Treg ratio.
76 The role of TH17 is still controversial with properties either 
inhibiting or stimulating tumor growth and progression.77, 78 At present, the role of 
TH17 in cancer is still not clear. Treg play an important role in controlling autoimmune 
pathogenesis48 and in inhibiting antitumor responses (Figure 3).79 Furthermore, a low 




Tumor cells are dependent for their function on the extracellular matrix (ECM), 
a component of the tumor stroma. The ECM consists (among others) of fibers of 
collagen, fibronectin and elastin together with proteoglycans (glycosaminoglycans) 
and polysaccharides (hyaluronic acid).80 The ECM is produced by resident cells, 
already present in the ECM. When produced, the ECM displays several functions. From 
providing structural support to the cells, allowing trafficking of cells, homeostasis, 
to serving as a reservoir for cytokines and growth factors.81 The cells within the 
microenvironment have the ability to remodel the ECM through altering the 
production of ECM components or producing proteases, such as MMP, thus changing 
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interactions with other cells or the matrix.82 For cancer cells to survive, grow and 
metastasize, a unique microenvironment has to be established in which cancer cells, 
cancer associated stromal fibroblasts (CAF), endothelial cells, inflammatory cells 
and ECM are functionally organized.83 CAF are known to promote tumor growth and 
invasion, probably by secreting more growth promoting factors and up-regulation of 
genes responsible for extracellular matrix remodeling.83 Besides the CAF, more tissue 
elements may affect tumor formation and behavior. One of the components with 
the ability to alter cell function is versican, a member of the chondroitin sulphate 
proteoglycan (CSPG) family. Versican plays diverse roles in adhesion, proliferation and 
migration of cells, all important processes in invasion or metastasis of cancer cells. 
Indeed, in most malignancies elevated levels of versican have been found.84 Versican 
expression correlates with a poor prognosis in cervical cancer, ovarian cancer and 
gastric gastrointestinal stromal tumors.82, 85, 86 (Cervical) cancer is often infiltrated 
with a large amount of leukocytes which respond to tumor cells by secreting growth 
factors, cytokines and chemokines.33 
3.2 Angiogenesis
ECM also provides a basis for blood- and lymphatic vessels. Tumor growth beyond 
a few millimeters and metastasis formation are processes, highly dependent 
on induction of angiogenesis. The interaction between cancer cells and tumor 
fibroblasts triggers an angiogenic switch in fibroblasts in experimental tumors.87 New 
blood vessels are formed to ensure that tumor cells are provided with oxygen and 
nutrients.88 Inflammatory cells in the tumor stroma play a major role in angiogenesis, 
possibly acting as initiator of tumor neovascularization by production of angiogenic 
factors.89 One of the strongest angiogenic factors is vascular endothelial growth 
factor (VEGF), a potent mitogen, which stimulates endothelial cells to proliferate 
and migrate. This is achieved by binding VEGF to the VEGF receptor2 (VEGFR2) after 
which a strong tyrosine kinase activity is induced, leading to signals for stimulation 
of vascular endothelial cell survival and growth as well as promotion of angiogenesis 
via the mitogen-associated protein kinase (MAPK) pathway.90 New blood vessels are 
formed either by sprouting of local blood vessels (angiogenesis) or de novo by in 




both mechanisms are operative and take place concomitantly.91 Neovascularization 
is possible after degradation of the ECM by proteases. Matrix metalloproteinases 
represent a family of proteinases which is associated with proteolysis of a variety 
of substrates and play an important role in this process.92 Besides having a role in 
degradation of ECM macromolecules (proteoglycans and collagens), particular MMP 
are also capable of cleaving connective tissue growth factor (CTGF) such as VEGF, 
thereby releasing its angiogenic activity.93 New blood vessels are often leaky, dilated 
and tortuous due to lack of the pericyte cover. Lymphatic endothelial cells have even 
less developed junctions with frequently large interendothelial gaps and impaired 
basement membranes, leading to easier penetration by tumor cells and metastasis 
formation.94
4 outline of tHis tHesis
The aim of this thesis was to investigate the influence of (pro-inflammatory) 
cytokines, produced by cervical cancer cells, on the tumor microenvironment (e.g. 
composition of inflammatory cells, angiogenesis and extracellular matrix alterations) 
and its association with clinical parameters like lymph node metastases and survival 
in cervical carcinoma.
chapter 2 concentrates on the chemokine CCL2, the expression by cervical cancer 
cells and its association with TAM in the tumor. CCL2 is thought to be involved in 
the attraction of monocytes to the tumor site where these monocytes differentiate 
into TAM. TAM are able to produce various cytokines, possibly leading to tumor 
progression. CCL2 mRNA expression level was investigated by RNA-in	situ hybridization 
(RISH). The immunohistochemical scoring method for the ISH used in this chapter was 
validated by a real-time quantitative polymerase chain reaction (RT-PCR) technique. 
Expression level of CCL2 was divided in 3 categories: absent, low and high expression 
level. The samples showing a lack of expression of CCL2 were investigated for loss 
of heterozygosity in the region where the CCL2 gene is located on chromosome 
17. Besides TAM, several types of antigen presenting cells are present in the tumor 
microenvironment. The activation, differentiation and migration of these cells by 
GM-CSF, TNF-α and IL-12 was investigated in chapter 3. GM-CSF, TNF-α and IL-12 
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were also detected by RISH to determine the cellular location of these cytokines. 
GM-CSF as well as TNF-α, expressed by cervical carcinoma cells, were proposed to 
play a role in the attraction of inflammatory cells to the tumor site, the differentiation 
of inflammatory cells and (in the case of TNF-α) influencing the migration of LHC 
from the tumor site. The expression level of IL-12p40 was furthermore investigated 
in relation to clinicopathological parameters. The IL-12 family consists of several 
members of which IL-12 and IL-23 share the IL-12p40 subchain. In chapter 4 the 
role of IL-12p40 was further investigated by examining the expression level of IL-
12p40 as well as IL-23p19, the specific subchain for IL-23. IL-12 is thought to induce 
an antitumor immune response whereas endogenous IL-23 may promote tumor 
progression. Since IL-23 plays an important role in the IL-17/IL-23 pathway leading 
to expansion and maintenance of T
H17 cells, tissue sections were also investigated 
for the presence and location of IL-17 producing cells. The IL-17/IL-23 pathway is 
induced by IL-1 and IL-6 and both cytokines are thought to play an important role in 
the induction of TH17 cells in humans. Expression of both cytokines was investigated.
Tumor growth is dependent on the supply of oxygen and nutrition. Angiogenesis has 
a key role in this process and many factors contribute to the formation of new blood 
vessels. In chapter 5 different factors associated with angiogenesis were investigated 
of which VEGF-A seems to be the most important one. Newly formed blood vessels 
(CD105 positive cells) were stained to differentiate these vessels from vessels already 
present in the tumor stroma (CD31 positive cells) and the location of the vessels in the 
tumor was determined. Other factors important in angiogenesis are those capable 
of modulating the microenvironment, clearing the way for tumor expansion. One 
of these factors is Matrilysin (MMP-7) which was investigated in chapter 6. MMP-7 
can be up-regulated by different mechanisms, hypoxia in later tumor stages being 
one of them. MMP-7 is not only produced by epithelial cells but also by endothelial 
cells within the tumor stroma. Presence of MMP-7 was compared with the presence 
of CD34 (a pan-endothelial marker) in vivo and sprout formation in vitro. Besides 
having an effect on membrane-adhering properties, MMP-7 is also capable of 
releasing/cleaving bioactive molecules. chapter 7 focuses on other alterations 
in the extracellular matrix (e.g. versican). Versican is a member of chrondroitin 




in different biological processes. Versican expression is related to tumor growth by 
hampering cell adhesion and regulating angiogenesis. The expression of versican 
was investigated in relation to the number of inflammatory cells and relevant clinical 
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To determine whether CCL2 mRNA expression is beneficial or detrimental for 
cervical cancer patients, the association between the expression of this molecule 
by cervical tumor cells, the number of tumor-associated macrophages (TAM), and 
clinicopathological parameters such as recurrence, relapse-free survival, and overall 
patient survival was investigated. In cervical cancer samples from 93 untreated 
cervical cancer patients, the CCL2 mRNA expression level was quantified using RNA-
in	 situ hybridization and verified using real-time quantitative RT-PCR. The number 
of TAM was determined using immunohistochemistry. Furthermore, the study 
investigated whether lack of CCL2 expression was due to genetic alterations near the 
17q11.2 (CCL2 genomic) region. CCL2 mRNA expression by cervical tumor cells was 
associated with the number of TAM (P<0.001). Lack of CCL2 mRNA expression (15 
samples; 16%) was associated with increased cumulative relapse-free survival (log-
rank test, P=0.030), increased cumulative overall survival (log-rank test, P=0.024), 
reduced local and distant recurrence, reduced vascular invasion, and smaller tumor 
size (<40 mm). The absence of CCL2 mRNA expression corresponded with loss of 
heterozygosity (LOH) at 17q11.2 in five of six samples. The increased cumulative 
relapse-free survival and cumulative overall survival of cervical cancer patients lacking 
tumor cell-associated CCL2 mRNA suggest that the TAM support tumor progression, 
presumably by promoting angiogenesis and production of growth-factors. 





Cervical carcinoma is an important health problem, being the second most common 
cancer among women worldwide and ranking first in many developing countries.1 
Infection with human papillomavirus (HPV) is the key factor in the development of 
cervical intraepithelial neoplasia and invasive cervical carcinoma.1, 2 Four HPV types 
(16, 18, 31 and 45) account for almost 75 – 80% of the invasive cancers and HPV 
DNA is present in more than 90% of premalignant and malignant squamous lesions 
of the uterine cervix.1, 2 Cervical tumor cells are able to impede an effective immune 
response. Different immune escape mechanisms have been observed. Cervical 
cancer cells down-regulate human leukocyte antigen (HLA)3, 4, express FAS-ligand5, 
6 or protease inhibitor (PI)-97 and have been shown to produce immunoregulatory 
cytokines.8, 9
At present, the presence of an inflammatory infiltrate and the production 
of immunomodulatory cytokines by cancer cells is thought to contribute to 
carcinogenesis.10-12 Previously, we observed that IL-1α and IL-1β, IL-8, IL-12p35, IL-15, 
TGF-β1 and CCL2 mRNA was produced by at least nine of ten cervical cancer cell lines. 
In contrast to the other cytokines, CCL2 was produced in only 30% of normal primary 
cervical epithelial cell cultures,8 suggesting up-regulation of CCL2 in cervical cancer 
cell lines. CCL2 is a well-known chemo-attractant for human monocytes, memory T 
cells, and natural killer (NK) cells.13, 14 Furthermore, CCL2 was shown to be involved 
in the attraction of monocytes to the tumor site.15-19 The attracted monocytes 
differentiate into tumor-associated macrophages (TAM) at the tumor site13, 20, 21 and 
are thought to produce various cytokines that promote tumor progression.20-22 An 
association between TAM and microvascular density or angiogenesis was often 
observed.15, 23-25 Although the association between CCL2 expression by tumor cells 
and the recruitment of monocytes to the tumor site is becoming increasingly clear, 
the relationship between expression of CCL2 by tumor cells and clinical parameters 
such as positive lymph nodes, relapse or survival is unclear. Only a limited number 
of studies, including non-small cell lung cancer, breast cancer, esophageal squamous 
cell cancer, gastric cancer, and pancreatic cancer, have addressed the association 
between tumor-tissue derived CCL2 expression and clinical parameters.15, 17-19, 25, 26 
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The aim of the present study was to determine whether CCL2 mRNA expression 
by cervical tumor cells, resulting in the attraction of monocytes that subsequently 
differentiate into TAM, is beneficial or detrimental for cervical cancer patients. For this 
purpose, we have investigated the association between CCL2 expression by cervical 
tumor cells, the number of TAM and clinicopathological parameters such as relapse 
free-survival and overall survival of cervical carcinoma patients. Furthermore, we 
have investigated whether the lack of CCL2 expression was due to genetic alterations 
near the 17q11.2 (CCL2 genomic) region.
MAteriAl And MetHods
Patient material
Between 1985 and 1995, 254 untreated patients suffering from FIGO (Fédération 
Internationale des Gynécologie et d’Obstétrique) stage IB and IIA primary cervical 
carcinoma underwent a radical hysterectomy type III with lymphadenectomy. Of 
the tissue samples available, 93 were randomly chosen. Tissues were routinely 
embedded in paraffin wax after 10% formalin fixation. The tissue samples from each 
patient were examined by a pathologist for the presence of tumor. Of the 93 samples, 
80 were squamous cell carcinomas, seven adenocarcinomas and six adenosquamous 
carcinomas. Of the 93 samples, 70 (75%) were classified as FIGO stage IB and 23 
(25%) as FIGO stage IIA. Human tissue samples were used according to the guidelines 
of the Ethics Committee of the Leiden University Medical Center.
Preparation CCL2 rnA-probe
For the CCL2 RNA probe, E. coli HB101 containing a pGEM®-7Zf(+) vector (Promega, 
Madison, WI) inserted with CCL2 DNA (ATCC, Manassas, VA) was used.27 Plasmids 
were isolated using the QIAfilter Maxi KITS protocol (Qiagen, Hilden, Germany). The 
sequence of the PCR product was confirmed by DNA sequencing. The recombinant 
plasmids were linearized with either EcoR I or BamH I (both Boehringer, Mannheim, 
Germany). Both strands were translated in a digoxigenin (DIG)-labeled RNA probe 
according to the manufacturer’s instructions (Boehringer). The concentrations of the 
DIG-labeled sense and antisense RNA probes were determined on a 1% agarose gel 
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stained with ethidium bromide (Sigma, St. Louis, MO). Probes were stored at -20˚C 
until further use.
rnA-in situ hybridization
RNA-in	situ hybridization (RISH) was performed as previously described.27 In short, 
3 μm thick paraffin-embedded sections were pretreated and hybridized with 100 ng/
ml DIG-labeled RNA probe diluted in hybridization mixture containing 0.3 M NaCl, 
0.03 M saline-sodium citrate (2x SSC). Hybridization was allowed for 16 h at 50˚C 
in a humidified chamber. Slides were washed for 30 min in 50% formamide/2x SSC 
at 42˚C; for 45 min in 0.1x SSC with 20 mM β-mercaptoethanol (Merck, Darmstadt, 
Germany) at 50˚C; and for 30 min with 2 U/ml ribonuclease (RNase) T1 (Boehringer) in 
2x SSC, 1 mM EDTA at 37˚C. RNA hybrids were detected using mouse anti-digoxigenin 
(1:2000, Sigma-Aldrich Chemie, Steinham, Germany) followed by rabbit anti-mouse 
Ig (1:50; DAKO, Glostrup, Denmark) and mouse alkaline phosphatase anti-alkaline 
phosphatase (APAAP; DAKO).28 
immunohistochemical staining
Serial sections of formalin-fixed, paraffin-embedded cervical carcinoma, 3 μm thick, 
were mounted on aminopropylethoxysilane-coated slides. Sections were dewaxed 
and rehydrated. Endogenous peroxidase was blocked with 0.3% H2O2 in methanol 
for 20 min. After rinsing the sections in phosphate-buffered saline (PBS), antigen 
retrieval was performed by treating the sections for 20 min at 37°C with 0.1% trypsin 
(Sigma-Aldrich Chemie), 0.1% CaCl2, pH 7.4. Sections were incubated with PBA 
[PBS containing 1% bovine serum albumin (BSA) (Sigma)], followed by an overnight 
incubation at room temperature with monoclonal antibody (MAb) directed against 
CD68 (1:1600, IgG1; DAKO). Subsequently, immunohistochemical staining was 
performed as previously described.27
semi-quantitative evaluation of immunohistochemical and risH results
The staining of CCL2 in the tumor cells was scored as previously described.29 Intensity 
was scored as none (0), mild (1), moderate (2) or intense (3) at low magnification 
(x100). Furthermore, the percentage of positive tumor cells was determined and 
Chapter 2
40
divided into groups (from 0 to 5): 0% (0, absent); 1% to 5% (1, sporadic); 6% to 25% 
(2, local): 26% to 50% (3, occasional); 51% to 75% (4, majority) and 76% to 100% (5, 
large majority). The two parameters were combined, representing the sum of both 
the percentage and the staining intensity of the positive cells, resulting in an overall 
score (0 or 2-8). The scores were combined into three groups: category 0 (score 
0, no expression); category 1 (scores 2, 3, 4 and 5, low expression) and category 2 
(scores 6, 7 and 8, high expression). CCL2 expression was scored by two independent 
researchers without knowing the identity or clinical outcome of patients.
real-time quantitative rt-Pcr
The CCL2 RNA concentration in paraffin-embedded tissue sections was measured 
by real-time quantitative RT-PCR (qRT-PCR), using PALM Laser Micro-Beam System 
(PALM Microlaser Technologies AG, Bernried, Germany), dissected tissue material 
and the TaqMan technology.30 Five mm paraffin sections of the cervical cancer tissues 
were cut and mounted on a glass slide coated with a 1.35 mm polyethylene layer 
PALM® LPC-Membrane (PALM Microlaser Technologies AG). After drying (overnight, 
37oC), paraffin wax was removed and tissue sections were again dried (at least 
4 h, 37oC). Cervical carcinoma tumor fields were selected and microdissected into 
50 ml of lysis buffer [20 mM Tris (pH 7.4), 1 mM EDTA (pH 8.0), 2% sodium dodecyl 
sulphate].31 500 mg/ml proteinase K (Invitrogen Corporation, Carlsbad, Germany) 
was added and incubated for 16 h at 60oC. After centrifugation of the samples at 
13 000 g for 5 min at 4oC, total RNA was extracted by adding 500 ml TRIzol® Reagent 
(Invitrogen Corporation) according to the manufacturer’s protocol. After dissolving 
the RNA in 10 ml of RNase-free water, reverse-transcription was performed 
according to the manufacturer’s protocol for 90 min at 42oC in a final volume of 
20 ml containing 1x AMV-RT buffer (Roche Diagnostics, Mannheim, Germany) and 
random primers (Invitrogen Corporation). QRT-PCR was done on a TaqMan ABI 7700 
Sequence Detection System (Applied Biosystems, Weiterstadt, Germany). Besides 
CCL2,32 three housekeeping genes were also measured: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine guanine phospho-ribosyltransferase (HGPRT) 
and TATA box-binding protein (TBP)33 (Table 1). Primers and probes were chosen to 
span introns, therefore avoiding the detection of DNA. For each measured gene, a 
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calibration curve was determined using a serial dilution of total RNA from healthy 
human spleen tissue. The average expression level of the housekeeping genes 
was calculated for each sample as well as the relative RNA concentration of CCL2, 
normalized to the housekeeping genes. The average of the samples belonging to the 
same RISH category was calculated and the category with high CCL2 expression was 
set to 1.00. 
table 1. Primers and probes used for qRT-PCR
Gene Primers and probes Label GenBank accession No
CCL2 forward   5’-tcgctcagccagatgcaat-3’  S71513
 reverse    5’-ccacaatggtcttgaagatcaca-3’   
 probe      5’-tcaccagcagcaagtgtcccaaagaa-3’ FAM  
HPRT forward   5’-tgacactggcaaaacaatgca-3’  NM_000194
 reverse    5’-ggtccttttcaccagcaagct-3’   
 probe       5’-cttgaccatctttggattatactgcctgacca-3’ TET  
GAPDH forward   5’-ttccaggagcgagatccct-3’  NM_002046
 reverse    5’-cacccatgacgaacatggg-3’   
 probe       5’-cccagccttctccatggtggtgaa-3’ FAM  
TBP forward   5’-cacgaaccacggcactgatt-3’  X54993
 reverse    5’-ttttcttgctgccagtctggac-3’   
 probe       5’-tgtgcacaggagccaagagtgaaga-3’ FAM  
Preparation of cervical cancer cell suspensions for flow-cytometric analysis
The method for DNA flow-cytometric analysis of single cell suspensions from paraffin-
embedded material, as described by Leers et al,34 was optimized for cervical cancer. 
Two 50 mm thick sections were cut from five formalin-fixed, paraffin-embedded 
cervical cancer cases and placed in 10 ml glass tubes. The sections were dewaxed 
three times for 5 min in 3 ml of xylene and rehydrated in a descending ethanol range. 
After a wash in 3 ml of PBS, the sections were immersed in 3 ml of cold citrate solution 
(10 mM, pH 6.0) and incubated for 80 min at 80°C in a water bath. The sections were 
allowed to cool down to room temperature, centrifuged (5 min, 500 g), and digested 
for 10 min at 37°C in a water bath in 3 ml of 0.05 M Tris-HCl buffer complemented 
with 10 mM CaCl2 and 0.1% trypsin (Sigma). Three milliliters of PBA was added to 
block the digestion, which was followed by mechanical treatment by mincing with a 
pipette tip. Next, the samples were filtered through a 50 mm mesh nylon filter and 
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washed three times in 3 ml of PBA (5 min, 500 g). The cell pellet was resuspended 
in PBA and the single cell suspension was aliquoted into samples of 1x106 cells. To 
each sample, 100 ml of MAb directed against keratin [AE1/AE3 (1:100) and MNF116 
(1:50; DAKO) diluted 1:40 in PBA] was added. After overnight incubation at room 
temperature, the samples were washed twice in PBA. Next, 100 ml of the secondary 
antibody fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG1 F(ab’)2 
(DAKO) diluted 1:100 in PBA was added to the pellet. Incubation for 30 min in the 
dark was followed by washing three times with 3 ml of PBA. DNA staining solution 
was prepared in PBA, containing 0.1% ribonuclease A (RNase; Sigma) and 1 mM 
propidium iodide (PI; Calbiochem, San Diego, CA). Cells were incubated with 0.5 ml 
of DNA staining solution for 30 min at 37°C to activate the RNase. The samples were 
kept at 4°C for at least 2.5 h in the dark before flow-cytometric analysis and sorting. 
Negative control samples omitting the primary antibody were treated the same way.
flow sorting
Flow sorting was performed using a FACStar Plus flow cytometer (BD Biosciences). A 
life gate was set on the FL3-W versus FL3-A pulse processor. Cells were sorted based 
on keratin expression (FITC) and DNA content (PI). Both positive and negative cell 
fractions were collected for DNA extraction.
dnA extraction
DNA from 11 flow-sorted tumor cell samples was extracted by the method described 
by Abeln et al.35 In short, flow-sorted tumor cells and normal cells were resuspended 
in isolation buffer [0.3 mg/ml proteinase K in 10 mM Tris-HCL (pH 8.3), 1 mM EDTA, 
0,5% Tween 20] at a concentration of 1000 cells/ml. After overnight incubation at 
56°C in a water bath and 5 min inactivation at 100°C in a heat block, 1000 cells were 
used as a template for the PCR reactions.
Analysis of loss of heterozygosity
Two sequence tagged site (STS) markers (D17S1880 and D17S1872) were 
chosen to measure if the CCL2 gene was lost. DNA was extracted from flow-
sorted keratin-positive (cervical cancer cells) and keratin-negative (stromal and 
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inflammatory cells) material. Subsequently, this material was investigated for loss 
of heterozygosity (LOH) using the following fluorescein-labeled primers: D17S1880, 
5’-GTTTCTTGACAGAATTTGAACACTTTG-3’ and 5’-AGGGATTGCTTGAGCC-TET-3’; 
D17S1872, 5’-AATTGGGTCCAGAGAGCA-3’ and 5’-CCAACTCTAGGACTGGGG-TET-3’ 
(Isogen Bioscience BV, Maarssen, The Netherlands). The unlabeled primer of 
D17S1880 was modified (underlined part of sequence) to eliminate misinterpretation 
of the profile of the allele.36 As a positive control, normal endometrial tissue of the 
same samples was investigated. Polymerase chain reaction (PCR) amplification was 
carried out in a 12 μl reaction buffer mixture, containing 2 mM MgCl2, 0.01% BSA, 0.2 
mM of each deoxynucleotide-triphosphate, 1.25 units of AmpliTaq Gold™ (Applied 
Biosystems, Foster City, CA), and 6 pmol of both oligonucleotide primers. PCR cycles 
were 5 min at 96oC, 33 cycles of 45 s at 94oC, 1 min 5 s at 55oC, and 45 s at 72oC 
followed by 6 min at 72oC in a GeneAmp 9700 thermocycler (Applied Biosystems). PCR 
products were run on an ABI PRISM™ 310 Genetic Analyzer for 20 min and analysed 
with GeneScan Analysis® 3.1 (both Applied Biosystems, Nieuwekerk a/d IJssel, The 
Netherlands).37 The allelic imbalance factor was determined and the range for LOH 
was defined as LOH ≤0.55 or ≥1.80. The cut-off points were previously empirically 
determined by Cleton-Jansen et al.38 
statistical analysis
Data from immunohistochemistry as well as RISH are given as the mean ± the standard 
deviation (SD). Statistical analysis was performed using SPSS 10.0 (SPSS Inc, Chicago, 
IL). Data were processed using either the chi-square test or the Fisher’s exact test, 
depending on the number and distribution of the compared groups. Kaplan-Meier 
survival curves were generated to assess differences in relapse-free period (defined 
as the observation time in months from surgery to relapse of the disease) or survival 





cervical cancer cells express CCL2
In the present study, we have investigated the CCL2 expression of cervical carcinoma 
cells, using a RISH technique, in 93 cervical cancer tissues. Both the percentage 
of positive tumor cells and the intensity of cytoplasmic staining were scored. As a 
control for the quality of the mRNA in this material, the expression of β-actin mRNA 
was measured in all the samples. All tissue samples strongly expressed β-actin 
mRNA. Inflammatory cells in the stroma that are known to produce CCL2 (especially 
TAM) served as an internal positive control. Of the 93 tissue samples, 15 samples 
did not show CCL2 staining (16%), 31 showed low CCL2 expression (33%), and 47 
high expression of CCL2 (51%) (Figure 1). Five of the seven adenocarcinomas were 
positive for CCL2 expression, whereas all six adenosquamous tumors were observed 
to express CCL2. To confirm the validity of our semi-quantitative scoring system for 
the RISH results, we also measured the relative expression of CCL2 in 15 selected 
cervical carcinoma samples. Five tissue samples were randomly chosen from each 
CCL2 expression category (five from category 0, five from category 1, and five from 
category 2). To minimize contamination with stromal or inflammatory cells, tumor 
fields were selected and isolated using the PALM Laser Micro-Beam System. The 
mean mRNA expression of CCL2 using qRT-PCR with the TaqMan probe was for (RISH) 
category 0, 0.10 ± 0.06; category 1, 0.22 ± 0.07; and category 2, 1.00 ± 0.24. The 
significant correlation (P=0.005) between the RISH and QRT-PCR results demonstrates 
that the scoring system used for the RISH is indeed a semi-quantitative assessment of 
the amount of CCL2 mRNA (Figure 2).
 





Figure 1. CCL2 (RISH) and CD68 (immunohistochemical) staining of cervical 
carcinoma. 
figure 1. CCL2 (RISH) and CD68 (immunohistochemical) staining for monocytes/macrophages in cervical 
carcinoma. Panels (a), (b) and (c) represent strong, weak and no expression of CCL2 mRNA respectively. 
(d) Sense probe for CCL2 (negative control). Monocytes/macrophages are indicated by arrows. Panels (e) 
and (f) represent positive and negative immunohistochemical staining of monocytes/macrophages (anti-
CD68), respectively; sections are counterstained with Mayer’s haematoxylin. (a-f) Scale bar = 100 μm. See 
page 191 for color figure.
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figure 2. Correlation of CCL2 mRNA expression identified by RISH and qRT-PCR. The results of CCL2 RISH on 
paraffin-embedded cervical cancer tissue were compared with the results of a qRT-PCR using PALM Laser 
Micro-Beam System dissected paraffin-embedded cervical cancer tissue sections. Techniques are specified 
in the Materials and methods section.
Association between CCL2 expression by cervical cancer cells and the number of 
tAM
CCL2 is known to attract human monocytes, memory T cells and NK cells.13, 14 
Therefore, the presence of CCL2 mRNA in cervical carcinoma cells was associated with 
the amount of inflammatory infiltrate (comprising T cells, B cells, TAM, granulocytes, 
and NK cells).39 The inflammatory infiltrate was quantified in three categories (minor, 
moderate, and extensive).28 No significant association was found between CCL2 
expression (absent or present) and the amount of inflammatory infiltrate (P=0.982) 
(data not shown). Because CCL2 has been shown to be involved in the attraction 
of monocytes to the tumor site,15-19 a relationship between CCL2 expression by 
cervical carcinoma cells and the number of TAM was subsequently determined. 
TAM were predominantly located in the tumor stroma, although they were also 
observed between the tumor cells. The number of TAM in the tumor stroma showed 
a significant correlation with the number of TAM within the tumor fields (Figure 3; 
r2=0.58, P<0.001). A positive correlation between CCL2 score and the number of 
TAM in the tumor parenchyma, the tumor stroma, and the total number of TAM 
was observed (Figure 4; P<0.03, P=0.0008 and P=0.0017, respectively). Based on the 
prominent relationship between the number of stromal TAM and the CCL2 score, 
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stromal TAM were divided into two groups (according to the median value of 20) and 
associated with the expression of CCL2 by cervical carcinoma cells (none, low, high). 
The three groups differed statistically significantly from each other (P=0.001) and a 
shift from the group with <20 TAM per high-power field of view (HPF) to the group 
with ≥20 TAM per HPF was evident (Table 2).
figure 3. Correlation between the number of TAM within the tumor fields and in the tumor stroma. TAM 
were stained immunohistochemically with an anti-CD68 MAb as described in the Materials and methods 
section. The square roots of the number of TAM are displayed. The square roots are computed to make 
variances approximately constant.
figure 4. Relationship between CCL2 mRNA expression (none, low, high) in cervical tumor cells and 
the number of TAM in the tumor parenchyma (open bars), the tumor stroma (grey bars), and the total 
number of TAM (black bars) in cervical cancer tissue sections. CCL2 mRNA expression was detected by 








CCL2 expression in cervical carcinoma cells
Significance P-valueAbsent Low High
 <20 per HPF 9* 22 14 0.001†
 ≥20 per HPF 6 9 33  
 
* number of patients/cervical carcinomas
† chi-square test
correlation between CCL2 expression by cervical cancer cells and clinicopathological 
parameters
Subsequently, CCL2 expression of cervical carcinoma cells was associated with 
clinicopathological parameters. No significant association was found with histology, 
HPV status, depth of infiltration or parametrial invasion. CCL2 expression by cervical 
carcinoma cells was associated with post-operative radiotherapy, recurrent disease, 
tumor size, vascular invasion, lymph node metastasis and distant metastasis (Table 
3). Considering these latter parameters, an increase in P value (P=0.010 compared 
with P=0.045 for CCL2 expression) was found only in the case of tumor size and 
number of stromal TAM (≥20). A Kaplan-Meier plot was generated to determine the 
relationship between CCL2 expression and cumulative disease-free survival (DFS) 
over a 5-year period. Since there was no significant difference between low and high 
CCL2 expression (Figure 5A; log-rank test P=0.695) and DFS, these categories were 
combined leading to two categories (either with or without CCL2 expression; log-
rank test, P=0.030, Figure 5B). In addition, the cumulative overall survival was plotted 
(log-rank test, P=0.024, Figure 5C). The mean cumulative overall survival of the CCL2-
negative category was 90 ± 21 months, which was statistically significantly different 
from the CCL2-positive category, which had an overall survival of 60 ± 24 months 
(P=0.024; spanning a maximal follow up of 10 years). In a multivariate analysis 
against two of the most predictive prognostic parameters, lymph node metastases 
and recurrence of disease, absence of CCL2 was not statistically significant (data not 
shown).
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figure 5. Cumulative relapse-free survival and cumulative overall survival stratified by CCL2 mRNA 
expression in cervical carcinoma cells. Detection of CCL2 mRNA and Kaplan-Meier analysis are specified 
in the Materials and methods section. (A) Cumulative disease-free survival stratified by CCL2 mRNA 
expression [none (circle), low (diamond) and high (triangle)] in cervical carcinoma cells. (b) Cumulative 
disease-free survival stratified by CCL2 mRNA expression [absent (circle) and present (low and high) 
(triangle)] in cervical carcinoma cells. (c) Cumulative overall survival stratified by CCL2 mRNA expression 
[absent (circle) and present (low and high; triangle)] in cervical carcinoma cells.
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table 3. Summary of clinicopathological features of the patients and tumors.
Patient and tumor
characteristics




Post-operative RT No 11 34 0.048
 Yes 4 44  
Recurrent disease 
(within 5 years)* 
No 14 50 0.023
Yes 1 27  
Histology Squamous 13 59 0.507
 Adeno and
Adenosquamous
2 19  
HPV status* 16, 18 10 57 0.197
 Other 0 14  
Tumor size* <40 mm 12 49 0.045
 ≥40 mm 1 26  
Depth of infiltration* <15 mm 11 49 0.502
 ≥15 mm 4 22  
Parametrial invasion* No 15 62 0.054
 Yes 0 15  
Vascular invasion* No 10 30 0.049†
 Yes 5 46  
Lymph node metastasis No 14 54 0.045
Yes 1 24  
Distant metastasis* No 15 55 0.011
 Yes 0 22  
 
Statistical analysis was based on Fisher’s exact test.
* Only data for cervical carcinoma samples with a determined HPV type were included; other types 
included HPV31 (n=2), HPV33 (n=6), HPV35 (n=1), HPV45 (n=2), HPV58 (n=1), HPV59 (n=1), HPV68 (n=1). 
† chi-square test.
Absence of CCL2 expression is associated with genetic alterations near the CCL2 
(17q11.2) genomic region
To determine if the absence of RISH staining was due to genetic alterations near 
the CCL2 (17q11.2) genomic region, LOH analysis of the CCL2 gene was performed 
using six tissue samples without CCL2 mRNA expression and five with CCL2 mRNA 
expression. The tissue samples were randomly selected from both groups. Two STS 
markers, D17S1880 positioned at the centromeric side and D17S1872 positioned 
at the telomeric side of the CCL2 gene, were chosen. To obtain pure tumor cell 
populations and to avoid contamination with stromal or inflammatory cells, dissected 
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tumor cells were sorted on the basis of their keratin expression by flow cytometry. 
LOH was found in five of the six samples without CCL2 expression (Figure 6). Only one 
tissue sample, as well as the five control samples with high CCL2 expression, showed 
retention. Comparison of both groups (with and without CCL2 expression) showed a 
statistically significant difference (P=0.015).
figure 6. LOH of the CCL2 (MCP-1) genomic region in cervical carcinoma, assessed using STS markers 
D17S1880 and D17S1872. Five tumors without CCL2 mRNA expression displayed LOH at either one side 
or both sides of the CCL2 gene. In five tumors (7-11) with CCL2 expression, no LOH was found. The LOH 
technique is specified in the Materials and methods section. 
discussion
In the present study we found a relationship between CCL2 expression by cervical 
tumor cells, the presence of TAM, and clinicopathological parameters. In our study, 
84% of the cervical cancers showed staining for CCL2 mRNA. In an earlier study with 
a limited number of tumor samples, Riethdorf et al16 found a comparable number of 
squamous cell carcinomas of the cervix (three of five, 60%) to be positive for CCL2. 
In a more recent study by Kleine-Lowinsky et al,40 no expression of CCL2 was found in 
four cases of cervical carcinoma. The reason for the discrepancy between our study, 
Riethdorf et al’s study, and the latter study is not clear, but it might be related to the 
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smaller number of tumor samples used in the study by Kleine-Lowinsky et al. Cervical 
cancer cells have the capacity to produce CCL2, as demonstrated by the constitutive 
CCL2 production of HeLa and inducible CCL2 expression of SiHa.41 The expression of 
CCL2 by cervical cancer cells in vivo may be either repressed by expression of E6 or 
E7 proteins41 or induced by stimuli (e.g., cytokines) from the tumor environment that 
induce nuclear factor (NF)-kappaB activation.42 Also, in other tumor types, such as 
breast cancer, pancreatic, gastric and esophageal cancer, a variable proportion of the 
tumor cells were found to express CCL2.15, 17, 24, 25, 43, 44 
Using RISH, we have demonstrated that the majority of cervical carcinoma cells from 
tumors classified as FIGO stage IB or IIA express CCL2 mRNA. The semi-quantitative 
scoring method used to quantify the results29 was substantiated using qRT-PCR. The 
observation that category 0 [no CCL2 expression detectable (RISH)] did show CCL2 
expression with the qRT-PCR technique indicates that the latter method is more 
sensitive. Similar findings with regard to the increased sensitivity of the qRT-PCR 
technique compared with RISH have been described by other groups.45, 46
As previously shown, CCL2 has been identified as a major chemokine inducing the 
recruitment of macrophages to human tumors such as those of the cervix,16 ovary,47, 
48 lung,18, 49 and breast.17, 44 Also, in our study, CCL2 mRNA expression was associated 
with the number of TAM. This association was observed only for TAM and not for 
the extent of inflammatory infiltrate present. The lack of a significant correlation 
between CCL2 expression and the amount of inflammatory infiltrate, the significant 
association between tumor-derived CCL2 and TAM, and the association between 
CCL2 expression and survival support the concept that TAM play a role in tumor 
progression of cervical carcinoma. This view is strengthened by the observation 
that high numbers of stromal TAM (>20) are associated with tumor size. This view 
that inflammatory tumor-educated macrophages promote tumor progression 
and metastases is becoming more and more accepted.12, 20-22 It is thought that the 
inflammatory infiltrate is attracted to the tumor site and remains at the tumor 
site through the action of cytokines such as macrophage colony-stimulating factor 
(M-CSF) and CCL2. However, as observed in a previous study, the number of TAM does 
not correlate significantly with relapse in cervical cancer.50 This may be explained by 
the complexity of signals provided by the multitude of cytokines and chemokines 
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present in the tumor environment, and the presence of different subpopulations of 
TAM that may respond differently to these signals.
Cervical cancer patients without CCL2 expression had the most favorable prognosis. 
Similar results were reported by Ueno et al17 in a group of breast cancer patients. 
It should be noted that in the latter study, the CCL2 production of tumors (thus 
including stroma, TAM, and cancer cells) was associated with survival, whereas in our 
study, CCL2 mRNA expression by cancer cells exclusively was associated with survival. 
Although there is a positive relationship between TAM and CCL2, only the absence of 
CCL2 is significantly associated with prognosis. It is noteworthy that the only patient 
who died from disease in the group without detectable CCL2 was a patient with a 
high number of TAM (over 40 stromal TAM per HPF). This high number of TAM may 
have been induced by the presence of other cytokines such as M-CSF. In the group 
of patients with high expression of CCL2, it was observed that high expression was 
associated with a high number of TAM. However, even if CCL2 was expressed by the 
tumor, the number of TAM was low (less than 20), suggesting that other factors also 
play a role in the recruitment and survival of TAM.22, 51
Patients divided into groups with or without postoperative pelvic radiotherapy52 
differed in CCL2 expression. The statistically significant association of CCL2-positive 
cervical cancer cells with relapse and post-operative radiotherapy suggests that 
CCL2-expressing tumor cells behave in a more malignant fashion. This behavior is 
supported by the observations of Neumark et al who reported that murine mammary 
adenocarcinoma cancer cell clones with a high malignant phenotype expressed high 
levels of CCL2 in contrast to their low malignant phenotype counterparts.53
Lack of expression of CCL2 RNA correlated with LOH in the region containing the 
CCL2 gene (chromosome 17q11.2). Five of the six samples without detectable CCL2 
expression investigated showed LOH of one or both STS markers flanking the CCL2 
gene, suggesting that LOH is a mechanism by which CCL2 RNA expression is prevented. 
However, loss of one CCL2 allele does not explain the lack of CCL2 RNA expression. 
The absence of CCL2 RNA expression suggests that the other CCL2 allele is also 
impaired (e.g., a mutation in the CCL2 gene or methylation of the CCL2 promoter). 
Similar results were found for the relationship between absence of mRNA expression 




Our data from cervical carcinoma uphold the concept that tumors modify their 
environment by expressing particular cytokines and chemokines, thus modifying the 
function of TAM in such a way that tumor progression rather than an anti-tumor 
response is supported.
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Pro-inflammatory cytokines are important in modifying the activity, differentiation, 
and migration of antigen-presenting cells (APC) and may influence the survival 
of cancer patients. The study assessed whether granulocyte-monocyte colony-
stimulating factor (GM-CSF), tumor necrosis factor (TNF)-a and interleukin (IL)-12, 
expressed by cervical cancer cells, are important for the activity, differentiation, and 
migration of APC.
In 90 patients with cervical carcinoma the number of monocytes/tumor associated 
macrophages (TAM), mature dendritic cells (DC), and Langerhans’ cells (LHC) was 
determined using immunohistochemistry. An RNA-in	 situ	 hybridization technique 
was used to measure the expression level of GM-CSF, TNF-a, IL-12p35 and IL-12p40. 
Tumor-associated macrophages were detected intraepithelial as well as in the 
stroma of the tumor. LHC were only detected intraepithelial and mature DC only 
in the tumor stroma. The number of TAM correlated positively with the number of 
mature DC. The expression levels of GM-CSF and TNF-a correlated positively with the 
number of TAM and DC. TNF-a showed a negative correlation with the number of 
LHC. A significant correlation between the expression of functional IL-12 (IL-12p40) 
and stromal TAM was found. The expression of GM-CSF, TNF-a and IL-12p40 did not 
correlate significantly with disease-free survival. However, high IL-12p40 expression 
was associated with a favorable cumulative overall survival. These results suggest 
that GM-CSF as well as TNF-a, produced by cervical carcinoma cells, may play a 
role in the differentiation of monocytes into mature DC. Furthermore, TNF-a may 
influence the migration of LHC from the tumor. 




Cervical cancer is a leading cause of morbidity and mortality among women 
worldwide, especially in the developing countries.1, 2 Infection with oncogenic 
types of human papillomavirus (HPV) is an important factor in the development of 
cervical cancer.3, 4 The persistent HPV infection induces an inflammatory response. 
Cervical cancer cells are often surrounded by a large number of inflammatory cells. 
Approximately half of these cells are cells with antigen-presenting characteristics.5 
Although these cells are capable of generating an antitumor response, this does not 
occur.6, 7 At present, it is thought that the inflammatory cells are suppressed in their 
antitumor properties and support tumor growth rather than eliminate cancer cells.8, 9 
Inflammatory cells are attracted to the tumor site by locally produced cytokines and 
chemokines.10, 11 Cervical cancer cells are known to produce an extensive range of 
cytokines.12, 13 In addition to attracting inflammatory cells, these cytokines influence 
the activation status and function of the infiltrating antigen-presenting cells (APC) 
and the stroma and thus influence the course of the disease.11, 14 We have shown 
that expression of chemokine (C-C motif ligand 2 (CCL2) by the cervical cancer cells 
is associated with an increased number of tumor-associated macrophages (TAM) 
and a decreased disease-free survival of cervical carcinoma patients.15 Furthermore, 
we have observed a down regulation of the expression level of pro-inflammatory 
cytokines, such as granulocyte-monocyte colony-stimulating factor (GM-CSF), tumor 
necrosis factor (TNF)-α and interleukin (IL)-12 in cervical carcinoma cell lines.12 
GM-CSF, TNF-α and IL-12 are important in profiling immune reactivity.10, 16 GM-CSF 
and TNF-α are involved in differentiation and survival of dendritic cells (DC) and 
Langerhans’ cells (LHC) and IL-12 is known to stimulate effector cell populations 
such as cytotoxic T cells and natural killer (NK) cells.17, 18 Our observations in vitro 
are consistent with a hypothesis that presumes that increased local proinflammatory 
cytokine expression would promote antitumor immunity. This suggests that patients 
with cervical cancer producing these proinflammatory cytokines may follow a 
relatively more benign course.
To test this hypothesis we quantified different subsets of APC (TAM, LHC and DC) 
and measured the mRNA expression levels of GM-CSF, TNF-α and IL-12 in tumors of 
90 patients with cervical carcinoma. Subsequently, we determined the association 
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between mRNA expression with clinicopathological parameters, disease-free survival 
(DFS), and cumulative overall survival (OS) of the cervical carcinoma patients.
MAteriAls And MetHods
Patient material
Between 1985 and 1995, 254 untreated patients suffering from primary cervical 
carcinoma with stage IB and IIA underwent a radical hysterectomy type III with 
lymphadenectomy. From the tissue obtained, 90 tissue samples were available for 
research. Tissues were routinely embedded in paraffin after 10% formalin fixation. 
The tissue samples of each patient were examined by a pathologist for the presence 
of tumor. Tumor percentage varied between 30% and 80%. The characteristics of the 
patients are depicted in Table 1. Human tissue samples were used according to the 
guidelines of the Ethical Committee of the Leiden University Medical Center.
table 1. Summary of clinicopathologic features of patients and tumors
Patient and tumor characteristics Outcome N*
Age 46, mean 90






Tumor size† < 40 mm 67
≥ 40 mm 18
Depth of infiltration† < 15 mm 61




Parametrial invasion† No 75
Yes 14





HPV indicates human papillomavirus.
* N, number of patients/cervical carcinomas. 
† The number of reported cases is affected by incidental missing cases.
‡ Only data for cervical carcinoma samples with a determined HPV type were included, other subtypes 
included HPV31 (n=2), HPV33 (n=6), HPV35 (n=1), HPV45 (n=2), HPV58 (n=1), HPV59 (n=1), HPV68 (n=1). 
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Preparation of GM-csf-, tnf-a-, il-12p35- and il-12p40-probe
RNA was isolated from frozen human spleen using TRIzol® (Invitrogen, Breda, The 
Netherlands) and first-strand cDNA synthesis with oligoDT primers and reverse 
transcriptase AMV (both Roche Diagnostics, Mannheim, Germany) were both done 
according to the manufacturer’s instructions. Oligonucleotide primers for GM-CSF, 
TNF-a, IL-12p35 and IL-12p40 were chosen on the basis of known sequences (see 
Table 2) and cDNA encoding for the different cytokines was amplified. A pGEM®-
3Zf(+) Vector (Promega, Madison, WI) was linearized with SmaI and the polymerase 
chain reaction (PCR) products were cloned into the vector. After transferring the 
vector to E. coli strain Top 10 (Invitrogen Corp., San Diego, CA) the plasmids were 
isolated by using the QIAfilter Maxi KITS protocol (QIAGEN, Hilden, Germany). The 
sequence of the PCR product was confirmed by DNA sequencing. Plasmids were 
linearized with BamH1 and EcoR1 (both Boehringer, Mannheim, Germany) in the 
case of GM-CSF, TNF-a and IL-12p40 or BamH1 and SacI in the case of IL-12p35 using 
One-Phor-All Buffer Plus (Amersham Biosciences, Roosendaal, The Netherlands). 
Both strands were translated in a digoxigenin (DIG)-labeled RNA probe according 
to manufacturer’s instructions (Roche Diagnostics). The concentration of the DIG-
labeled sense and antisense RNA probes were determined on a 1% agarose gel 
stained with ethidium bromide (Sigma, St. Louis, MO). Probes were stored at -20°C 
until further use.
rnA-in situ hybridization
The RNA-in	 situ hybridization (RISH) was performed as previously described.19, 20 
In brief: 3 μm thick paraffin sections were pretreated and hybridized with 100 ng/
ml DIG-labeled RNA probe diluted in hybridization mixture containing NaCl and 
saline-sodium citrate (SSC; Table 2). Hybridization was allowed for 16 h at either 
50°C (GM-CSF and TNF-a) or 42°C (IL-12p35 and IL-12p40) in a humidified chamber. 
Slides were washed for 30 min in 2x SSC followed by 45 min in 0.1x SSC with 20 
mM β-mercaptoethanol (Merck, Darmstadt, Germany), both at the hybridization 
temperature (see Table 2). Subsequently, the slides were incubated for 30 min with 
2 U/ml ribonuclease (RNase) T1 (Roche Diagnostics) in 2x SSC, 1 mM EDTA at 37°C. 
RNA hybrids were detected using mouse anti-DIG (1:2000, Sigma-Aldrich Chemie, 
Steinham, Germany), rabbit anti-mouse Ig (1:50, DAKO, Glostrup, Denmark), and 



















































































































































































































































































































































Serial sections, 3 μm thick, of formalin-fixed and paraffin-embedded tissue were 
mounted on aminopropylethoxysilane-coated slides. Sections were deparaffinized 
and rehydrated. Endogenous peroxidase was blocked with 0.3% H2O2 in methanol for 
20 min. Antigen retrieval was performed by treating the sections either for 10 min 
at 37°C using 1 mM EDTA pH 8.0 (mouse anti-CD1a) or by treating the sections for 
10 min at 37°C with 0.1% trypsin (Sigma-Aldrich Chemie), 0.1% CaCl2, pH 7.4 (mouse 
anti-CD68 and mouse anti-DC-Lamp). Sections were incubated with PBA [1% bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS)], followed by an overnight 
incubation at room temperature with monoclonal antibody (MAb) directed against 
CD1a (1:100, IgG1 kappa, clone 1CA04; Neomarkers, Fremont, CA), CD68 (1:1600, 
IgG1, DAKO) or DC-Lamp (1:20, IgG1, clone 104.G4; Immunotech, Marseille, 
France). Subsequently, immunohistochemical staining was performed as previously 
described.20 For all three tested antibodies human tonsil served as a positive control.
(semi-)quantitative evaluation of risH and immunohistochemistry
RISH was scored as previously described.21 Intensity was scored as none (0), mild 
(1), moderate (2), or intense (3) at low magnification (x100). Furthermore, the 
percentage of positive tumor cells was determined and divided in groups (from 0 
to 5): 0% (0, absent), 1% to 5% (1, sporadic), 6% to 25% (2, local), 26% to 50% (3, 
occasional), 51% to 75% (4, majority), and 76% to 100% (5, large majority). The sum 
of both the percentage and the staining intensity of the positive cells resulted in 
an overall score (0 or 2-8). The scores were combined into three groups: category 
0 (score 0, no expression), category 1 (scores 2, 3, 4 and 5, low expression), and 
category 2 (scores 6, 7 and 8, high expression). mRNA expression was scored by 
two independent researchers without knowing the identity and clinical outcome of 
patients. CD1a-, CD68- and DC-Lamp-positive cells were quantified in the tumor by 
counting the number of stained cells per 6, randomly selected, high-power field of 
view (HPF, x400; Figure 1). 
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figure 1. Immunohistochemical and RISH staining of paraffin sections of cervical carcinoma are shown. 
Carcinoma cells are indicated by a T, whereas S represents tumor stroma. (a-c) Immunohistochemical 
staining of cervical carcinoma. (a) Staining for monocytes and macrophages (anti-CD68). Staining is 
present intraepithelial as well as in the tumor stroma. (b) Staining for mature dendritic cells [DC (anti-DC-
Lamp)] seen as nests in the tumor stroma. (c) Staining for Langerhans’ cells [LHC (anti-CD1a)]. Staining can 
be seen intraepithelial. Positive cells are clearly visible by a dark-brown precipitation. Sections (a-c) are 
counterstained with Mayer haematoxylin. (d-h) RNA-in	situ hybridization (RISH) for cytokines in the same 
cervical carcinoma sample as shown in (a-c). (d) Negative control. (e) GM-CSF shows a weak expression in 
both cervical carcinoma cells and in inflammatory cells in the tumor stroma. (f)	TNF-α is strongly expressed 
in cervical carcinoma cells as well as in some of the cells in the tumor stroma. (g) IL-12p35 is strongly 
expressed in the cervical carcinoma cells as well as in inflammatory cells in the tumor stroma. (h) IL-12p40 
shows a moderate expression in the tumor cells and a strong expression in some of the cells in the tumor 
stroma. Positive signal in RISH is seen as a (dark) blue precipitation. Sections (d-h) are not counterstained. 
Original magnification, x80. See	page	192	for	color	figure.




Data from immunohistochemistry as well as RISH were given as the mean ± the 
standard deviation (SD). Statistical analysis was done using SPSS 12.0 (SPSS, Chicago, 
IL). Data were processed by using the chi-square test, the Kruskal-Wallis H test, and 
analysis of variance (ANOVA), depending on the number and distribution of the 
compared groups. Kaplan-Meier survival curves were generated to assess differences 
in disease-free period [defined as the observation time in months from surgery to 
recurrence of the disease (disease-free survival) (DFS)] or cumulative overall survival 
(defined as time in months from surgery to death due to cervical cancer) (OS). A 
Cox regression was used for multivariate survival analysis. P<0.05 was considered 
statistically significant.
results
number and distribution of tAM, lHc and dc
To investigate the association between the number of APC, expression of 
proinflammatory cytokines by cervical cancer cells, and survival, the number of 
TAM, LHC and mature DC in the tumor was determined. TAM were observed most 
abundantly in the tumor stroma but were also present between the tumor cells 
(intraepithelial). LHC were observed only intraepithelial in similar numbers as TAM. 
In contrast to LHC, mature DC were only detected in the tumor stroma (Figure 1). The 
number of mature DC was lower than the number of TAM in the tumor stroma. There 
was a positive correlation between the number of stromal TAM and the number of 
DC (Figure 2; r2=0.371, P<0.001). There was no significant association between either 
TAM and LHC or DC and LHC (data not shown). 
Chapter 3
68









figure 2. Graph shows association between the number of stromal tumor-associated macrophages (TAM) 
and mature dendritic cells (DC). A positive correlation between the number of stromal TAM compared 
with the number of mature DC was observed (quadratic regression, r2=0.371, P<0.001). Displayed are the 
square roots of the counted cells.
expression of TNF-a, GM-CSF and il-12 (IL-12p35 and IL-12p40) in cervical cancers
Subsequently, the expression of TNF-a, GM-CSF, and IL-12 mRNA in cervical cancer 
was determined. Cancers were scored for staining intensity as well as percentage of 
cancer cells positive for cytokine expression. RNA of all the investigated cytokines 
could be detected, although in different expression patterns (Table 3). A positive 
correlation between GM-CSF and TNF-a expression was observed (data not shown, 
r2=0.515, P<0.001). 
Functional IL-12 is composed of 2 subunits (IL-12p35 and IL-12p40). Therefore, we 
measured both IL-12p35 and IL-12p40. A positive correlation between IL-12p35 
and IL-12p40 was found (data not shown, r2=0.405, P<0.001). IL-12p35 was more 
abundantly expressed than IL-12p40. All samples that expressed IL-12p40 also 
expressed IL-12p35, indicating that IL-12p40 is a parameter for functional IL-12. 
GM-CSF, TNF-α, and IL-12 in cervical cancer
69
3
table 3. Correlation between GM-CSF-, TNF-α- and IL-12p40 expression and the mean number of stromal 
TAM, mature DC and LHC in cervical carcinoma
TAM
Cytokine N* (%) Expression level Stromal Intraepithelial DC LHC
GM-CSF 45 (50) Absent   (category 0) 12 8 2 9
15 (17) Low        (category 1) 21 13 7 6
30 (33) High       (category 2) 21 13 5 6
P-value < 0.001 < 0.001 < 0.001 0.159
TNF-α 43 (48) Absent   (category 0) 13 8 3 8
31 (34) Low        (category 1) 19 11 5 9
16 (18) High       (category 2) 23 14 3 3
P-value 0.004 0.007 0.004 0.003
IL-12p40 41 (46) Absent   (category 0) 14 9 4 9
28 (31) Low        (category 1) 19 11 4 7
21 (23) High       (category 2) 18 11 2 5
P-value 0.044 0.115 0.172 0.252
TAM indicates tumor-associated macrophages; DC dendritic cells; LHC Langerhans’ cells.
* N = number of tumors, total number was 90 tumors. The scores were combined into three groups: 
category 0 (score 0; absent expression), category 1 (scores 2, 3, 4 and 5; low expression) and category 2 
(scores 6, 7 and 8; high expression) as described in Materials and methods section. 
Statistical significant P-values are bold.
Association between TNF-a, GM-CSF and IL-12 and APc in cervical cancer
Since TNF-a is known to participate in the attraction of inflammatory cells to the 
tumor site, we determined the association between expression of TNF-a and the 
number of stromal TAM.8 Expression of TNF-a showed a positive correlation with the 
number of stromal TAM (Table 3; χ2=11.084, P=0.004). As expected from the positive 
correlation between the expression of TNF-a and GM-CSF, also a positive correlation 
between GM-CSF and the number of TAM was found (χ2=37.606, P<0.001). 
TNF-a, as well as GM-CSF, are known to differentiate monocytes/macrophages (e.g., 
TAM) into mature DC.22, 23 Indeed, an association between expression of TNF-a and 
the number of mature DC was found. Low expression of TNF-a was associated with 
more DC per HPF compared with the absence of detectable TNF-a expression (Table 
3; χ2=10.892, P=0.004). A similar correlation was found between GM-CSF and DC 
(χ2=17.961, P<0.001). No further increase in the number of mature DC was observed 
in tumors displaying a high TNF-a or high GM-CSF expression level. In addition, an 
association between the number of intra-epithelial TAM and TNF-a and GM-CSF was 
found (Table 3; χ2=9.952, P=0.007 and χ2=15.790, P<0.001, respectively).
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Expression of TNF-a showed a negative correlation with the number of LHC (Table 
3; χ2=11.478, P=0.003). No significant association was found between the expression 
level of GM-CSF and LHC.
A significant correlation between the expression of functional IL-12 (IL-12p40) and 
stromal TAM was found (Table 3; χ2=6.228, P=0.044). No significant association 
between intraepithelial TAM, mature DC and LHC and the expression level of 
functional IL-12 was found.
Patients
Of the total group of 90 patients, 68 patients were diagnosed as FIGO stage IB 
and 22 as FIGO stage IIA and all underwent a radical hysterectomy combined with 
pelvic lymphadenectomy (Table 1). Twenty four of these patients had lymph node 
metastasis. Forty-seven patients received postoperative radiotherapy because of 
either tumor-positive lymph nodes or a combination of 2 of the following unfavorable 
prognostic parameters: depth of infiltration ≥ 15 mm or > 2/3 of the cervix, tumor 
size ≥ 40 mm and the presence of vasoinvasion. Twenty-seven patients suffered 
recurrent disease. Sixty-three patients were alive, 6 suffered from a recurrence, and 
22 patients had died of disease; 5 died from causes unrelated to the primary disease, 
but showed no evidence of disease as concluded from the clinical record. FIGO stage 
and tumor size were associated with the presence (category 0 versus category 1+2) 
of GM-CSF (P=0.014 and P=0.022, respectively). No significant association with FIGO 
stage or tumor size with either the presence or expression level (low, category 0+1, 
or high, category 2) of TNF-a, IL-12p35 or IL-12p40 was found.
TNF-a, GM-CSF, IL-12 expression and patient survival 
To investigate the relation between the expression of the investigated cytokines and 
survival, Kaplan-Meier plots were created. A log-rank test was used to determine 
statistical differences in survival. Neither GM-CSF expression, TNF-a nor IL-12p40 
expression showed a difference in disease-free survival (data not shown). However, 
there was a statistical difference in cumulative overall survival when comparing 
low expression of IL-12p40 with no or high expression of IL-12p40 (Figure 3; log-
rank test 5.79, P=0.016 and log-rank test 4.59, P=0.032 respectively; Table 4). When 
performing a multivariate analysis using a Cox regression model, IL-12p40 was not an 
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independent prognostic parameter in cervical carcinoma when tested against lymph 
node metastasis and depth of tumor infiltration (data not shown).
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figure 3. Graph shows association between GM-CSF, TNF-α, IL-12p40 expression and cumulative overall 
survival in cervical carcinoma. No expression is represented as the curve with a circle; low expression level 
by a triangle; and high expression level by a diamond. Patients with low IL-12p40 expression showed a 
worse prognosis compared with no or high IL-12p40 expression (log-rank test 5.79, P=0.016 and log-rank 
test 4.59, P=0.032, respectively; Table 4). 
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table 4. Association between GM-CSF, TNF-α, IL-12p40 expression and cumulative overall survival in 
cervical carcinoma 
Compared expression levels
Cytokine No vs Low No vs High Low vs High
GM-CSF 1.60 (0.206) 2.67 (0.102) 0.00 (0.977)
TNF-α 0.11 (0.743) 0.68 (0.411) 0.31 (0.577)
IL-12p40 5.79 (0.016) 0.07 (0.793) 4.59 (0.032)
Shown are the log-rank test and (P-value) of compared expression levels.
Statistical significant P-values are bold.
discussion
In the present study we found a positive relationship between TAM and DC associated 
with TNF-α-	 and GM-CSF- expression and a negative relation between LHC and 
TNF-α	expression in cervical carcinoma. There was no significant relation between 
IL-12 expression and the investigated APC except for stromal TAM, but IL-12p40 did 
show a correlation with cumulative overall survival. However, IL-12p40 was not an 
independent prognostic parameter in cervical carcinoma when tested against lymph 
node metastasis and depth of tumor infiltration.
From the APC investigated, TAM were the most abundant. There was a significant 
correlation between the number of intraepithelial TAM and the number of TAM in 
the tumor stroma, suggesting that TAM migrate from the stroma to the parenchyma 
(data not shown). Although TAM have the capability to destroy tumor cells, at 
present it is thought that TAM support the progression of the tumor.8, 9, 24 This is also 
supported by the study of Bingle et al who demonstrated that in the majority of 
the investigated cases the presence of an inflammatory infiltrate was detrimental to 
the patients.25 Mature DC (DC-Lamp-positive cells) were only observed in the tumor 
stroma. The number of mature DC correlated with the number of TAM in the stroma, 
suggesting that a part of the total number of TAM in the stroma differentiates into 
mature DC. This is further supported by the correlation between GM-CSF, TNF-α 
and the number of mature DC. Both GM-CSF and TNF-α are known to play a role in 
the differentiation of monocytes into mature myeloid DC in vitro.17 In contrast, the 
number of LHC did not correlate with either the number of TAM, or the number of 
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mature DC. It has been shown that in the presence of GM-CSF, TNF-α and TGF-β, 
DC may further differentiate into LHC.17 Although in a previous report we have 
shown that TGF-β is expressed by cervical tumor cells, no significant association 
between either TAM and LHC or mature DC and LHC was observed, suggesting that 
no substantial differentiation from mature DC into LHC occurred.26 This implies that 
the LHC are remnants of a resident population initially present in the epithelial layer 
of the cervix.27
Monocytes are known to be attracted to the tumorsite by certain chemokines.28 We 
have previously shown that CCL2 expressed by cervical tumor cells is associated with 
the presence of TAM at the tumor site.15 In addition to CCL2, TNF-α expression is often 
correlated with large numbers of inflammatory cells.8, 29 Indeed, a positive association 
between TNF-α expression and stromal TAM was found. In the present study even a 
more pronounced association between the expression of GM-CSF and the number 
of TAM (both intraepithelial as well as in the tumor stroma) was found. This is in 
agreement with the previously reported effect of GM-CSF on migration of LHC/DC 
into organotypic cultures of HPV-transformed keratinocytes.30 A similar positive 
correlation between the presence of GM-CSF, TNF-α and the number of mature DC 
in breast cancer tissue was reported by Tsuge et al.31 In contrast, Trutmann et al did 
not report a significant association between expression of GM-CSF and number of 
mature DC in colorectal cancer.32 A high level of TNF-α is known to induce migration 
of LHC to peripheral lymph nodes.33 The association between high TNF-α expression 
with low numbers of intraepithelial LHC suggests that migration of LHC to peripheral 
lymph nodes occurred. This is in accordance with previous observations of Giannini 
et al,27 who reported that increased TNF-α expression was associated with a reduced 
density of LHC in the transformation zone of the uterine cervix. Although high levels 
of TNF-α may lead to apoptosis, the presence of early HPV oncogene E6 presumably 
protects the cervical tumor cells from apoptosis by binding to the TNF-α receptor.34 
IL-12p35 mRNA is produced ubiquitously by cervical cancer cells. It has been reported 
that, although there is a high expression of IL-12p35 mRNA, due to preferential 
splicing, this does not result in protein expression unless IL-12p40 is also present.18 
Production of IL-12p40 is much more restricted. It has been suggested that IL-12p40 
plays a role in polarizing the immune response toward an antiviral response.35 
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Furthermore, low levels of IL-12 may support tumor growth. Our observations are 
consistent with a model whereby proinflammatory cytokines such as CCL2 and 
TNF-α attract monocytes to the tumor site. At the tumor site differentiation of 
TAM into mature DC occurs because of the presence of both GM-CSF and TNF-α. 
Adequate activation of TAM is prevented by high levels of active TGF-β.36 DC seem to 
be pushed towards the T-regulatory state, thus preventing an adequate anti-tumor 
response. The high amounts of TNF-α presumably induce migration of resident LHC 
to peripheral lymph nodes. 
Despite the migration of these APC to draining lymph nodes, this does not seem 
to result in an effective immune response, as shown by the lack of a significant 
correlation between the presence of TAM, mature DC, LHC, TNF-α, GM-CSF, and 
disease-free survival or cumulative overall survival. Although a previous study 
suggested that high TNF-α production was associated with an increased disease-free 
survival in non-small cell lung carcinoma, we did not find such an association.37 A 
study by Ninck et al also found a relation between the expression of growth factors 
(such as GM-CSF) and disease-free survival, but not by GM-CSF alone.38 Disease-
free survival correlated with a poorer prognosis when head and neck squamous cell 
carcinoma simultaneously produced 3 or more growth factors. Paleri et al examined 
the production of IL-12 protein in head and neck squamous cancer.39 Those authors 
did not find a significant correlation between IL-12 and disease-free survival. However, 
they did observe a trend that high production of the IL-12 protein was associated 
with an improved survival. Jones et al examined IL-12p35 and IL-12p40 expression in 
B-cell non-Hodgkin lymphoma.40 In that study high IL-12p40 levels were common in 
patients with a favorable prognosis. In our study no expression and high expression 
of IL-12p40 correlated significantly with a favorable cumulative overall survival, 
whereas a low expression level of IL-12p40 corresponded with a poorer cumulative 
overall survival. The similar results observed with a lack of IL-12p40 expression and 
high IL-12p40 expression may be related to the observation that IL-12p40 can form 
dimers. These IL-12p40 dimers have been reported to block the IL-12 receptor.18 In 
both cases, lack of IL-12p40 expression or high IL-12p40 expression, a similar effect 
can be anticipated. 
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When the patients with and without post-operative radiotherapy were compared 
with respect to IL-12p40 expression, it was observed that a higher amount of IL-
12p40 expression was significantly correlated with radiotherapy (P=0.030, data 
not shown). Therefore, the effect of IL-12p40 could be (partially) influenced by this 
clinicopathological parameter. Alternatively, a favorable cumulative overall survival 
of patients with a high expression level of IL-12p40 can be explained by the capacity 
of this cytokine to increase the lytic activity and production of interferon-γ of natural 
killer cells and cytotoxic T-lymphocytes.35 Elimination of target cells further requires 
migration of T-cells (and natural killer cells). Peritumoral stroma is essential for this 
migration.41 Indeed, it was found that the percentage of stroma present in cervical 
carcinoma between no detectable IL-12p40 and high IL-12p40 versus low IL-12p40 
expression was decreased from 45% to 36%, respectively (P=0.020, data not shown), 
suggesting that an increased amount of stroma may facilitate T-cell migration. 
Interestingly, an association between high expression of IL-12p40 and high expression 
of TGF-β was observed (P=0.024). It has been shown that in cervical carcinoma there 
is a skewing in the direction of a TH2 profile.
42 The presence of TH2 cytokines (IL-4) 
is thought to enhance the development TH3. TH3 are known to produce substantial 
quantities of TGF-β. The association between high expression of IL-12p40 and high 
expression of TGF-β may suggest that TGF-β either derived from TH3 (tumor or 
stroma) may antagonize the effect of proinflammatory cytokines (e.g., IL-12p40) and 
subvert the cytokine profile in a direction that promotes tumor development.
The expression of different chemokines and cytokines such as CCL2, IL-12p40 TGF-β, 
and TGF-β target genes [e.g., plasminogen activator inhibitor (PAI)-1] are thought to 
reflect the condition of the tumor microenvironment. Although this knowledge will 
not have a direct effect on the present clinical management of cervical carcinoma, 
these parameters may be helpful to predict the further course of the disease. 
Furthermore, when HPV vaccines become available for the treatment of metastasized 
cervical carcinoma, the cytokine profile may be important to discriminate patients 
with a beneficial immune response from nonresponding patients.  
In conclusion, the data presented in this study support the hypothesis that 
expression of cytokines by tumor cells is directed at attracting inflammatory cells to 
induce a smoldering inflammatory response that supports tumor growth and tumor 
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progression. However, a high expression level of IL-12p40 accompanied by sufficient 
intratumoral stroma seems to tip the balance between tumor and inflammatory 
response and results in a more favorable cumulative overall survival. 
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Previously, we have shown that low IL-12p40 mRNA expression by cervical cancer cells 
is associated with a poor survival of cervical cancer patients. Since IL-12p40 is both 
a subcomponent of IL-12 and IL-23, the aim of this study was to elucidate the role 
of IL-12p40 in cervical cancer. We have measured the expression of IL-23p19 mRNA, 
IL-12p35 mRNA and IL-12p40 mRNA using mRNA in	situ hybridization. IL-1 and IL-6 
were measured by immunohistochemistry. Since IL-23 is a component of the IL-17/
IL-23 pathway, a pathway induced by IL-1 and IL-6 in humans, we have studied IL-1 
and IL-6 expression. Only a high number of stromal IL-6 positive cells was shown to 
associate with poor disease-specific survival. The worst disease-specific survival was 
associated with a subgroup of patients that displayed a high number of IL-6 positive 
cells and low IL-12p40 expression (P<0.001). Both a high number of IL-6 positive 
cells and a high number of IL-6 positive cells plus low IL-12p40 expression were 
shown to be clinicopathological parameters independent of lymph node metastasis, 
parametrial involvement and Sedlis score (P=0.009 and P=0.007, respectively). Our 
results with IL-6 and IL-12p40 are in accordance with the hypothesis that the IL-17/
IL-23 pathway plays a suppressive role in cervical cancer.




Cervical cancer is a leading cause of morbidity and mortality among women 
worldwide, especially in the developing countries.1, 2 Infection with oncogenic 
types of human papillomavirus (HPV) is an important factor in the development of 
cervical cancer.3, 4 The persistent HPV infection induces an inflammatory response. 
Inflammation is an important component in the majority of tumor types. The 
outcome of this inflammatory response surrounding the cancer cells is dependent 
on the composition of the inflammatory infiltrate and locally produced signaling 
molecules.5 Although inflammatory cells within the neoplastic lesion are capable of 
generating an anti-tumor response this does not efficiently occur. 6, 7 
Inflammatory cells are attracted to the tumor site by locally produced cytokines and 
chemokines.8, 9 Cervical cancer cells are known to produce an extensive range of 
cytokines and chemokines, such as CCL2, GM-CSF, TNF-α and IL-12.10-12 In addition 
to attracting inflammatory cells, these cytokines and chemokines influence the 
activation status and function of infiltrating antigen presenting cells and stromal 
cells, thus influencing the course of the disease.9, 13 
In a previous study we have shown that high expression levels or undetectable 
levels of IL-12p40 mRNA in cervical carcinoma are associated with an improved 
overall survival compared to low amounts of IL-12p40 that was associated with poor 
survival.14 As IL-12 is known to stimulate effector cell populations such as cytotoxic T 
cells and natural killer cells,15, 16 our results suggest a dual role for IL-12p40. 
The IL-12 cytokine family includes IL-12, IL-23, IL-27 and IL-35.17 From this family 
IL-12 and IL-23 share the IL-12p40 subchain. IL-12 is composed of IL-12p40 and IL-
12p35 whereas IL-23 is composed of IL-12p40 and IL-23p19. IL-23 plays, amongst 
others, an important a role in the IL-17/IL-23 pathway resulting in the maintenance 
and expansion of TH17 cells.
18 In addition to IL-23, IL-1 and IL-6 are thought to play 
an important role in the induction of TH17 cells in humans.
19 The effect of IL-23 on 
cancer progression or cancer eradication is still not clear.20, 21
To further delineate the role of IL-12p40 in cervical carcinoma, we have quantified 
the mRNA expression levels of IL-23p19 and compared its expression level with IL-
12p35 and IL-12p40 to investigate the relative importance of IL-12 and IL-23 in the 
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tumor microenvironment. In addition, we have investigated the role of IL-1 and IL-6 
in the tumor microenvironment by determining both the number of IL-1 positive 
cells and the number of IL-6 positive cells. Finally, we have assessed the association 




Between 1985 and 1995, 254 untreated patients suffering from primary cervical 
carcinoma with stage IB and IIA underwent a radical hysterectomy type III with 
lymphadenectomy. From the tissue obtained, based on the availability of the 
material, 90 tissue samples were accessible for research. Tissues were routinely 
embedded in paraffin after 10% formalin fixation. The tissue samples of each patient 
were examined by a pathologist for the presence of tumor. Tumor percentage varied 
between 20% and 90%, median 60%. The characteristics of the patients are depicted 
in Table 1. Forty-seven patients received postoperative radiotherapy because of 
either tumor positive lymph nodes or the presence of positive risk factors described 
by the Sedlis criteria22(a combination of 2 of the following unfavourable prognostic 
parameters: depth of infiltration ≥ 15 mm (deep stromal invasion; middle or deep 
third), tumor size ≥ 40 mm and presence of vasoinvasion). Human tissue samples 
were used according to the guidelines of the Ethical Committee of the Leiden 
University Medical Center.
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table 1. Summary of clinicopathological features of patients and tumors
Patient and tumor characteristics Outcome N*
Age 45 (mean) 90






Tumor size† < 40 mm 37
≥ 40 mm 26
Depth of infiltration† < 15 mm 58




Sedlis criteria• Positive 28
Negative 52
Parametrial invasion† No 74
Yes 14






* N=number of patients/cervical carcinomas. 
† The number of reported cases is affected by incidental missing cases.
• Sedlis criteria{Sedlis, 1999 2345 /id}: a combination of 2 of the following unfavorable prognostic 
parameters: depth of infiltration ≥15 mm or >2/3 of the cervix, tumor size ≥ 40 mm and presence of 
vasoinvasion. 
‡ Only data for cervical carcinoma samples with a determined HPV type were included. Other subtypes 
included HPV31 (n=2), HPV33 (n=6), HPV35 (n=1), HPV45 (n=3), HPV58 (n=1), HPV59 (n=2), HPV68 (n=1). 
Preparation of IL-12p35, IL-12p40 and IL23p19-probes
RNA was isolated from frozen human spleen using TRIzol® (Invitrogen™, Breda, 
The Netherlands) and first-strand cDNA was synthesized with oligoDT primers and 
Reverse Transcriptase AMV (both Roche Diagnostics, Mannheim, Germany), both 
according to manufacturer’s instructions. Oligonucleotide primers for IL23-p19, IL-
12p35 and IL-12p40 were chosen on the basis of known sequences (Table 2) and 
cDNA encoding for the different cytokines was amplified. A pGEM®-3Zf(+) Vector 
(Promega, Madison, WI) was linearized with SmaI and the PCR products were cloned 
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into the vector. After transferring the vector to E. coli strain Top 10 (Invitrogen Corp., 
San Diego, CA), the plasmids were isolated by using the QIAfilter Maxi KITS protocol 
(QIAGEN, Hilden, Germany). The sequence of the PCR product was confirmed by 
DNA sequencing. Plasmids were linearized with BamH1 and EcoR1 (both Boehringer, 
Mannheim, Germany) in case of IL-12p40, BamH1 and SacI in case of IL-12p35 and 
SacII, SalI and SpeI (Boehringer) in case of IL-23p19 using One-Phor-All Buffer Plus 
(Amersham Biosciences, Roosendaal, The Netherlands). Both strands were translated 
in a digoxigenin (DIG) labeled RNA probe according to manufacturer’s instructions 
(Roche). The concentration of the DIG-labeled sense and antisense RNA probes were 
determined on a 1% agarose gel stained with ethidium bromide (Sigma, St. Louis, 
MO). Probes were stored at -20°C until further use.
rnA-in situ hybridization
The RNA-in	situ hybridization (RISH) was performed as previously described.23, 24 In 
short: 3 μm thick paraffin sections were pre-treated and hybridized with 100 ng/ml 
DIG labeled RNA probe diluted in hybridization mixture containing NaCl and saline-
sodium citrate (SSC; Table 2). Hybridization was allowed for 16 hrs at either 55°C (IL-
23p19) or 42°C (IL-12p35 and IL-12p40), in a humidified chamber. Slides were washed 
30 min in 2x SSC followed by 45 min in 0.1x SSC with 20 mM β-mercaptoethanol 
(Merck, Darmstadt, Germany), both at used hybridization temperature (Table 
2). Subsequently the slides were incubated for 30 min with 2 U/ml ribonuclease 
(RNase) T1 (Roche) in 2x SSC, 1 mM EDTA at 37°C. RNA hybrids were detected using 
subsequently mouse anti-digoxigenin (1:2000, Sigma-Aldrich Chemie, Steinham, 
Germany), rabbit anti-mouse Ig (1:50, DAKO, Glostrup, Denmark) and mouse alkaline 
phosphatase anti-alkaline phosphatase(APAAP; DAKO).10









































































































































































































































Serial sections, 3 μm thick, of formalin-fixed and paraffin-embedded tissue were 
mounted on aminopropylethoxysilane-coated slides. Sections were deparaffinized, 
rehydrated and treated with 0.3% H2O2 in methanol for 20 min to block endogenous 
peroxidase activity. 
Antigen retrieval was performed (0.01 M citrate, pH 6.0) and sections were rinsed 
in phosphate-buffered saline (PBS). Subsequently, sections were stained overnight 
using either a 1:100 dilution of an affinity purified polyclonal goat anti-human IL-1ß 
antibody (AF-201-NA; R&D Systems, Minneapolis, MN) or a 1:300 dilution of anti-
human polyclonal rabbit anti-IL-6 antibody (Abcam, Cambridge, UK). For anti-IL-1 
the slides were incubated with a goat HRP-polymer kit (Biocare Medical, Concord, 
CA) according to the manufacturer’s instructions. For anti-IL-6 the slides were 
incubated with respectively a biotinylated swine anti-rabbit antibody (1:200; DAKO) 
and subsequently incubated with a biotinylated horseradish peroxidase–streptavidin 
complex (1:100; DAKO). Immune complexes were visualized with diaminobenzidine 
as previously described.24
(semi-)quantitative evaluation of risH and immunohistochemistry
RISH was scored as previously described.25 Intensity was scored as none (0), mild (1), 
moderate (2) or intense (3) at low magnification (100x). Furthermore, the percentage 
of positive tumor cells was determined and divided in six groups: 0% (0, absent), 
1-5% (1, sporadic), 6-25% (2, local), 26-50% (3, occasional), 51-75% (4, majority) 
and 76-100% (5, large majority). The sum of both the percentage and the staining 
intensity of the positive cells resulted in an overall score (0 or 2 to 8). The scores were 
combined into three groups: category 0 (score 0, no expression), category 1 (scores 
2, 3, 4 and 5, low expression) and category 2 (scores 6, 7 and 8, high expression). 
mRNA expression was scored by two independent researchers without knowing the 
identity and clinical outcome of patients. IL-1 positive cells and IL-6 positive cells 
were quantified in the tumor by counting the number of stained cells per 6, randomly 
selected, high-power field of view (HPF, 400x). 




Data from immunohistochemistry as well as RISH are given as the mean ± the SD. 
Statistical analysis was done using SPSS 17.0 (SPSS Inc., Chicago, IL). Data were 
processed by using the chi-square test. Kaplan-Meier survival curves were generated 
to assess differences in disease-free period (defined as the observation time in 
months from surgery to relapse of the disease (disease-free survival)) or cumulative 
disease-specific survival (defined as time in months from surgery to death due to 
cervical cancer). A Cox regression was used for multivariate survival analysis. P<0.05 
was considered statistically significant.
results
Patients
Of the group of 90 patients, 68 patients were diagnosed as FIGO stage IB and 21 as 
FIGO stage IIA and all underwent radical hysterectomy combined with pelvic lymph 
adenectomy (Table 1). Forty-seven patients received postoperative radiotherapy 
because of either tumor positive lymph nodes or meeting the terms of the Sedlis 
criteria22 (a combination of 2 of the following unfavorable prognostic parameters: 
depth of infiltration ≥ 15 mm, tumor size ≥ 40 mm and presence of vasoinvasion). 
Twenty five patients suffered from recurrent disease. At the end of the study seventy 
patients were alive, 7 suffered from a recurrence and 18 patients had died of disease.
expression of IL-23p19, IL-12p35 and IL-12p40 in cervical cancer
Since IL-12p40 is both a subunit of IL-12 as well as IL-23, we have determined the 
expression of IL-23p19. Both of IL-23p19 and IL-12p40 were expressed by cervical 
tumor cells (Figure 1A and Figure 1C). The expression of IL-12p40 was stronger than 
the expression of IL-23p19. IL-23p19 was expressed in 63% of the samples (n=54), 
IL-12p40 was expressed in 54% of the samples (n=90) and IL-12p35 was expressed 
in 84% of the samples (n=90; Table 3). All samples that expressed either IL-23p19 
or IL-12p40 also expressed IL-12p35 mRNA. In contrast, 13 out of 44 samples that 
expressed IL-12p40 did not express IL-23p19. 
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figure 1 The expression of IL-23p19, IL-12p40 and IL-6. The expression of IL-23p19 and IL-12p40 were 
determined using RNA-in	 situ hybridization (RISH) and the expression of IL-6 was determined using 
immunohistochemistry as described in the Materials and methods section (magnification, x250). (A) 
Cervical tumor, IL-23p19 RISH. Tumor cells stain positive (moderate) for IL-23p19; (b) Negative (sense) 
control of IL-23p19 RISH; (c) Cervical tumor, IL-12p40 RISH. Tumor cells stain positive (strong) for IL-12p40; 
and (d) Negative (sense) control of IL-12p40 RISH. (e) IL-6 staining of cervical cancer tissue. Both cells in 
the epithelial compartment (EC) as well as cells in the stroma express IL-6. Arrows indicate positive stromal 
cells. Detail (x400, magnification) of IL-6 positive cells in the stroma; and (f) Association between cells in 
the epithelial compartment with low (IL-6 EC low) and high IL-6 (IL-6 EC high) expression and disease-
specific survival. No significant association between low or high IL-6 expression of the epithelial cells with 
disease-specific survival was observed. See	page	193	for	color	figure.
IL-12p40 in cervical cancer
89
4
A positive correlation between IL-23p19 and IL-12p40 was found (n=54, r2=0.117, 
P=0.011; data not shown). No statistically significant correlation between IL-23p19 
and IL-12p35 was found (n=54, r2=0.061, P=0.072; data not shown). 
table 3. Correlation between IL-23p19, IL-12p35 and IL-12p40 expression in cervical carcinoma
 IL-12p35   
Cytokine Expression level Absent Low High Total N* (%)
IL-12p40 Absent 14 21 6 41 (46)
Low      0 14 14 28 (31)
High      0 3 18 21 (23)
Total N* (%) 14 (16) 38 (42) 38 (42) 90 (100)
P-value <0.001
 IL-23p19   
Absent Low High Total N* (%)
IL-12p40 Absent 7 1 2 10 (19)
Low     8 5 11 24 (44)
High      5 4 11 20 (37)
Total N* (%) 20 (37) 10 (19) 24 (44) 54 (100)
P-value 0.188
 IL-23p19   
Absent Low High Total N* (%)
IL-12p35 Absent 1 0 0 1 (2)
Low 8 5 8 21 (39)
High 11 5 16 32 (59)
Total N* (%) 20 (37) 10 (19) 24 (44) 54 (100)
P-value     0.619
*N=number of tumors. The scores were combined into three groups: absent expression, low expression 
and high expression as described in the Materials and methods section. Statistical significant P-values are 
bold.
Association between il-12 and il-23 and disease-specific survival in cervical cancer
To investigate the relationship between the expression of IL-23p19, IL-12p35 and IL-
12p40, and disease-specific survival, Kaplan Meier plots were created. A log-rank 
test was used to determine statistical differences in disease-specific survival. Since 
absence of IL-12p40 will result in neither IL-12 nor IL-23, we first confirmed that 
expression of IL-12p40 was associated with poor disease-specific survival (Figure 2A; 
n=48, log-rank test 5.753, P=0.017) in this cohort. The expression of IL-12p35 (Figure 
2B; n=74, log-rank test 0.2019, P=0.653) and the expression of IL-23p19 (Figure 
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2C; n=33, log-rank test 1.930, P=0.165) were both not significantly associated with 
disease-specific survival. The expression of IL-23p19, IL-12p35 or IL-12p40 showed 
no significant difference in disease-free survival (data not shown). 
figure 2 Association between (A) IL-12p40, (b) IL-12p35 and (c) IL-23p19 expression and disease-specific 
survival in cervical carcinoma. IL-12p40, IL-12p35 and IL-23p19 were determined by RISH as described in 
the Materials and methods section. 
Presence of il-6 positive cells and association with disease-specific survival in 
cervical cancers
The presence of IL-23p19 suggests that IL-23 may sustain a TH17 positive cell 
population in cervical cancer. Since differentiation towards the IL-17/IL-23 pathway 
is thought to occur in the presence of IL-1 and IL-6 in humans,19 we have determined 
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the presence of IL-1 positive cells and IL-6 positive cells, using immunohistochemistry. 
IL-1 was predominantly expressed by cells in the stromal compartment. Occasionally 
tumor cells also showed weak IL-1 expression. No statistical significant association 
between low or high number of IL-1 expressing cells and disease-specific survival 
was observed (Figure 3A). IL-6 was expressed by both cells in the epithelial (tumor 
cell) compartment as well as cells in the stromal compartment (Figure 1E). No 
significant association was observed between low or high IL-6 expression of cells in 
the epithelial compartment and disease-specific survival (Figure 1F). Subsequently, 
we quantified the number of IL-6 positive cells in the stroma. The presence of a high 
number of IL-6 stromal positive cells (median 17 IL-6 positive cells/high powered 
field) significantly associated with disease-specific survival (Figure 3B; n=83, log-rank 
test 12.57, P<0.001). No statistical significant difference was observed for disease-
free survival (data not shown). We also determined whether disease-specific survival 
was associated with the presence of both a high number of IL-6 positive stromal cells 
and low IL-12p40. In this latter case an even stronger decrease in disease-specific 
survival was observed (Figure 3C; n=47, log-rank test 20.38, P<0.001). 
Association between low il-12p40 expression, high number of il-6 positive stromal 
cells and clinicopathological parameters
To determine the relevance of our findings we associated our immunological findings 
with clinicopathological parameters. First a univariate Cox analysis was performed, 
using the clinical parameters, Sedlis criteria (two out of three of the following criteria 
positive: tumor size ≥ 40 mm, vasoinvasion and deep stromal invasion), lymph node 
metastasis and parametrial involvement and the immunological parameters, low IL-
12p40 expression, high number of IL-6 positive cells and high number of IL-6 positive 
cells plus low IL-12p40 expression. In the univariate Cox analyses all the included 
parameters showed a significantly increased hazard ratio (Table 4). Subsequently, 
a multivariate Cox analysis with the three clinicopathological parameters and each 
of the significantly immunological parameters was performed. In this case two of 
the three immunological parameters, high number of IL-6 positive stromal cells 
(P=0.009; HR 7.447) and high number of IL-6 positive stromal cells and low IL-12p40 




figure 3 Association between high number of IL-1 positive cells, high number of IL-6 positive stromal 
cells, low IL-12p40 expression and disease-specific survival. The IL-1 expression and IL-6 expression were 
determined by immunohistochemistry as described in Materials and methods. IL-12p40 was determined 
by RISH as described in the Materials and methods section. 
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table 4. Cox regression of clinicopathological variables and IL-12p40, IL-23 and the number of IL-6-positive 
cells in cervical carcinoma
univariate Hazard ratio 95% ci P-value
Sedlis positive 4.354 1.608-11.789 0.004
Lymph node metastasis 3.266 1.286-8.296 0.013
Parametrial involvement 3.645 1.411-9.411 0.008
Low IL-12p40 5.231 1.156-23.661 0.032
High number of IL-6 cells 8.975 2.063-39.051 0.003
Low number of IL-6 cells Reference
High number of IL-6 cells/low IL-12p40 21.832 2.805-169.915 0.003
Multivariate Hazard ratio 95% ci P-value
Sedlis positive 3.848 1.270-11.663 0.017
Lymph node metastasis 1.333 0.439-4.052 0.612
Parametrial involvement 1.526 0.542-4.444 0.438
High number of IL-6 cells 7.447 1.659-33.432 0.009
Multivariate Hazard ratio 95% ci P-value
Sedlis positive 0.706 0.150-3.310 0.659
Lymph node metastasis 2.887 0.836-9.965 0.094
Parametrial involvement 1.168 0.283-4.822 0.830
Low number of IL-6 cells Reference
High number of IL-6 cells/low IL-12p40 20.123 2.248-180.147 0.007
Shown are the log-rank test and P-value of compared expression levels. 
Statistical significant P-values are bold.
discussion
In a previous study we found an association between low expression of IL-12p40 
and poor disease-specific survival, whereas high expression of IL-12p40 or lack of 
expression of IL-12p40 were associated with a favorable disease-specific survival.14 
Since IL-12p40 combines with both IL-12p35 and IL-23p19, to form IL-12 and IL-23, 
respectively, in the present study, we have further investigated the role of IL-12p40 
in cervical cancer.
Both IL-23p19 and IL-12p35 were expressed in the majority of the samples. Out 
of the 44 samples that expressed IL-12p40, 13 samples did not express IL-23p19. 
Since IL-12p35 expression seems to be ubiquitous in cervical cancer,14 the level of 
IL-12p40 or IL-23p19 expression most probably determines whether IL-12, IL-23 or 
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both are expressed. In our study, we observed a trend (P=0.061; n=54) between IL-
23p19 or IL-12p35 expression, whereas in the study of Wolf et al in ovarian cancer 
(n=112) a significant correlation between the expression of IL-23p19 and IL-12p35 
was found.26 The discrepancy between our results and the results of Wolf et al may 
be due to the smaller size of our study group. Very few studies have investigated 
the association between local expression of IL-12 or IL-23 and prognosis. Using 
immunohistochemistry, IL-12 has been associated with improved survival in patients 
with (advanced) gastric carcinoma.27, 28 In the study of Wolf et al, using RT-PCR, both 
IL-12p35 and IL-23p19 were associated with a superior outcome.26 In a multivariate 
analysis IL-12p35 was found to be an independent factor for overall survival of 
ovarian carcinoma. As stated previously, we have observed a statistically significant 
association between low expression of IL-12p40 and poor disease-specific survival in 
cervical carcinoma.14 In the present study and our previous study,14 we did not find a 
significant association between either IL-23p19 or IL-12p35 expression and disease-
specific survival. Since IL-23p19 and IL-12p35 are both expressed, it is important 
to determine which cytokine, IL-23 or IL-12, has a dominant effect on the tumor 
microenvironment. 
The molecular interaction between IL-23p19 and IL-12p40 has been studied by 
Beyer et al.29 These authors reported that the interface region of IL-23p19 and IL-
12p35 on IL-12p40 overlap. Due to different interresidue interactions of IL-12p35 
and IL-23p19 with IL-12p40, these molecules interact with a different affinity with 
IL-12p40. Therefore the availability of IL-12p40 in combination with the affinity for 
IL-12p35 and IL-23-p19 may result in skewing of the IL-12/IL-23 response. This is 
supported by experiments performed by Zwiers et al. These authors showed that in 
an experimental animal model polymorphic variants of IL-12p40 can skew IL-12/IL-23 
synthesis.30 Thus both differences in protein interactions between IL-23p19 and IL-
12p35 on the one hand and IL-12p40 on the other hand and genetic polymorphisms 
in the protein chains, such as IL-12p40, contribute to the amounts of IL-12 and IL-
23 formed. Our results support a previously suggested immunosuppressive role 
for IL-23.20 This is further supported by a study in ovarian carcinoma were genetic 
differences in the IL-23 receptor have been reported to influence prognosis.31
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In contrast, it has also been shown that overexpression of IL-23 reduces tumor 
growth and metastasis formation and that IL-23 is able tot elicit a strong cytotoxic 
T-cell memory response,21, 32 underscoring our view that the level of expression of the 
different cytokines and chemokines plays an import role in the final outcome. 
Our data suggest that in the presence of a limited amount of IL-12p40 the biological 
effect of IL-23 dominates, whereas in the presence of a high amount of IL-12p40 the 
biological effect of IL-12 prevails. Since IL-12 polarizes the immune response towards 
an anti-viral response,33 the favorable cumulative overall survival of patients with a 
high IL-12 positive cell density,27, 28 high expression level of IL-12p3526 and IL-12p4014 
can be explained by the capacity of this cytokine to increase the lytic activity and 
the production of interferon-γ of natural killer cells and cytotoxic T-lymphocytes.33 
Interestingly, we previously observed an association between high expression of IL-
12p40 and high expression of TGF-β (P=0.024),14 suggesting that the tumor cells are 
selected to counter act the effect of IL-12 or skew the response to the IL-17/IL-23 
pathway.
In humans, in addition to IL-1, IL-6 and TGF-β have been implicated to play a role in 
the IL-17/IL-23 pathway.19, 34 Previously, we have shown that it is likely that activated 
TGF-β is present in the tumor microenvironment, since PAI-1, a target gene of TGF-β, 
is expressed and expression of PAI-1 is associated with survival.35 Furthermore, both 
the integrin αvβ6 and active matrix metalloproteinase-2, known to activate TGF-β, 
are associated with poor disease-specific survival.36, 37 Even though the role of TGF-β 
in inducing TH17 in humans has been questioned, TGF-β may suppress TH1 and TH2 
development thus favoring TH17 development.
38, 39
In our study, low or high numbers of IL-1 positive cells were not associated with 
disease-specific survival. The presence of a high number of IL-6 expressing stromal 
cells was significantly associated with poor disease-specific survival (P<0.001). 
Previously, IL-6 has been implicated as an autocrine or paracrine growth factor for 
cervical cancer.40, 41 IL-6 has been shown to induce VEGF transcription via the STAT3 
signaling pathway, thus promoting an angiogenic switch.42 Indeed, blockade of the 
IL-6 receptor on cervical cancer cell lines was shown to interfere with cell survival 
signals and blocked expression of VEGF.43 
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As HPV vaccines will become available for the treatment of metastasized cervical 
carcinoma, the local cytokine/chemokine profile may be important to discriminate 
patients with a beneficial immune response from non-responding patients.  
In conclusion, IL-12p40 plays at least a dual role in cervical carcinoma by associating 
with both IL-23p19 and IL-12p35. We have shown that low IL-12p40 expression was 
significantly associated with poor disease-specific survival (P=0.017). Also a high 
number of stromal IL-6 producing cells was shown to associate with poor disease-
specific survival (P<0.001). The worst disease-specific survival was observed in a 
subgroup of patients that displayed a high number of stromal IL-6 expressing cells 
and low IL-12p40 expression (P<0.001). Furthermore, both a high number of stromal 
IL-6 expressing cells and a high number of stromal IL-6 plus IL-12p40 expression 
were shown to be independent clinicopathological parameters compared to lymph 
node metastasis, parametrial involvement and Sedlis score (P=0.009 and P=0.022 
respectively). Our results with IL-6 and IL-12p40 are in accordance with the hypothesis 
that the IL-17/IL-23 pathway plays a suppressive role in cervical cancer.
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In this study, we have investigated the role of endoglin (CD105), a regulator of 
transforming growth factor (TGF)-β1 signaling on endothelial cells, basic fibroblast 
growth factor (bFGF) and vascular endothelial growth factor (VEGF)-A in cervical 
cancer. We have measured the number and determined the location of both newly 
formed (CD105-positive) and the overall number of (CD31-positive) blood vessels, and 
bFGF and VEGF-A expression using immunohistochemistry in 30 cervical carcinoma 
specimens. Vascular endothelial growth factor-A mRNA expression was determined 
using RNA-in	 situ hybridization. CD105- and CD31-positive vessels and bFGF- and 
VEGF-A-positive cells were predominantly present in the stroma. The presence 
of CD105- and CD31-positive vessels in the stroma did neither correlate with the 
number of VEGF-A-positive cells nor the number of bFGF-positive cells. However, 
the number of CD105- and CD31-positive vessels was associated with the expression 
of VEGF-A mRNA in the epithelial cell clusters (P=0.013 and P=0.005, respectively). 
The presence of CD105-positive and CD31-positive vessels was associated with the 
expression of αvβ6 (a TGF-β
1 activator; P=0.013 and P=0.006, respectively). Clinically, 
the number of CD105-positive vessels associated with the number of lymph node 
metastasis (P<0.001). Furthermore, the presence of CD105-positive vessels within 
the epithelial cell clusters associated with poor disease-free survival (P=0.007). 




Cervical cancer is the second most common cancer among women worldwide 
and one of the main causes of cancer-related death in the developing countries.1 
The prognosis of patients is, amongst others, dependent on tumor size, lymph 
node metastasis, capillary lymphatic space involvement, infiltration of the tumor 
in the cervix, infiltration of the tumor in the parametria and absence of tumor at 
the surgical margins.2 Cervical tumors are composed of malignant epithelial cells, 
tumor stroma, comprising the tumor vasculature, and an inflammatory infiltrate. A 
significant association between tumor vascular density and poor clinical outcome 
has been reported.3-5 Growth and metastatic capacity of solid tumors depend on 
tumor vascular density and angiogenesis.6, 7 Hypoxia in the centre of the epithelial 
cancer cell nests is thought to be a driving force behind angiogenesis.8 
Tumors promote angiogenesis by secreting factors, like vascular endothelial growth 
factor (VEGF)-A, basic fibroblast growth factor (bFGF)7, 9 and transforming growth 
factor (TGF)-β1. In addition, the presence of an inflammatory infiltrate is thought to 
be of great importance in neovascularisation.10 
A marker for angiogenesis is endoglin.11 Endoglin, designated CD105, is a 90 kDa 
(under reducing conditions) TGF-β type III auxiliary receptor involved in the regulation 
of TGF-β1 signaling in endothelial cells. Overexpression of CD105 inhibits TGF-β/
ALK5 signaling and TGF-β-induced growth inhibition, whereas knockdown of CD105 
inhibits TGF-β/ALK1 signaling and endothelial cell proliferation.12 CD105 is required 
for efficient TGF-β/ALK1 signaling on proliferating endothelial cells.13 In contrast to 
CD31, which is expressed on blood vessels both in normal tissue and in malignant 
lesions, endoglin is found predominantly on peritumoral and intratumoral blood 
vessels. The expression of CD105 on tumor-associated blood vessels makes CD105 a 
potential molecular target for therapy.11 
TGF-β1 plays a dual role in cancer: early in tumor development it acts as a tumor 
suppressor, inhibiting epithelial cell proliferation, whereas late in cancer development 
it suppresses the activity of the immune system and induces regulatory T cells.14 TGF-β1 
also plays an important role in angiogenesis by promoting proliferation and migration 
of endothelial cells at low TGF-β1 concentrations, whereas high concentrations lead 
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to cytostasis and promote vessel maturation.13 Furthermore, TGF-β1 is known to 
induce VEGF expression.15 Earlier, we have reported on the expression of TGF-β1, 
plasminogen activator inhibitor (PAI)-1 and fibronectin (both target gene products of 
TGF-β1) and αvβ6 (activator of TGF-β1) in cervical carcinoma. 
16-18 
In this study, we have expanded our observations on the role of TGF-β1 in cervical 
cancer by measuring the number and determining the location of CD105-positive 
blood vessels. To further analyze the role of endoglin as an TGF-β1 associated 
regulatory molecule in the angiogenic process, we have compared the number 
and location of the newly formed CD105-positive vessels with the number and 
location of CD31-positive blood vessels (total number of blood vessels) and we have 
measured the expression of the pro-angiogenic factors, VEGF-A and bFGF. Finally, the 
clinicopathological relevance of CD105 in cervical carcinoma was assessed. 
MAteriAls And MetHods
Patient material
A total of 30 patients treated with radical abdominal hysterectomy and bilateral 
pelvic lymph node dissection for uterine cervical cancer (Wertheim-Meigs 
procedure) was included in this study. According to the Fédération Internationale 
de Gynécologie et d’Obstétrique (FIGO) staging system for cervical carcinoma19 10 
patients were selected for FIGO stage IIA or more, whereas the other 20 patients 
were randomly selected patients with a FIGO stage IB. Patients had received no 
therapy before surgery. Treatment occurred between 1985 and 1994. Tissues had 
been fixed routinely in 10% v/v formalin and embedded in paraffin. Samples were 
used according to the guidelines of the Ethical Committee of the Leiden University 
Medical Center. The patient characteristics are shown in Table 1.
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table 1. Summary of clinicopathological features of patients and tumors
characteristics of patients and tumors outcome n*
Age 45, mean 30
29 – 72, range
FIGO stage ≤IB 20
≥IIA 10
Lymph node metastasis No 16
Yes 14
Tumor size† <40 mm 16
≥40 mm 12
Infiltration depth† <15 mm 15
≥15 mm 9
Vascular space involvement No 10
Yes 20
Parametrial invasion No 20
Yes 10





* N=number of patients/cervical carcinomas.
† Cases missing.
immunohistochemistry
Immunohistochemical analysis was performed on 3 μm paraffin sections, mounted 
on aminopropylethoxysilane-coated slides. Sections were deparaffinized, rehydrated 
and treated with 0.3% v/v H2O2 in methanol for 20 min to block endogenous 
peroxidase activity. Antigen retrieval was performed, if necessary, and sections were 
rinsed in phosphate-buffered saline (PBS) followed by an incubation with 1% w/v 
bovine serum albumin (BSA) in PBS. Subsequently, sections were stained for CD68,20 
ανβ6,16 fibronectin,18 VEGF-A, bFGF, matrix metalloproteinase (MMP)-2,21 CD31 and 
CD105 (see Table 2 for characteristics of the primary antibodies). All antibodies 
were diluted in 1% BSA in PBS. In case of CD68, ανβ6, bFGF, MMP-2 and CD31 a 
biotinylated secondary rabbit anti-mouse antibody was used (1:200, DAKO, Glostrup, 
Denmark). For VEGF-A, a biotinylated swine anti-rabbit antibody, and for fibronectin, 
biotinylated rabbit anti-goat antibody was used (both 1:400, DAKO). All slides 
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were subsequently incubated with a biotinylated horseradish peroxidase (HRP)-
streptavidin complex (1:100, DAKO) and immune complexes were visualized with 
diaminobenzidine. Staining for CD105 was performed with a CSA Detection System 
(DAKO), according to the manufacturer’s protocol. Negative controls consisted of 
tissue sections where the primary antibody was replaced by an (irrelevant) antibody 
(DAKO) directed against the same isotype as the primary antibody.








ανβ6 2G2 Mouse β6 Citrate
0.01 M
1:2000 on* 4°C Biogen Idec, Cambridge, 
MA
bFGF 6 Mouse bFGF Citrate
0.01 M
1:600 on 4°C BD Biosciences, Franklin 
Lakes, NJ




1:400 on RT Neomarkers, Fremont, 
CA
CD68 KP-1 Mouse Macrophages Trypsin
0.1% w/v
1:1600 on RT† DAKO, Glostrup, 
Denmark
CD105 SN6H Mouse Endoglin None 1:2000 1 h RT DAKO, Glostrup, 
Denmark
Fibronectin Goat Fibronectin Pepsin
0.4% w/v
1:1000 on RT Sigma, St. Louis, MO
MMP-2 CA-4001 Mouse Proform of 
MMP-2
None 1:200 on RT Neomarkers, Fremont, 
CA
VEGF-A Rabbit VEGF-A Pepsin
0.4% w/v
1:100 2 h RT Santa Cruz Biotechnology 
Inc., Santa Cruz, CA
bFGF = basic fibroblast growth factor; MMP-2 = matrix metalloproteinase-2;VEGF-A = vascular endothelial 
growth factor-A. 
*on = overnight
†RT = room temperature
Probe preparation and rnA-in situ hybridization
Oligonucleotide primers were chosen on the basis of known sequences [5’ 
GCCTCCGAAACCATGAACTTT 3’ (sense) and 5’ CCGCATAATCTGCATGGTGAT 3’ 
(antisense)] (Gen Bank accession number GI065522.1). 
Cervical carcinoma sections were stained for VEGF-A mRNA as previously 
described.20 In short: 3 μm paraffin sections were pre-treated and hybridized with 
100 ng/ml digoxigenin (DIG)- labeled RNA probe diluted in hybridization mixture 
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containing 0.3 M NaCl and 0.03 M saline-sodium citrate (SSC). Hybridization was 
allowed for 16 h at 50°C in a humidified chamber. Slides were washed for 30 min 
in 50% v/v formamide/2x SSC at 42°C, followed by 45 min in 0.1x SSC with 20 mM 
β-mercaptoethanol at 50°C and 30 min with 2 U/ml ribonuclease (RNase) T1 (Roche 
Diagnostics, Mannheim, Germany) in 2x SSC, 1 mM EDTA at 37°C. RNA hybrids 
were detected using subsequently mouse anti-digoxigenin (1:2000, Sigma-Aldrich 
Chemie, Steinham, Germany), rabbit anti-mouse Ig (1:50, DAKO) and mouse alkaline 
phosphatase anti-alkaline phosphatase (APAAP, DAKO). The sense probe of each 
antisense VEGF-A mRNA probe served as a negative control. A cervical cancer sample 
stained for TGF-β1 mRNA served as a positive control. 
evaluation of immunohistochemical staining and rnA-in situ hybridization
CD68-, VEGF-A- and bFGF- positive cells were quantitated by counting the number 
of stained cells per five, randomly selected, high-power fields of view (HPF, x400). 
CD68-positive cells at the border of the epithelial-stromal interface were counted 
as present or absent. CD31- and CD105-positive vessels were quantitated by first 
searching for a high density of vessels at low magnification (x200, the so called “hot-
spots”) in the tumor stroma, followed by counting the number of positive vessels in 
five of these hot-spots at high magnification (HPF, x400).22 The presence of CD105-
positive vessels within the epithelial cell clusters or at the epithelial-stroma interface, 
were counted as present or absent. Fibronectin was scored at the epithelial-stroma 
interface as described by Havenith et al,23 dividing the immunoreactivity in either 
<75% immunoreactivity or >75% immunoreactivity. 
The staining of VEGF-A mRNA as well as VEGF-A protein, PAI-1, MMP-2 and ανβ6 
in the tumor cells was scored as described earlier.24 Intensity was scored as none 
(0), weak (1), moderate (2) or strong (3) at low magnification (x100). Furthermore, 
the percentage of positive tumor cells was determined and divided into groups, 
numbered from 0 to 5: 0% (0, absent), 1% to 5% (1, sporadic), 6% to 25% (2, local), 
26% to 50% (3, occasional), 51% to 75% (4, majority) and 76% to 100% (5, large 
majority). The two parameters were combined, representing the sum of both the 
percentage and the staining intensity of the positive cells, resulting in an overall 
score (0 or 2-8). Owing to low expression of VEGF-A, the scores were combined into 
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two groups: category 0 (score 0, no expression) and category 1 (score 2-8, expression 
present). Expression was scored by two independent researchers without knowing 
the identity and clinical outcome of patients. 
statistical analysis
Data from immunohistochemistry as well as RNA-in	situ	hybridization are given as 
the mean ± the standard deviation (SD). Statistical analysis was performed using 
SPSS 14.0 (SPSS Inc., Chicago, IL). Data were processed by using a chi-square test, 
the Mann-Whitney U-test or the Fisher’s exact test, depending on number and 
distribution of the compared groups. Kaplan-Meier survival curves were generated to 
assess differences in disease-free survival (defined as the observation time in months 
from surgery to relapse of the disease) or cumulative overall survival (defined as time 
in months from surgery to death owing to cervical cancer). P<0.05 was considered 
statistically significant.
results
number and location of cd105- and cd31-positive blood vessels 
First, we have investigated the relationship between the number and location 
of (newly formed) blood vessels, using anti-CD105 and anti-CD31 (providing an 
estimate of the total number of blood vessels) monoclonal antibodies (Figure 1A 
and 1B, respectively). The number of newly formed stromal CD105-positive vessels 
(mean 5 ± 1) was lower than the number of stromal CD31-positive vessels (mean 9 ± 
1). The number of CD105-positive vessels ranged from 0 to 20, whereas the number 
of CD31-positive vessels ranged from 2 to 23. In 8 out of 30 cases CD105-positive 
vessels were located within the epithelial cell clusters, whereas in 18 out 30 cases 
CD31-positive vessels were observed within these clusters. There was a significant 
correlation between the expression of CD105- and CD31-positive vessels in the 
stroma (r2=0.747, P<0.001; Figure 2). 
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number and location of veGf-A and bfGf-positive cells 
Subsequently, we have investigated the number and location of bFGF- and VEGF-A-
positive cells (Figure 1C and 1D, respectively). Basic fibroblast growth factor-positive 
cells were predominantly observed in the stroma. The number of bFGF-positive cells 
ranged from 0 to 71 (mean 24 ± 5). Only 3 out of 30 cases showed bFGF expression 
within the epithelial cell nests. These cells were mainly located at the epithelial-
stromal interface. Another 6 tumors showed bFGF positive cells within the necrotic 
centers of epithelial nests, whereas tumor cells showed a negative staining. VEGF-A 
was both measured at the protein level using immunohistochemistry and at the 
mRNA level using RNA-in	situ hybridization (Figure 1E). VEGF-A positive cells were 
mainly observed in the stroma. The number of VEGF-A positive cells ranged from 0 
to 77 (mean 11 ± 3). Weak VEGF-A protein expression was observed throughout the 
epithelial cell clusters with an increased intensity at the epithelial-stromal interface 
(16 out of 30 cases; Figure 1D). In addition, VEGF-A (mRNA) expression was observed 
in the epithelial cell clusters (14 out of 30 cases). Expression of VEGF-A (mRNA) within 
the epithelial cell clusters did not correlate with VEGF-A protein expression within 
the epithelial cell clusters, but did associate with the number of VEGF-A positive cells 
in the stroma (P=0.048, Figure 3A). 
Association between blood vessels, bfGf and veGf-A
No significant association between the presence of CD105-positive vessels in the 
tumor or the total number of CD105-positive and CD31-positive vessels in the stroma, 
and the number of bFGF- or VEGF-A-positive cells in the stroma was observed (data 
not shown). However, both the number of CD105-positive and the number of CD31-
positive vessels in the stroma associated significantly with expression of VEGF-A 
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figure 1. Expression and location of CD105- and CD31- positive vessels, bFGF, VEGF-A fibronectin, αvβ6, 
PAI-1 and CD68-positive cells. 
Expression and location of CD105- and CD31- positive vessels, bFGF and VEGF-A were determined using 
immunohistochemistry as well as RNA-in	situ hybridization (RISH) as described in Materials and methods 
section (magnification, x125). (A) CD105 vascular staining, (A1) Detail (magnification, x400) of vessels 
present in the tumor stroma as well as in the epithelial cell clusters. (b) CD31 vascular staining, (b1) detail 
(magnification, x400) of vessels present in the tumor stroma as well as in the epithelial cell clusters. (c) 
bFGF, positive staining of the border of the epithelial cell clusters and cells in the stromal compartment. 
(d) VEGF-A immunohistochemical staining with increased positive staining of the borders of the epithelial 
cell clusters, (d1) detail (magnification, x400) of VEGF-A positive stromal cells. (e) VEGF-A RISH with weak 
cytoplasmic staining of the epithelial cell clusters. (f) Negative (sense) control of VEGF-A RISH. Expression 
and location of fibronectin, αvβ6, PAI-1 and CD68-positive cells (magnification, x400). (G) fibronectin, 
positive staining (>75%) of the stromal compartment. (H) αvβ6, positive staining (strong intensity; of the 
border) of the epithelial cell clusters. (i) PAI-1, positive staining of the epithelial cell clusters. (J) Positive 
































figure 2. Correlation between CD105- and CD31-positive vessels.
Number of stromal CD105- and CD31-positive vessels was determined using immunohistochemistry as 



















































































































































































































































figure 3. Association between VEGF-A (mRNA) expression measured in the epithelial cell clusters and the 
number of VEGF-A positive cells and blood vessels.
(A) Correlation between VEGF-A (mRNA) expression measured in the epithelial cell clusters and the 
number of VEGF-A positive cells (Mann-Whitney U-test, P=0.048) in tumor stromal compartment; (b) 
Correlation between VEGF-A (mRNA) expression measured in the epithelial cell clusters and the number 
of stromal CD105-positive vessels (Mann-Whitney U-test, P=0.013); (c) Correlation between VEGF-A 
(mRNA) expression measured in the epithelial cell clusters and the number of stromal CD31-positive 
vessels (Mann-Whitney U-test, P=0.005). 
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Association between blood vessels and tumor-associated macrophages
As angiogenic factors are also produced by tumor-associated macrophages (TAM), 
we have enumerated the number of CD68-positive cells25 and correlated their 
number with the number of CD105- and CD31-positive stromal vessels. The presence 
of CD105-positive vessels in the tumor was significantly associated with total (stroma 
and epithelial cell clusters) number of CD68-positive cells (P=0.004; Figure 4A). 
However, the number of CD105-positive vessels in the stroma was not significantly 
correlated with the total number of CD68-positive cells. In addition, there was a 
significant correlation between the number of CD31-positive vessels in the stroma 

















































































































figure 4. Association between tumor-associated macrophages and blood vessels.
(A) Association between the number of total (stroma and epithelial cell clusters) tumor-associated 
macrophages and the presence of CD105-positive vessels (Mann-Whitney U-test, P=0.004); (b) Correlation 
between the total number of tumor-associated macrophages and the number of stromal CD31-positive 
vessels (Pearson, r2=0.150, P=0.034).
Association between blood vessels and tGf-β1 target gene products PAi-1 and 
fibronectin and the tGf-β1 activator ανβ6 
To explore the role of TGF-β1 in the generation of CD105-positive vessels both the 
presence of CD105-positive blood vessels in the epithelial cell clusters and the 
number of blood vessels in the stroma were associated with the presence of PAI-1 
in the epithelial cell clusters17 and the amount of fibronectin in the stroma,18 both 
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target genes of TGF-β1. Neither the presence of CD105-positive vessels within the 
epithelial cell clusters nor the number of stromal CD105-positive vessels associated 
significantly with PAI-1 expression (data not shown). However, an association 
between the number of stromal CD31-positive vessels and high levels of fibronectin 
(>75%) was found (P=0.038; data not shown). Furthermore, a significant association 
between the number of stromal CD31-positive vessels and moderate or strong 
staining intensity (vs no or weak staining intensity at the epithelial-stromal interface) 
of ανβ6 was observed (P=0.006; Figure 5B). Although a difference between the 
number of stromal CD105-positive vessels and moderate or strong staining intensity 
(vs no or weak staining intensity at the epithelial-stromal interface) of ανβ6 was 
observed (Figure 5A), this difference was not significant (P=0.053). In addition, an 
association between the total number of TAM and ανβ6 staining intensity was found 
(P=0.002; Figure 5C). 
Association between blood vessels and clinicopathological parameters
Finally, we have associated both the presence of CD105-positive blood vessels within 
the epithelial cell clusters and the number of stromal CD105- or CD31-positive blood 
vessels with the FIGO stage, lymph node metastasis, tumor size, infiltration depth, 
vascular space involvement, parametrial invasion, human papilloma virus (HPV) 
status and histology. No significant associations were found between the majority 
of these parameters and the presence of CD105-positive blood vessels within the 
epithelial cell clusters or the number of stromal blood vessels. Only the presence 
of CD31-positive vessels in the epithelial cell clusters associated significantly with 
vascular space involvement (Fisher’s exact test, P=0.021). 
The number of both CD105- and CD31-positive stromal vessels was significantly 
associated with the presence of positive lymph nodes (P=0.005 and P=0.011, 
respectively).
In addition, the number of CD105-positive stromal vessels was significantly 
associated with the number of positive lymph nodes (P<0.001; Figure 6A). Finally, 
the presence of CD105-positive vessels within the epithelial cell clusters showed a 
negative relationship with disease-free survival (Figure 6C; P=0.007). Sample size was 
too small to calculate whether or not this is an independent prognostic variable. 



















































































figure 5. Association between αvβ6 expression and CD31-positive vessels and tumor-associated 
macrophages.
(A) Association between the presence of moderate/strong αvβ6 intensity and the number of stromal 
CD105-positive vessels (Mann-Whitney U-test, P=0.053); (b) Association between the presence of 
moderate/strong αvβ6 intensity and the number of stromal CD31-positive vessels (Mann-Whitney U-test, 
P=0.006); (c) Association between the presence of moderate/strong αvβ6 intensity and the total number 
of tumor-associated macrophages (Mann-Whitney U-test, P=0.002).
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figure 6. Association between CD105-positive vessels, the number of positive lymph nodes and survival.
(A) Correlation between the number of stromal CD105 positive vessels and the number of positive lymph 
nodes (r2=0.615; P<0.001); (b) Overall survival (Kaplan-Meier, Log-rank 1.55, P=0.214); (c) Disease-
free survival (Kaplan-Meier, log-rank 7.28, P=0.007), both stratified by presence of CD105-positive 
vessels within the epithelial cell clusters of cervical carcinoma. CD105 absent in epithelial cell clusters is 
represented as the curve with a circle, CD105 present in epithelial cell clusters is represented by a square.




In this study, we have investigated the role of endoglin (CD105), a regulator of TGF-β1 
signaling on endothelial cells, bFGF and VEGF-A expression in 30 cervical carcinoma 
specimens. Most vessels were detected in the stroma as could be expected, as a pre-
existing vascular network is necessary for developing new vessels.26 Only one recent 
study has reported on the expression of CD105 in cervical cancer.27 In agreement with 
this study, we also observed a positive correlation between the number of (newly 
formed) CD105- and (total number) CD31-positive vessels. In addition, we observed 
both CD105- and CD31-positive vessels within the epithelial cancer cell clusters. As 
blood vessels originate from the vasculature in the stroma, we assume that these 
vessels are embedded in a thin layer of stroma and surrounded by epithelial cancer 
cells.
Subsequently, we have assessed the association between the number of CD105-
vessels and bFGF- and VEGF-A expressing cells. We did not observe an association 
between bFGF-expressing cells with the number of CD105 (or CD31)-positive vessels. 
An increase in bFGF mRNA expression has been reported during cervical tumor 
development,28, 29 whereas a decrease in bFGF mRNA expression was reported in the 
study of Soufla et al.30 To our knowledge, our study is the first study on bFGF-expressing 
cells in cervical carcinoma at the protein level using immunohistochemistry. Our 
study confirmed the absence of a statistical significant association between bFGF 
and VEGF-A expression in cervical cancer (data not shown) as earlier shown by Van 
Trappen et al using PCR-analysis.29
A negative association between VEGF-A protein expression and microvessel density, 
was reported by Tjalma et al in a study comprising 152 cervical carcinoma patients.31 
In our study, we did not find an association between either the number of CD105 
(or CD31)-positive vessels (microvessel density) and VEGF-A protein expression. 
In contrast to the study of Tjalma et al, in our study we have also determined 
the presence of VEGF-A mRNA expressing cells. We were able to show a positive 
association between expression of VEGF-A mRNA and both CD105 expression 
and CD31 expression, suggesting that expression of VEGF-A mRNA is positively 
associated with microvessel density. The associations remained significant even 
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after a Bonferroni’s correction for multiple testing by a factor 3. The presence of 
VEGF-A mRNA only detectable in the centre of the epithelial cell clusters, suggests 
that this is caused by hypoxia.32 Although VEGF-A is considered to be one of the most 
important factors involved in angiogenesis,26 surprisingly VEGF-A protein present 
at the epithelial-stromal interface did not correlate with the number of CD105 (or 
CD31)-positive vessels. This might be explained by consumption of VEGF-A protein 
by target cells. 
The role of TAM in pressing an angiogenic switch has been highlighted by Lin and 
Pollard,33 suggesting that TAM significantly contribute to angiogenesis. TAM are 
known to contain many proangiogenic factors, such as VEGF,34 TNF -α,35 CXCL-8,36 
bFGF,37 and proteases such as MMP-2 and MMP-9.38 These MMP are able to free pro-
angiogenic cytokines, such as TGF-β1 and VEGF-A, from the matrix. Indeed, we could 
show a positive association between the presence of CD105-positive vessels in the 
tumor, the stromal number of CD31-positive vessels and the total number of TAM. 
In contrast, an earlier study by Davidson et al, using CD31 as a vessel marker did not 
find this association.39 Our results suggest that the presence of TAM is associated 
with neo-angiogenesis. However, there was no significant relationship between the 
number of VEGF-A-positive cells in stroma or VEGF-A protein in the epithelial cancer 
cell clusters and the number of TAM. This suggests that other factors in addition 
to VEGF-A contribute to angiogenesis. These factors may be induced by cytokines 
from TAM or liberated from the extracellular matrix by MMP derived from TAM. In 
addition, we did not observe a significant association between MMP-2 expressed at 
the border between the epithelial cancer cells and VEGF-A protein.21 
TGF-β1 plays an important role in angiogenesis, by promoting proliferation and 
migration of endothelial cells or promoting vessel maturation.13 Furthermore, TGF-β1 
is known to induce VEGF expression.15 We did not observe an association between the 
presence or the number of CD105-positive vessels and PAI-1, fibronectin (surrogate 
markers of TGF-β1 activity), ανβ6 and MMP-2 (activators of TGF-β1) expression. 
However, the total number of (CD31-positive) vessels correlated with the expression 
of ανβ6. In addition, ανβ6 correlated significantly with the amount of fibronectin 
(P=0.037, data not shown), which is one of the factors that supports blood vessel 
growth.16 Interestingly, ανβ6 is also known to upregulate MMP-9 expression and thus 
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may also contribute to the release of VEGF-A from the extracellular matrix.40 
On the basis of all our findings, we suggest that TGF-β1 also plays a central role in 
the progression of cervical carcinoma (Figure 7). Latent TGF-β1 is produced amongst 
others by cervical cancer cells, secreted and stored in the extracellular matrix. This 
TGF-β1 is then processed by either the epithelial cell specific integrin ανβ6
16, 41 or 
by MMP, especially active MMP-221 in complex with MMP-14 and tissue inhibitor 
of metallo proteinase (TIMP)-2 on the cell membrane of cervical cancer cells at 
the epithelial cell-stroma border. Active TGF-β1 can induce VEGF in the epithelial 
cancer cells and differentiates fibroblasts surrounding the epithelial cancer cells into 
myofibroblasts. Furthermore, active TGF-β1, depending on the local concentration, 
either promotes endothelial proliferation and migration or promotes cytostasis 
and vessel maturation. In addition, active TGF-β1 acts as an immunosuppressor by 
blocking the activity of the inflammatory cells and inducing FoxP3-positive regulatory 
cells42 and TH17 cells.
43 
The prognostic value of CD105 and CD31 has been assessed earlier in breast, colon 
and ovarian carcinomas.44-47 High expression of CD105 correlated with increased 
risk of metastasis in lymph node-positive breast carcinoma patients.45 In this latter 
study, CD105 was shown to have an improved predictive value compared with CD31. 
In agreement with this study, in cervical carcinoma we observed an association 
between the number of CD105-positive vessels and the number of positive lymph 
nodes. With respect to survival, only the presence of newly formed vessels (CD105) 
within the epithelial cell clusters was correlated with a poor disease-free survival. 
Our study suggests that the presence of CD105-positive vessels in the epithelial 
cell clusters may be of use as a (poor) prognostic factor in cervical carcinoma. This 
is important as CD105 has been proposed as a marker of tumor vasculature and a 
potential target for therapy of cervical carcinoma.11
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figure 7 Role of TGF-β1 in cervical cancer. 
Cervical tumors are composed of malignant epithelial cells, tumor stroma, comprising the tumor 
vasculature extra cellular matrix and (myo)fibroblasts, and an inflammatory infiltrate. Latent TGF-β1 is 
produced amongst others by cervical cancer cells, secreted and stored in the extracellular matrix. TGF-β1 
can be activated by the epithelial cell specific integrin ανβ6 or by matrix metalloproteinases (MMP), 
especially active MMP-2 in complex with MMP-14 and TIMP-2 on the cell membrane of cervical cancer 
cells at the epithelial cell-stroma border. Active TGF-β1 induces VEGF in the epithelial cancer cells and 
differentiates fibroblasts into myofibroblasts. Depending on the local concentration, active TGF-β1, 
promotes endothelial proliferation and migration or promotes cytostasis and vessel maturation. Active 
TGF-β1 acts as an immunosuppressor by blocking the activity of the inflammatory cells and inducing 
FoxP3-positive regulatory cells and TH17 cells. See	page	196	for	color	figure.
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Overexpression of matrilysin (MMP-7) is predominantly associated with epithelial 
(pre)malignant cells. In the present study MMP-7 expression is also found in 
endothelial cells in various human cancer types. Endothelial MMP-7 was associated 
with CD34 and/or CD105 expression. These immunohistochemical data were 
confirmed by RT-PCR on VEGF-stimulated endothelial cells. In addition, MMP-7 was 
also identified in sprouting endothelial cells in vitro. The potential clinical relevance 
of endothelial MMP-7 was assessed for cervical cancer patients by evaluating the 
association with overall survival. In contrast to MMP-7 in malignant epithelial cells, 
MMP-7 expression in endothelial cells showed a significant association with poor 
survival (log-rank 5.12, P=0.02, n=30). Our data suggest that MMP-7 is involved in 
tumor angiogenesis, thereby contributing to malignant growth and hence associated 
with decreased survival. 




Matrilysin (matrix metalloproteinase-7, MMP-7) has long been regarded as the 
MMP exclusively produced by epithelial cells. Up-regulation of epithelial MMP-7 in 
early stage tumors is a consequence of mutations in the Wnt-signaling pathway.1 
In later tumor stages, hypoxia contributes to the induction of MMP-7 expression.2 
Only few non-epithelial cell types have been described to express MMP-7 in vivo. 
The first indication for MMP-7 production by endothelial cells in tumor tissue came 
from Nagashima et al,3 but this important finding has never been confirmed. We 
evaluated the presence and the role of MMP-7 in endothelial cells in cancer. First, 
we investigated MMP-7 expression in endothelial cells within various tumor types 
in relation to co-expression with pan-endothelial marker CD34 and proliferating 
endothelium associated marker CD105.4 Secondly, using real time (RT)-PCR, we 
determined whether VEGF, the classical initiator of angiogenesis, was able to induce 
MMP-7 expression in sprouting endothelial cells in vitro. In addition, we determined 
the effect of an MMP inhibitor on sprouting endothelial cells, in which MMP-7, 
either directly or indirectly, could be involved. Finally, to evaluate a potential clinical 
implication, we assessed the association between MMP-7 expression in tumor 
endothelial cells and survival of cervical cancer patients.
MAteriAl And MetHods
Patient material
A total of 254 patients with untreated primary cervical carcinoma underwent a 
radical hysterectomy type III with lymphadenectomy between 1985 and 1995. Tissue 
samples were fixed in 10% formalin and embedded in paraffin. Samples from 30 
patients were included in this study: mean age 45 years (range 29-72); FIGO stage: 
(20), IIA (8), IIB/IIIB (2); lymph node metastases: No (16), Yes (14); distant metastases: 
No (13), Yes (17); tumor size: <40 mm (16), ≥40 mm (12); infiltration depth <15 mm 
(15), ≥15 mm (9); vascular space involvement: No (10), Yes (20); parametrial invasion: 
No (20), Yes (10); HPV status: 16/18 (19), other types (6); tumor classification: 
squamous cell carcinoma (25), adenocarcinoma (1), adenosquamous carcinoma 
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(4). In addition, formalin-fixed, paraffin-embedded tissue blocks from patients with 
breast (n=5), stomach (n=5), colon (n=5), and prostate cancer (n=5) were used. 
Human samples were used according to the guidelines of the ethical committee of 
the Leiden University Medical Center.
cells, chemicals and antibodies
Human umbilical vein endothelial cells (HUVEC) were isolated.5 Cells from passage 3 
to 6 were grown in M199 medium (Invitrogen, Breda, The Netherlands) containing 
20% heat inactivated Fetal Calf Serum (FCS) (Perbio Science, Etten-Leur, The 
Netherlands), 0.05 mg/ml heparin, 2 mM Glutamine, 100 U/ml Penicillin, 100 µg/
ml Streptomycin (Invitrogen) and 12.5 μg/ml Endothelial Cell Growth Supplement 
(Sigma-Aldrich Chemie, Steinham, Germany) in fibronectin coated culture flasks 
(0.05 mg/ml). Human recombinant VEGF165 was from Calbiochem (Calbiochem, San 
Diego, CA). Antibodies: MMP-7 [clone 111433, IgG2B mouse monoclonal detecting 
pro and active MMP-7 (R&D systems, Abingdon, UK)], monoclonal antibody (MAb) 
directed against CD34 (Invitrogen), MAb CD105 (DAKO, Glostrup, Denmark).
immunohistochemistry
Paraffin sections were stained as previously described.6 Deparaffinized and rehydrated 
4 μm sections were quenched for endogenous peroxidase with 0.3% H2O2 in methanol 
before overnight incubation with primary antibodies diluted in PBA [phosphate-
buffered saline (PBS), 1% bovine serum albumin (BSA)]. Biotinylated rabbit anti-
mouse immunoglobulin followed by horseradish peroxidase (HRP)-streptavidin 
complex (both DAKO) were applied for 30 min each. Immune complexes were 
visualized using 0.05% diaminobenzidine (DAB, Sigma-Aldrich Chemie), containing 
0.0038% H2O2 in 0.05 M Tris-HCl buffer (pH 7.6) resulting in brown precipitate or 
alternatively Nova Red (Vector Laboratories, Burlingame, CA) resulting in red 
staining, and counterstained with Mayer’s hematoxylin. Citrate antigen retrieval was 
used when indicated by the manufacturer. Appropriate tissue sections were included 
as positive controls and incubation with PBA without primary antibodies served as 
negative controls. MMP-7 staining in tumor and endothelial cells was independently 
scored by 2 individuals, integrating the percentage of cells stained and the intensity 
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of staining in a total score ranging from 0 to 8.6 A score from 0-4 was considered as 
low and 5-8 as high.
rnA isolation and real-time rt-Pcr
Total RNA was isolated from HUVEC cultured on fibronectin, gelatin or collagen I 
coated 6 well plates with or without 100 ng VEGF per well, using the RNeasy Mini kit 
(Qiagen, Hilden, Germany). Reverse transcriptase PCR was carried out in 1 µg RNA 
using random primers and a cDNA synthesis kit (Promega, Leiden, The Netherlands). 
MMP-7 expression was quantified using real-time quantitative PCR according to 
the TaqMan method (Applied Biosystems, Weiterstadt, Germany) with GAPDH 
as endogenous housekeeping gene.7 Double-stranded MMP-7 cDNA was used as 
positive control.
sprouting assay
Endothelial spheroids were prepared from HUVEC8, 9 in complete M199 medium 
containing 0.1% carboxymethylcellulose (Sigma-Aldrich) and 20% FCS, and seeded 
into non-adherent round bottom 96 well plates. After 24 h the spheroids were 
embedded in 1 mg/ml collagen matrix (Vitrogen 100; Nutacon, Leimuiden, The 
Netherlands) containing 20% FCS and treated with or without 100 ng/ml VEGF in 
complete M199 medium. Sprout-formation started after 3 h. Following overnight 
incubation, the spheroids containing collagen matrix were fixed in formalin and 
embedded in paraffin for immunohistochemical analysis.
MMP-7 activity assay
MMP-7 activity in cell culture media was determined using a recently developed 
immunocapture-based activity assay.10
immunoblot
Samples were analyzed on 15% SDS-PAGE under non-reducing conditions. Proteins 
were transferred to a nitrocellulose membrane (Whatman, Dassel, Germany). 
Blots were washed with PBST [PBS containing 0.05% Tween-20 (Merck, Darmstadt, 
Germany)] 3 times for 5 min. Non-specific binding was blocked with 0.2 % gelatin in 
Chapter 6
128
PBST for 30 min at room temperature. MMP was detected by incubation with anti-
MMP-7 antibody (IgG2B mouse monoclonal antibody, R&D), followed by biotinylated 
goat-anti-mouse antibodies and Streptavidin-HRP (both DAKO). Coloration was 
performed using DAB.
statistical analysis
Spearman correlations between parameters, survival curves, log-rank analyses and 
multivariate Cox analyses were performed using the SPSS 10.0 software package 
(SPSS Inc., Chicago, IL). P values ≤0.05 were considered significant.
results
Representative stainings of MMP-7 in endothelial cells in respectively stomach, colon, 
breast, cervix, and prostate cancer tissue is shown in Figure 1A-E. The unexpected 
staining of MMP-7 in endothelial cells was confirmed using three other anti-MMP-7 
antibodies with similar results [rabbit polyclonal RP1MMP-7 (Triple Point biologics, 
Forest Grove, OR), rabbit polyclonal anti-MMP-7 (Abgent, Oxfordshire, UK) and goat 
polyclonal anti-MMP-7 (R&D)], data not shown. The presence of MMP-7 expression 
in endothelial cells was associated with co-staining for CD34 and CD105 in sequential 
sections from the same tissue, suggesting that these cells were of neo-angiogenic 
origin (Figure 1). MMP-7 expression in endothelial cells was in general less intense 
than expression in epithelial cells. MMP-7 staining in endothelial cells did not correlate 
with the expression in epithelial cells in the same sections (r2=0.069, P=0.716, n=50).




figure 1. Immunohistochemical staining of endothelial cells for MMP-7, indicated by arrows in gastric 
cancer (A), colonic cancer (b), breast cancer (c), cervical cancer (d), prostate cancer (e), and in in vitro 
sprouting HUVEC cells (f). Inserts I and II indicate respectively CD34 and CD105 staining in sequential 
section from the same tissue. The inserts in (f) show VEGF-induced endothelial cell sprouting in control 
and Marimastat-treated HUVEC spheroids. Arrowheads indicate epithelial cell staining. Bars correspond 
with 100 μm in (A-e) and with 300 μm in (f). See	page	197	for	color	figure.
MMP-7 expression is not expected to be present in endothelial cells. Therefore, we first 
demonstrated that endothelial cells are indeed able to express MMP-7 by evaluating 
MMP-7 mRNA levels in HUVEC. Unstimulated HUVEC, cultured on fibronectin, did 
not express detectable quantities of MMP-7 mRNA (>40 cycles of RT-PCR). However, 
when grown on gelatin or collagen type I, HUVEC did express MMP-7 mRNA, and 
VEGF stimulation up-regulated MMP-7 mRNA expression more than 3-fold after 16 
h (comparative Ct method: dCt 11.84 versus 10.43 respectively). Longer periods of 
VEGF stimulation resulted in decreasing levels of MMP-7 mRNA. Increased mRNA 
levels were reflected by the MMP-7 level in the conditioned medium. Serum-free 
medium from VEGF-stimulated HUVEC contained a similar level of MMP-7 as found 
in HT-29 colon cancer cell medium as quantified by a specific MMP-7 activity assay 
(24 versus 15 ng/ml respectively) and illustrated on the immunoblot in Figure 2 in 







figure 2. Immunoblot staining MMP-7 in endothelial cells and culture medium.
rec: recombinant active MMP-7; hom: homogenates of HUVEC grown on collagen type I and treated with 
100 ng/ml VEGF; med: serum-free culture medium of HUVEC treated with VEGF. Arrows indicate presence 
of active (18 kDa) and pro-form (28 kDa) of MMP-7.
Subsequently, we used a 3-dimensional in vitro endothelial cell sprouting model to 
confirm our immunohistochemical and cell culture data. Figure 1F shows the presence 
of MMP-7 in VEGF-treated sprouting HUVEC. As expected, these cells stained also for 
CD105. Without VEGF stimulation HUVEC did not form sprouts and also stained less 
intense for MMP-7 and CD105 (data not shown). Addition of 1μg/ml Marimastat, a 
broad-range MMP inhibitor, prevented VEGF-mediated sprout formation completely 
(insert Figure 1F), suggesting the involvement of MMP activity in tumor angiogenesis.
We evaluated the relation of MMP-7 expression in endothelial cells as well as cancer 
cells from the 30 cervical cancer patients with the clinicopathological parameters 
described in the Materials and methods section. None of these parameters were 
significantly correlated with MMP-7, except for the expression in endothelial 
cells with survival [low (score 0-4) versus high (score 5-8), log-rank 5.12, P=0.02, 
Figure 3A]. MMP-7 expression in tumor cells of these patients was not correlated 
with survival (log-rank 1.91, P=0.17, Figure 3B). In multivariate analysis against all 
the clinicopathological parameters all the univariate significant parameters, i.e. 
endothelial MMP-7 staining, FIGO stage, infiltration depth, and parametrial invasion 
lost their statistical significance due to the clinicopathological parameter distant 
metastasis (17 of 18 deceased patients had distant metastasis).
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
figure 3. Kaplan-Meier survival curves for cervical cancer patients stratified for low (score 0-4) and high 
(score 5-8) MMP-7 immunohistochemical staining.
(A) MMP-7 in endothelial cells (log-rank 5.12, P=0.02). (b) MMP-7 in cancer cells (log-rank 1.91, P=0.17).
discussion
Previously, MMP-7 has been found in early adenoma epithelial cells, in malignant cells 
at the invasive front, and in colon-derived liver metastases.11, 12 MMP-7 staining was 
also demonstrated in colonic endothelial cells adjacent to MMP-7 positive malignant 
epithelial cells, without detectable MMP-7 mRNA levels in endothelial cells.3 Our 
results show the presence of MMP-7 in angiogenic endothelial cells in various 
cancer types. Endothelial MMP-7 expression was not dependent on the proximity of 
malignant MMP-7 expressing epithelial cells, suggesting an endogenous endothelial 
origin. RT-PCR data indicated that endothelial cells under angiogenic conditions are 
indeed able to express MMP-7. Moreover, we have shown that under conditions 
closely resembling the in vivo neo-angiogenic process, MMP-7 up-regulation in 
endothelial cells coincides with sprout formation. Addition of Marimastat, a broad-
range MMP inhibitor, prevented sprout formation completely without affecting 
cell viability. This suggests that endothelial cell-derived MMP are involved in neo-
angiogenesis. From all MMP, especially MMP-7 could be of key importance in cancer, 
because it acts locally due to its cell membrane-adhering properties, secondly 
because it is able to activate other pro-MMP like MMP-2, -8 and -9, and thirdly 
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because of its capacity to release/cleave other important bioactive molecules.13 The 
importance of MMP-7 in angiogenesis was underlined by the clinical data from our 
study, showing an association between endothelial MMP-7 expression and decreased 
survival in cervical cancer patients. Multivariate analysis did not reveal endothelial 
MMP-7 staining as an independent prognostic marker against clinicopathological 
parameters, but this was probably due to the strength of one of these parameters 
in this small population: 17 of the 18 deceased patients had a distant metastasis. 
Support for endothelial MMP-7 as a prognostic indicator was recently provided by a 
study in 156 renal cell cancer patients.14
In conclusion, MMP-7 expression was demonstrated in endothelial cells of various 
tumors and was associated with decreased survival in a cohort of cervical carcinoma 
patients. Considering the role of MMP-7 as local activator of proteinases and other 
biologically active proteins, specific inhibition of MMP-7 could contribute to inhibition 
of angiogenesis and anti-cancer therapy in general.
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Cervical carcinoma is the second most frequent cancer type in women worldwide. 
Both inflammatory cells and stromal cells are important for tumor progression. 
Stromal cells produce growth factors and extracellular matrix and provide an 
adequate environment for angiogenesis. Versican, a member of the extracellular 
matrix, has been shown to have a role in tumor progression. 
The aim of this study was to investigate versican expression, its association with 
tumor-infiltrating inflammatory cell subsets and with clinicopathological parameters 
in human cervical cancers. We have studied the expression of versican in 149 cervical 
cancers using immunohistochemistry and RNA-in	 situ hybridization. Versican was 
predominantly expressed in the stroma (myofibroblasts). Using quantitative real-
time PCR, V0 was found to be the most prominent isoform. High stromal versican 
expression was significantly associated with a low number of tumor-infiltrating 
T cells (P=0.018) and particularly a low number of CD8-positive T cells (cytotoxic 
T cells; P=0.002). Stromal versican expression was significantly higher in patients 
with an infiltration depth ≥15 mm (P=0.004) and patients with parametrial invasion 
(P=0.044). Stromal versican expression was not associated with survival. Our results 
suggest that versican expression in the stromal compartment of cervical cancers 
results in reduced numbers of intraepithelial CD8-positive T cells and enhanced local 
invasion.




Cervical carcinoma is the second most common cancer type in women world wide.1 It 
is caused by a persistent infection with high-risk human papillomavirus (HPV) types. 
Next to malignant epithelial cells, this tumor consists of inflammatory cells and stromal 
cells. Both inflammatory and stromal cells are important for tumor progression.2, 3 In 
cervical carcinoma there is a high amount of inflammatory infiltrate, and we have 
recently shown a correlation between a high number of intraepithelial regulatory T 
cells (Treg) and poor survival of cervical carcinoma patients.4 Stromal cells produce 
growth factors and extracellular matrix (ECM) components and provide an adequate 
environment for angiogenesis. One of these ECM components is versican, which is 
a member of the large aggregating chondroitin sulphate proteoglycan (CSPG) family 
that has been implicated in tumor progression.5 Versican is composed of a N-terminal 
globular G1 domain, a central glycosaminoglycan attachment region (GAG) and 
a C-terminal selectin-like G3 domain.6 Four isoforms are generated by alternative 
splicing: V0 containing both GAGα and GAGβ domains, V1 containing the GAGα 
domain, V2 containing the GAGβ domain, and V3 consisting only of the globular 
domains.7 Recently, a fourth isoform, V4, has been found in breast cancer.8 The 
different isoforms are implicated in different biological processes. The V0 isoform is 
highly expressed during embryonic development,9 whereas in adult human tissues the 
V1 isoform is most prevalent.10 V0 and V1 are also the predominant isoforms found in 
cancer tissue.11-14 Versican expression promotes tumor growth by destabilizing focal 
cell contacts, thus hampering cell adhesion and regulating angiogenesis.10, 15 Indeed, 
increased levels of versican have been reported in different tumor types such as 
adenocarcinomas,16-18 squamous cell carcinomas,19, 20 sarcomas,21 mesothelomas,22 
and malignant melanomas.23 In addition, versican expression has been associated 
with tumor progression and decreased survival in various tumor types.24-26 In cervical 
cancer, versican has been suggested to enhance tumor invasion and metastases 
formation.20
In this study, we have investigated the presence, isotype and location of versican 
in cervical carcinoma. We have determined the association between the presence 
of versican and the presence of different tumor-infiltrating inflammatory cell 
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subsets. In addition, we have investigated the association of versican with several 




A total of 149 patients treated with radical hysterectomy and bilateral pelvic lymph 
node dissection for uterine cervical cancer were included in this study. Patients 
did not receive preoperative radiotherapy or chemotherapy. Treatment occurred 
between 1985 and 1999. Tissues had been fixed routinely in 10% formalin and 
embedded in paraffin. All tissues were retrieved from the archives of the Department 
of Pathology, Leiden University Medical Center. Samples were used according to the 
guidelines of the ethical committee of the Leiden University Medical Center. Clinical 
parameters were stored in a prospective database (administered by the department 
of Gynecology) containing over 200 items per patient. The patient characteristics are 
shown in Table 1.
immunohistochemistry
Immunohistochemical analysis was performed on 4 μm paraffin sections, mounted 
on aminopropylethoxysilane-coated slides. Sections were deparaffinized, rehydrated 
and treated with 0.3% H
2O2 in methanol for 20 min to block endogenous peroxidase 
activity. Antigen retrieval was performed (0.01 M citrate, pH 6.0) and sections were 
rinsed in phosphate-buffered saline (PBS). Subsequently, sections were stained 
for versican (overnight) using a 1:200 dilution of anti-human versican monoclonal 
antibody (clone 2B1, IgG1; Seikagaku Corporation, Tokyo, Japan) in PBS containing 
1% bovine serum albumin (BSA). The slides were incubated with Powervision-Poly-
HRP-goat anti-mouse/rat/rabbit IgG (Immunogenic, Duiven, the Netherlands) and 
immune complexes were visualized with diaminobenzidine. CD68-positive cells, 
CD1a (Langerhans’ cells)-positive intraepithelial cells or DC-LAMP-positive stromal 
dendritic cells were visualized as described previously.27
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table 1. Clinicopathological patient characteristics
Clinicopathological variable Category N* (%) Association with high
versican expression (P)
FIGO IB1   59 (46) 0.831
IB2/IIA   69 (54)
Histology Squamous 111 (77) 0.391
Adeno/adenosquamous   34 (23)
Lymph node metastasis No   98 (66) 0.078
Yes   50 (34)
Largest tumor diameter <40 mm   67 (49) 0.465
>40 mm   70 (51)
Vasoinvasion No   56 (40) 0.205
Yes   84 (60)
Infiltration depth <15 mm   82 (58) 0.004
>15 mm   60 (42)
Parametrial invasion No 123 (83) 0.044
Yes   25 (17)
HPV type HPV 16/18 101 (81) 0.963
Other   23 (19)
Recurrent disease No   87 (60) 0.937
Yes   59 (40)
* N<149 because data were not reported in the patient’s chart.
Bold values indicate P<0.05.
fluorescent immunohistochemisty
A double staining was performed with smooth muscle actin (SMA; clone ASM-1, IgG2a, 
1:300; Oncogene Research Product, Boston, MA) and mouse monoclonal anti-human 
versican (clone 2B1, IgG1, 1:200; Seikagaku Corporation) or mouse monoclonal anti-
human cytokeratin (clone AE1/AE3, IgG1, 1:500; DAKO Netherlands bv, Heverlee, 
Belgium). Furthermore, a double staining with mouse monoclonal anti-human 
versican and mouse monoclonal anti-CD8 (clone 4B11, IgG2b, 1:400; Novocastra 
Laboratories, Newcastle upon Tyne, UK) was performed. Antigen retrieval with 0.01 
M citrate pH= 6.0 was performed by boiling the slides for 10 min in a microwave.
The primary antibodies were diluted in 2% PBS/BSA in one mixture. The slides were 
incubated overnight with this mixture (100 ml per sample). The next day, the slides 
were washed with PBS. The slides were then incubated for 1 h with the secondary 
antibodies [100 ml per sample; goat-anti-mouse IgG2a ALEXA 546 (red), 1:200; goat-
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anti-mouse IgG1 ALEXA 488 (green), 1:200, and goat-anti-mouse IgG2b ALEXA 647 
(blue), 1:200]. All ALEXA antibodies were obtained from Invitrogen (Invitrogen, Breda, 
The Netherlands). After this, the slides were washed with PBS and then mounted 
with MOWIOL (a high quality anti-fade medium used for immunofluorescence).
rnA-in situ hybridization
Primers were chosen on the basis of the versican mRNA sequence (Gen Bank 
accession number GI_28144902): 5’-CAAGCATCCTGTCTCACGAA-3’ (sense) and 
5’-TTGGTATGCAGATGGGTTCA-3’ (anti-sense). Probes were prepared and cervical 
carcinoma sections were stained for versican mRNA as previously described.28 In short: 
3 μm paraffin sections were pre-treated and hybridized with 100 ng/ml digoxigenin-
labeled mRNA probe diluted in hybridization mixture containing 0.3 M NaCl and 
0.03 M saline-sodium citrate (SSC). Hybridization was allowed for 16 h at 55°C in 
a humidified chamber. Slides were washed for 30 min in 50% formamide/2x SSC at 
42°C, followed by 45 min in 0.1 x SSC with 20 mM β-mercaptoethanol at 50°C and for 
30 min with 2 U/ml ribonuclease T1 (Roche Diagnostics, Mannheim, Germany) in 2x 
SSC, 1 mM EDTA at 37°C. RNA hybrids were detected using subsequently mouse anti-
digoxigenin (1:2000; Sigma-Aldrich Chemie, Steinham, Germany), rabbit anti-mouse 
immunoglobulin (1:50; DAKO, Glostrup, Denmark) and mouse alkaline phosphatase 
anti-alkaline phosphatase (DAKO). A cervical cancer sample stained for TGF-β1 mRNA 
served as a positive control. 
evaluation of immunohistochemical staining and mrnA-in situ hybridization
Versican expression was scored as described by Ruiter et al.29 Intensity was scored 
as none (0), mild (1), moderate (2) or intense (3) at low magnification (x100). 
Furthermore, the percentage of positive tumor cells was determined and divided 
into groups: 0% (0, absent), 1% to 5% (1, sporadic), 6% to 25% (2, local), 26% to 50% 
(3, occasional), 51% to 75% (4, majority) and 76% to 100% (5, large majority). The two 
parameters were combined, representing the sum of both the percentage and the 
staining intensity of the positive cells, which resulted in an overall score (0 or 2-8). The 
scores were combined into two groups: category 0 (score 0-5, low expression) and 
category 1 (score 6-8, high expression). Expression was scored by two independent 
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researchers without knowing the identity and clinical outcome of patients. The data 
on T-cell infiltration in this patient series were previously published.4
Quantitative real-time Pcr
In all 2 mg of total RNA was transcribed to cDNA with Superscript II reverse 
transcriptase (Life Technologies, Grand Island, NY). Amplification reactions were 
performed with qPCR Core kit for SYBR Green (Eurogentec, Hampshire, UK) according 
to manufacturer’s protocol. Fluorescent PCR analysis was performed using the BIO-
RAD iCycler (BIO-RAD, Hercules, CA). The following PCR conditions were used: 10 
min at 95˚C, followed by 45 cycles of 15 seconds at 95˚C and 1 min at the appropriate 
annealing temperature. The household gene EEF1A1 was used for normalization 
of the expression data.30 Primers were designed according to Zhao et al.31 Relative 
quantification was performed using standard curves, followed by adjustment with 
the normalization factor, which was calculated using the Genorm program. The 
primer sequences are listed in Table 2.
table 2. Primer sequences for qRT PCR
Gene Sequence Size (bp)
EEF1A1 Forward: 5’- CTGGCAAGGTCACCAAGTCT-3’ 99
Reverse: 5’- CCGTTCTTCCACCACTGATT-3’
Versican	V0 Forward: 5’-CCAGCAAGCACAAAATTTCA-3’ 162
Reverse: 5’-TGCACTGGATCTGTTTCTTCA-3’
Versican	V1 Forward: 5’-CCCAGTGTGGAGGTGGTCTAC-3’ 124
Reverse: 5’-CGCTCAAATCACTCATTCGACGTT-3’
Versican	V2 Forward: 5’-TCAGAGAAAATAAGACAGGACCTGATC-3’ 135
Reverse: 5’-CATACGTAGGAAGTTTCAGTAGGATAACA-3’
Versican	V3 Forward: 5’-CCCTCCCCCTGATAGCAGAT-3’ 71
Reverse: 5’-GGCACGGGGTTCATTTTGC-3’
bp indicates base pair
statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL). Data were 
processed using a chi-square test, Student’s t-test, the Mann-Whitney U-test or 
the Fisher’s exact test, depending on the number and distribution of the compared 




versican is predominantly expressed in the stroma 
First, we investigated the presence and location of versican in 149 cervical cancer 
specimens using immunohistochemistry. Versican expression was predominantly 
observed in the stroma (Figure 1a-d). The expression of versican showed a 
heterogeneous staining pattern and was more pronounced at the invasive border 
in 127 out of 142 cervical cancer specimens. In 62 out of 149 specimens, versican 
expression was also found in the cervical carcinoma cells (Figure 1d, arrow). Tumors 
without versican expression were not observed. To quantify the versican expression, 
the scoring system of Ruiter et al was used.29 Weak immunoreactivity (score 2-5) 
was observed in 93 cases, and strong immunoreactivity (score 6-8) was observed in 
56 cases. As a control, the versican expression was determined in normal cervical 
tissue (Figure 1e). In this case, moderate expression of versican was found in the 
subepithelial tissue. As strong expression was found at the stromal-epithelial border, 
we determined whether tumor cell or (myo)fibroblast were associated with versican 
expression (Figure 2). For this purpose, immunofluorescent double staining with 
both anti-cytokeratin (tumor cells) and anti-SMA (myofibroblasts) and versican was 
performed. None of the tumor cells expressed in addition to keratin SMA (Figure 
2a). The majority of versican expression was associated with myofibroblasts and 
only a few versican-positive tumor cells were identified (Figure 2b). Strong versican 
expression was observed around blood vessels in the tumor stroma. 
To determine whether the tumor or the stromal cells in cervical carcinomas produce 
versican, RNA-in	situ hybridization was performed using placental tissue as a positive 
control. Placental tissue, strongly positive according to the qRT-PCR results, showed a 
weak staining at the tip of the villi. Only a weak expression of versican was detected 
in the cervical cancer tissue. The expression of versican in cervical cancer tissue was 
predominantly present in the stromal compartment (Figure 1f).
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figure 1. The expression and location of versican. 
The expression and location of versican was determined using immunohistochemistry as well as RNA-in 
situ hybridization as described in Materials and methods (x250 magnification). (a) Cervical tumor, weak 
versican staining; (b) Cervical tumor, moderate stromal versican staining; (c) Cervical tumor, strong stromal 
versican staining; and (d) Cervical tumor, strong stromal versican staining (x400 magnification). The arrow 
indicates a positive tumor cell. (e) Subepithelial versican staining in normal cervical tissue and (f) RNA-in 
situ hybridization cervical tumor with weak cytoplasmic staining of stromal cell clusters (magnification, 
x400). Arrows indicate positive stromal cells. See	page	198	for	color	figure.
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figure 2. The expression and location of versican by stromal cells and tumor cells. 
The expression and location of versican and smooth muscle actin (SMA) was determined using fluorescent 
immunohistochemistry as described in Materials and methods (magnification, x250). (a) Cervical tumor, 
strong stromal versican staining (green) and strong stromal SMA staining (red); the arrow indicates positive 
tumor cells, colocalization of versican and SMA in stromal cells (yellow). (b) Cervical tumor, strong stromal 
versican staining (green) and strong SMA staining of vessels (red). E, epithelial tumor cells; S, stroma; V, 
Vessel. See	page	199	for	color	figure.
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the v0 isoform is preferentially expressed in cervical cancer 
Because versican can be expressed in different isoforms (V0, V1, V2 and V3), their 
expression was measured using qRT-PCR in 8 cervical cancer cell lines and 20 cervical 
carcinoma samples. Normal lung and placenta tissue served as a positive control. 
The expression level of each isoform was normalized to the household gene EEF1A1. 
From the cell lines investigated, CC10B expressed V0, V1 and V2, CSCC 7 expressed V1 
and HeLa expressed V3. CaSki, CSCC1, CC8, CC11 and SiHa, did not express versican. 
To verify the mRNA expression pattern, versican protein expression was determined 
on cytospin preparations from CC10B and Caski. As expected, only CC10B showed 
prominent versican expression (data not shown). Previously, we have performed a 
cDNA microarray analysis on 32 tumor specimens.32 All the cervical cancer samples 
examined in that study expressed versican (data not shown). In the present study, 
we have investigated the versican isoforms expressed in 20 tumor samples. V0 was 
found to be the most prominent isoform (Figure 3). 
figure 3. The expression of versican isoforms in cervical cancer. 
Isoform expression was measured with qRT-PCR in 20 cervical specimens as described in Materials and 
methods. Versican expression was normalized against a household gene (EEF1A1). 
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High versican expression is associated with a decreased number of intraepithelial 
cd8-positive t-cells
As the composition of the ECM influences the migration of inflammatory cells,33 
we have also measured the association between inflammatory cells and versican 
expression. A statistically significant association was observed for tumors with a 
minor/moderate number of infiltrating inflammatory cells and tumors showing 
high versican expression (P=0.009; Table 3). Subsequently, we investigated whether 
this could be attributed to a particular chronic inflammatory cell subpopulation. 
Cell numbers were counted both in the stromal compartment and intraepithelial 
compartments. No statistically significant association was observed for tumors with 
a low (based on the median) number of tumor-associated macrophages (CD68-
positive cells, both stromal and intraepithelial), Langerhans’ cells (CD1a-positive 
cells; intraepithelial) or dendritic cells (DC-LAMP-positive cells; stromal) or natural 
killer (NK) cells and high versican expression. A statistically significant association 
between tumors with a low total number of intraepithelial CD3-positive T cells 
(P=0.018) and tumors with high versican expression was observed. No statistically 
significant association was observed for tumors with a low number of CD4-positive 
T cells, a low number of Treg cells or a low number of natural killer T (NKT)1 cells 
and tumors with high vesican expression. However, a strengthened statistically 
significant association between tumors with a low number of intraepithelial CD8-T 
cells (P=0.002) and tumors with high versican expression was observed. Using two-
color confocal microscopy we could confirm this relationship (Figure 4). Indeed, 
tumors with a high versican expression showed a lower number of intraepithelial 
CD8-positive T cells (Figure 5, P< 0.018, Student’s t-test)
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figure 4. The expression of versican and location of CD8-positive T cells. 
The expression of versican (green) and location of CD8-positive T cells was determined using fluorescent 
immunohistochemistry as described in Materials and methods (magnification, x250). The tumor is 
visualized as a phase-contrast Nomarski image (grey). (a) Cervical tumor, weak versican staining in the 
peripheral stromal area (green) was associated with a high number of intraepithelial CD8-positive T cells 
(blue); (b) Cervical tumor, strong versican staining in the peripheral stromal area (green) was associated 




table 3. Association between inflammatory cell subpopulations and versican expression




Minor/moderate infiltration IE†+stroma 101 NA* 0.009
Tumor-associated macrophages stroma 33 156 1.000
Tumor-associated macrophages IE 33 57 0.695
Dendritic cells stroma 33 1 0.418
Langerhans’cells IE 33 33 0.238
NK cells IE 74 0 0.918
T cells (low numbers) IE+stroma 74 180 0.018
CD4-positive T cells IE 74 36 0.573
Regulatory T cells stroma 70 24 0.508
Regulatory T cells IE 70 4 0.060
NKT1 cells IE 74 25 0.058
CD8-positive T cells 
(low numbers)
IE 74 94 0.002
* NA: not applicable.
† IE: intraepithelial. 
Bold values indicate P<0.05.
figure 5. Association between versican expression and intraepithelial CD8-positive T cells. Versican 
and CD8 expression were determined using (fluorescent) immunohistochemistry as described in the 
Materials and methods. Immunohistochemical versican scores were combined into two groups: low 
versican expression (score 0-5), and high versican expression (score 6-8), as described in the Materials and 
methods. CD8-positive T cells were quantified as described in the Materials and methods and expressed 
as number per mm2.
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versican expression is correlated with infiltration depth 
As an association was found between high numbers of CD8-positive T cells and 
limited expression of versican, we determined whether this was also reflected in 
an association with clinical parameters. We have associated high or low versican 
expression with FIGO stage, lymph node metastasis, tumor size, infiltration depth, 
vascular space involvement, parametrial invasion, HPV status and histology (Table 
1). Tumors with high versican expression were significantly associated with an 
infiltration depth ≥15 mm (P=0.004) and parametrial invasion (P=0.044). However, no 
statistically significant association between patients with tumors with high versican 
expression and patient survival was observed.
discussion
In the present study, we have investigated the expression of versican in cervical 
cancer and have correlated its expression with the presence of inflammatory 
cells and clinicopathological parameters. As observed by Kodama et al, versican is 
predominantly expressed in the stromal compartment, although occasionally tumor 
cells are also positive.20 As previously shown for breast tumors, in cervical tumors 
also intense versican staining was observed in the peripheral area of the tumors.34 
Using immunofluorescent double staining, we have shown that versican expression 
was associated with myofibroblasts. We have demonstrated that the predominant 
versican isotype in cervical cancer is V0. Previously, V0 and V1 were reported to 
be the predominant isoforms in other epithelial cancer types such as breast and 
prostate cancer.8, 11-14 The V1 isoform has been shown to enhance cell proliferation 
and to protect fibroblasts from apoptosis.35 Increased levels of versican have been 
found in brain tumors, cervical carcinomas, melanomas, breast cancer, prostate 
cancer, colorectal cancer, lung cancer, pancreatic cancer, endometrial cancer, oral 
cancer and ovarian cancer.12, 13, 16-18, 20, 23, 34, 36-39 
As the composition of the ECM influences the migration of inflammatory cells,33 
we have also measured the association between inflammatory cells and versican 
expression. Despite the reported production of versican isoforms V0 and V1 by 
human leukemic monocytes40 and the reported increased synthesis of versican by 
Chapter 7
150
hypoxic macrophages, no significant statistical association was observed for stromal 
or intraepithelial CD68-positive cells in our study. Recently, in a rat experimental 
model, fragments of versican were shown to activate toll-like receptor (TLR)2-
positive macrophages.41 We could demonstrate TLR2-positive macrophages in 
both the stroma and the epithelial compartment (data not shown). However, no 
statistically significant association between versican expression and the presence of 
TLR2-positive macrophages was observed. In addition, we did not find an association 
between TLR2-positive macrophages and TNF-α expression (data not shown). 
However, a statistically significant correlation between tumors with a low number of 
intraepithelial T cells and tumors with high versican expression was shown. Versican 
is known to bind several cytokines and chemokines, such as XCL1 (Lymphotactin), 
CCL5 (RANTES), CCL20 (LARC), and CCL21 (SLC), all of which are potent T cell 
chemoattractants.42 It is noteworthy that CCL5 expression has been associated with 
CD8-positive T-cell infiltration43 and that mouse 6Ckine (CCL21 in humans) when 
transfected into a colon carcinoma cell line has both antitumor activity mediated by 
CD8-positive T cells and angiostatic effects.44 This suggests that versican might act as a 
molecular sink, trapping CCL5 and CCL21, and offers an explanation for the reciprocal 
relationship between versican expression and the presence of CD8-positive T cells. 
We also have associated expression of versican with relevant clinical parameters 
such as lymph node metastasis, tumor size, infiltration depth and vascular space 
involvement. Although for breast, cervical, prostate, and other tumor types, increased 
versican expression has been associated with relapse and poor clinical outcome,12, 
16, 17, 19, 20, 36, 39, 45, 46 we could not demonstrate this association in our cervical cancer 
cohort. To exclude that this was related to the scoring system, we have also scored 
our data according to the method described by Kodama et al,20 (data not shown) 
but in this case also no statistically significant association was found. However, 
we did find a statistically significant association with an infiltration depth of ≥15 
mm (P=0.004). As there is a significant association between infiltration depth and 
survival, we stratified infiltration depth according to versican expression. The results 
show that (low or high) versican expression does not affect survival of cervical cancer 
patients with an infiltration depth of <15 mm, whereas in cervical cancer patients 
with infiltration depth of ≥15 mm, low versican expression predicts a poorer survival. 
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However, because of the limited number of cases (n=60), the survival difference 
between patients with a low versican or a high versican expression in this subgroup 
of cervical cancer patients was not significant (data not shown).
In the studies of Kodama et al,20, 45 the depth of stromal invasion (cervical cancer) 
and myometrial invasion (endometrial cancer) was also associated with versican 
expression, although in both studies only a trend (P=0.069 and P=0.052, respectively) 
was observed. However, experimental support for a role of versican in invasion was 
provided by functional studies demonstrating that versican is able to increase cancer 
cell motility47 and to reduce the attachment of cancer cells to fibronectin-coated 
surfaces.48
In conclusion, our results suggest that modulation of the ECM composition in the 
peripheral stromal area of cervical cancers influences the migration of cytotoxic T 
cells and enhances local invasion of the tumor cells.
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chapter 1 comprises a general introduction and the outline of this thesis. Cervical 
carcinoma is the third most frequent cancer type in women worldwide.1 In addition 
to the properties of cervical cancer cells, both inflammatory cells and stromal 
cells are important for tumor progression.2-4 Stromal cells produce growth factors 
and extracellular matrix and provide an adequate environment for angiogenesis.5-7 
Cervical carcinoma cells are able to influence this microenvironment by producing 
specific signaling molecules like cytokines, chemokines and proteinases.8 The net 
result of produced signaling molecules differs, depending on the tumor stage. 
Proinflammatory cytokines are important in modifying the activity, differentiation, 
and migration of antigen-presenting cells and may influence the survival of cancer 
patients.9, 10
In chapter 2, we determined whether CCL2 mRNA expression is beneficial or detrimental 
for cervical cancer patients. For this purpose the association between the expression 
of CCL2 by cervical tumor cells, the number of tumor-associated macrophages 
(TAM), and clinicopathological parameters such as recurrence, relapse-free survival, 
and overall patient survival was investigated. The CCL2 mRNA expression level was 
quantified in cervical cancer samples from 93 untreated cervical cancer patients, using 
RNA-in	situ	hybridization (RISH) and verified by using real-time quantitative RT-PCR. 
The number of TAM was determined using immunohistochemistry. Furthermore, we 
investigated whether lack of CCL2 expression was due to genetic alterations near the 
17q11.2 (CCL2 genomic) region. CCL2 mRNA expression by cervical tumor cells was 
associated with the number of TAM (P<0.001). Lack of CCL2 mRNA expression (15 
samples; 16%) was associated with increased cumulative relapse-free survival (log 
rank test, P=0.030), increased cumulative overall survival (log-rank test, P=0.024), 
reduced local and distant recurrence, reduced vascular invasion, and smaller tumor 
size (<40 mm). The absence of CCL2 mRNA expression corresponded with loss of 
heterozygosity (LOH) at 17q11.2 in five of six samples. The increased cumulative 
relapse-free survival and cumulative overall survival of cervical cancer patients lacking 
tumor cell-associated CCL2 mRNA suggest that the TAM support tumor progression, 
presumably by promoting angiogenesis and production of growth factors. 
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In chapter 3, we assessed whether GM-CSF, TNF-α, and IL-12, produced by cervical 
cancer cells, are important for the activity, differentiation and migration of antigen-
presenting cells. In 90 patients with cervical carcinoma the number of monocytes/
TAM, mature dendritic cells (DC), and Langerhans’ cells (LHC) was determined using 
immunohistochemistry. A RISH technique was used to measure the expression level 
of GM-CSF, TNF-α, IL-12p35, and IL-12p40. TAM were detected intraepithelial as 
well as in the stroma of the tumor. LHC were predominantly detected intraepithelial 
and mature DC predominantly in the tumor stroma. The number of TAM correlated 
positively with the number of mature DC. The expression levels of GM-CSF and TNF-α 
correlated positively with the number of TAM and DC. TNF-α showed a negative 
correlation with the number of LHC. A significant correlation between the expression 
of functional IL-12 (IL-12p40) and stromal TAM was found. The expression of GM-
CSF, TNF-α, and IL-12p40 did not correlate significantly with disease-free survival. 
However, high IL-12p40 expression was associated with a favorable cumulative 
overall survival. The results suggest that GM-CSF as well as TNF-α, produced by 
cervical carcinoma cells, may play a role in the differentiation of monocytes into 
mature DC. Furthermore, TNF-α may influence the migration of LHC from the tumor. 
Since IL-12p40 is both a subcomponent of IL-12 (composed of IL-12p40 and IL-12p35) 
and IL-23 (composed of IL-12p40 and IL-23p19),11 in chapter 4 we elucidated the role 
of IL-12p40 in cervical cancer. For this purpose we measured the expression of IL-
23p19 mRNA in 90 cervical cancer specimens using RISH and compared its expression 
with IL-12p40 and IL-12p35 expression. Since IL-23 is a component of the IL-17 
pathway,12 we also studied IL-1 and IL-6 expression using immunohistochemistry since 
both cytokines are known for their induction of the IL-17/IL-23 pathway. IL-12p40 
expression was significantly associated with poor disease-specific survival (P=0.017). 
Also a high number of stromal IL-6 producing cells was shown to associate with poor 
disease-specific survival (P<0.001). However, the worst prognosis was associated 
with a subgroup of patients that displayed a high number of stromal IL-6 expressing 
cells and low IL-12p40 expression (P<0.001). Furthermore, both a high number 
of stromal IL-6 expressing cells and a high number of stromal IL-6, plus IL-12p40 
expression showed to be independent clinicopathological parameters compared 
to lymph node metastasis, parametrial involvement and Sedlis score (P=0.009 and 
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P=0.022, respectively). Our results with IL-6 and IL-12p40 are in accordance with the 
hypothesis that the IL-17/IL-23 pathway plays a suppressive role in cervical cancer.
In chapter 5, we investigated the role of endoglin (CD105), a regulator of TGF-β 
signaling on endothelial cells13, bFGF and VEGF-A. We measured the number 
and determined the location of both newly formed (CD105-positive) and overall 
number of (CD31-positive) blood vessels, and bFGF and VEGF-A production 
using immunohistochemistry in 30 cervical carcinoma specimens. VEGF-A mRNA 
expression was determined using RISH. CD105- and CD31-positive vessels and bFGF- 
and VEGF-A-positive cells were predominantly present in the stroma. The presence 
of CD105- and CD31-positive vessels in the stroma did neither correlate with the 
number of VEGF-A-positive cells nor the number of bFGF-positive cells. However, 
the number of CD105- and CD31-positive vessels was associated with the expression 
of VEGF-A mRNA in the epithelial cell clusters (P=0.013 and P=0.005, respectively). 
The presence of CD105-positive and CD31-positive vessels was associated with the 
expression of αvβ6 (a TGF-β activator; P<0.013 and P=0.006, respectively). Clinically, 
the number of CD105- positive vessels associated with the number of lymph node 
metastasis (P=0.001). Furthermore, the presence of CD105-positive vessels within 
the epithelial cell clusters associated with poor disease-free survival (P=0.007).
In chapter 6, the expression of MMP-7 was investigated in different cancer types. 
Over-expression of matrilysin (MMP-7) is predominantly associated with epithelial 
(pre)malignant cells.14, 15 In addition to cancer cells, MMP-7 expression was found by 
immunohistochemistry in endothelial cells in various human cancer types. Endothelial 
MMP-7 was associated with CD34 and CD105 expression. The immunohistochemical 
data were confirmed by RT-PCR on VEGF-stimulated endothelial cells. Furthermore, 
MMP-7 was also identified in sprouting endothelial cells in vitro. The potential 
clinical relevance of endothelial MMP-7 was assessed for cervical cancer patients by 
evaluating the association with overall survival. In contrast to MMP-7 in malignant 
epithelial cells, MMP-7 expression in endothelial cells showed a significant association 
with poor survival (likelihood ratio 5.12, P=0.02, n=30). Our data suggest that MMP-
7 is involved in tumor angiogenesis, thereby contributing to malignant growth and 
thus associated with decreased survival.
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In chapter 7, we investigated versican expression, its association with tumor-
infiltrating inflammatory cell subsets and its association with clinicopathological 
parameters. Versican is a member of the extracellular matrix and has been put forward 
to play a role in tumor progression.16-18 We studied the expression of versican in 149 
cervical cancers using immunohistochemistry and RISH. Versican was predominantly 
expressed in the stroma (myofibroblasts). Using quantitative RT-PCR, V0 was found 
to be the most prominent isoform. High stromal versican expression was significantly 
associated with a low number of tumor-infiltrating T cells (P=0.018) and particularly 
a low number of CD8+ T cells (cytotoxic T cells, P=0.002). Stromal versican expression 
was significantly higher in patients with an infiltration depth ≥ 15 mm (P=0.004) and 
in patients with parametrial invasion (P=0.044). Stromal versican expression was not 
associated with survival. Our results suggest that versican expression in the stromal 
compartment of cervical cancers results in reduced numbers of intraepithelial CD8+ T 
cells and enhanced local invasion.
Growth and progression of cervical carcinoma is dependent on a complex interaction 
between cervical carcinoma cells and composition of the extracellular matrix.19, 20 
For local progression as well as metastasizing, the extracellular matrix needs to be 
rearranged creating space for tumor cells to expand and angiogenesis to secure 
supply of nutrients and oxygen and removal of waste products.21, 22 The net result 
of all contributing factors will lead to either progression or degradation of cervical 
cancer.23 In this thesis the role of contributing factors is investigated, e.g. cytokines, 
chemokines, inflammatory cells, the role of extracellular matrix and angiogenesis. 
future ProsPects
Cervical cancer remains a health problem worldwide. In Western countries numbers 
are (slowly) declining the past decades24 but in developing countries it still is often 
the most occurring malignancy among women.25 Screening for cervical cancer is a 
very powerful tool to detect (pre)cancerous lesions and is a relatively cheap and easy 
technique to perform. Besides the risk for false-negative results,26 there is also a risk 
for false-positive results, leading to the chance of over-treatment,27 especially in the 
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group of women under 25 years of age.28 Treatment of precancerous lesions and 
early stage cervical carcinoma gives excellent results but availability, accessibility and 
follow-up are not everywhere guaranteed.29 Since the majority of patients suffering 
from cervical cancer are not participating in cervical cancer screening,30-32 other 
methods are developed for early detection and/or prevention of developing cervical 
cancer. Self-collected vaginal specimens and visual inspection with acetic acid (VIA) 
on an outpatient base (“see and treat”) with immediate treatment of suspicious 
lesions or HPV detection in cervical swabs are investigated as alternatives.33-37 Still, 
for being an effective diagnostic tool, there must be a high coverage of screening 
(>80%), reproducibility and test properties must be sufficient and an effective 
treatment must be provided. HPV detection (self-collected or collected by a clinician) 
appears very promising38 with sensitivity and specificity equal to or better than the 
classical Pap smears.39
However, these screening programs are all part of secondary prevention 
measurements. The costs of primary prevention by educating the population (the use 
of condoms, stop smoking) can be high and the effect can be difficult to measure.40, 41 
Since the development of vaccines to prevent infection with cancer-associated high-
risk HPV type 16 and 18,42 there is an alternative which most likely will lead to a 
reduction of cervical cancer and also other malignancies caused by HPV like vulvar, 
vaginal and anal cancer.43, 44 Vaccination against HPV16/18 may be the first method 
to prevent a virally caused cancer. Especially when vaccines are developed which 
will target more high-risk HPV types, prevalence of HPV-associated malignancies will 
decline.45 
Unfortunately, once sero-conversion has occurred and/or (pre)malignant cervical 
lesions have developed, prevention by prophylactic vaccination is not an option. After 
infection of the cervical epithelium with HPV, there is a limited opportunity for antigen 
presenting cells and Langerhans’ cells within the epithelium to present antigens to 
the immune system since the viral particles do not cause lysis of the keratinocytes.46 
Without viremia, the chances for the systemic immune system to detect viral antigens 
leading to an adequate immune response are not optimal. Antibody responses to the 
capsid generally are weak and approximately half of the persons with a persistent 
high-risk HPV infection mount a measurable immune response.42 To overcome these 
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problems, therapeutic vaccination is under investigation, using synthetic long peptide 
vaccines (SLP).47 This immunotherapy is dependent on a cell-mediated immunity, 
needing antigen-presenting cells to present HPV antigens to T lymphocytes leading 
to a T-cell mediated immune response.48 In patients with premalignant vulvar lesions 
induced by high-risk HPV, encouraging therapeutic results have been reported.49-51 
Also the use of modified dendritic cells as a vaccine is currently under investigation, 
for instance by activating them by double stranded RNA, resulting in increased 
antigen presentation and T cell stimulatory capacity.52-54
The effect of immunotherapy is not only dependent on antigen-presenting cells and 
T-cells, but also on the microenvironment surrounding these inflammatory cells 
(stromal cells as well as tumor cells).55 Cytokines, chemokines and other components 
of this microenvironment like proteases are of great importance in activating 
antitumor immunity by, for instance, chemoattraction of antigen-presenting cells 
(CCL2),56 activation of CD8+ T lymphocytes (IL-17)57 and differentiation of monocytes 
into mature dendritic cells (GM-CSF and TNF-α).58, 59 For an optimal therapeutic 
vaccination in the future, a combination of a vaccine directed against multiple high-
risk HPV types with adjuvant treatment boosting the local immune response may lead 
to a better outcome. Currently biological therapies are developed and investigated 
in the treatment against cervical cancer. Examples are Tocilizumab (RoActemra®), a 
humanized anti-IL-6 receptor antibody that could be of importance by inhibiting an 
IL-6 induced angiogenic switch.60 Bevacizumab (Avastin®), a recombinant humanized 
anti-VEGF monoclonal antibody acting as an angiogenesis inhibitor. Bevacizumab 
is already used in phase II trials with limited activity in patients suffering from 
persistent or recurrent cervical carcinoma. Also Mapatumumab (HGS-ETR1), a human 
monoclonal antibody targeting the TNF-related apoptosis-inducing ligand-receptor 
1 (TRAIL-R1), is currently investigated in a phase IB/II-study. Both Bevacizumab as 
Mapatumumab are used as an adjuvant therapy in combination with chemotherapy 
or radiotherapy and chemotherapy respectively, in advanced cervical carcinoma. 
From these reagents a synergistic effect is anticipated.61-63 
Taking into account the differences in presence and amount of signaling molecules 
(cytokines and chemokines) as well as number and location of inflammatory cells, 
one can conclude that the host response elicited by neoplasms is complex and more 
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research is essential to find the best treatment. In the near future cervical carcinoma 
may become an even more rare disease due to a widely implemented prophylactic 
vaccination program, hopefully also available and affordable in developing 
countries. Furthermore, in these cases that cervical carcinoma does occur, maybe 
a personalized treatment can be offered by analyzing the primary tumor and tumor 
stroma characteristics in a biopsy of the tumor, leading to a specific (adjuvant) 
therapy in addition to surgery and/or radiotherapy whether or not in combination 
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In Hoofdstuk 1 wordt een algemene introductie gegeven over het voorkomen van 
baarmoederhalskanker in Nederland en wereldwijd. Vooral in Afrika, Azië en Zuid 
Amerika worden hoge incidenties gevonden. Uit epidemiologisch onderzoek en 
klinische data blijkt dat de ontwikkeling van baarmoederhalskanker een multifactorieel 
proces is waarin “high-risk” humaan papilloma virus (HPV) een centrale rol speelt. 
Waarschijnlijk wordt 75-80% van alle seksueel actieve mensen ooit met HPV besmet. 
Geschat wordt dat 90% van deze personen het HPV weet te elimineren, waarbij 
factoren als roken en het gebruik van immuunsuppressiva van groot belang lijken te 
zijn. Zodra het HPV zich heeft ingebouwd in het menselijk DNA treedt er expressie 
op van vroege HPV oncogenen E5, E6 en E7, welke verantwoordelijk zijn voor de 
ontwikkeling van pre-maligne voorstadia en uiteindelijk baarmoederhalskanker. 
Zodra baarmoederhalskanker is vastgesteld, is het afhankelijk van het FIGO stadium 
en het wel of niet aanwezig zijn van vergrote lymfklieren, waaruit de behandeling 
kan bestaan. In het algemeen worden lagere stadia behandeld met chirurgie en de 
hogere stadia met radiotherapie, eventueel in combinatie met chemotherapie of 
hyperthermie. Baarmoederhalskanker cellen zijn, evenals stromacellen en cellen 
behorend tot het immuunsysteem, in staat tot de aanmaak en verspreiding van 
cytokines. Dit zijn kleine signaalmoleculen welke in lage concentraties geproduceerd 
worden. Zij worden onderverdeeld in subcategorieën analoog aan de positie 
op het humaan DNA en het effect is vaak lokaal, maar kan ook op afstand zijn. 
Specifieke cytokines, onderzocht in dit proefschrift, worden beschreven waarbij 
vooral aandacht wordt besteed aan de ontsteking bevorderende cytokines. 
Baarmoederhalskanker cellen worden vaak omgeven door een ontstekingsinfiltraat, 
bestaande uit voornamelijk lymfocyten, macrofagen, dendritische cellen (DC) en in 
mindere mate natural killer (NK) cellen. De interactie tussen het ontstekingsinfiltraat, 
het tumorstroma bestaande uit onder meer fibroblasten en bloed- en lymfevaten, en 
de tumorcellen (het tumor micromilieu) bepaalt of dit leidt tot antitumor activiteit of 
juist tot tumor progressie. 
Chemokines zijn een specifiek soort cytokine die geproduceerd worden door 
verschillende celtypen, waardoor in het bijzonder ontstekingscellen zoals 
monocyten, welke in het weefsel differentiëren tot macrofagen, worden 
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aangetrokken. In Hoofdstuk 2 wordt de relatie tussen de mate van CCL2, ook wel 
monocyte chemotactic protein (MCP)-1 genoemd, expressie in de tumorcellen en 
de aanwezigheid van tumor-geassocieerde macrofagen (TAM) onderzocht. Er is, 
mede door gebrek aan een goedwerkend antilichaam op paraffine coupes, gekozen 
voor het ontwikkelen van een mRNA-probe dat niet de hoeveelheid CCL2 als eiwit, 
maar de hoeveelheid CCL2 als mRNA aangeeft met behulp van een mRNA-in	 situ 
hybridisatie (RISH) methode. De gebruikte scoringsmethode, waarbij de intensiteit 
van de aankleuring en het percentage positieve tumorcellen wordt opgeteld, werd 
gevalideerd met behulp van een real-time quantitative polymerase chain reaction 
(qRT-PCR). De expressie niveaus (geen, lage en hoge expressie) berekend met deze 
scoringsmethode correleerden goed met de uitslagen van de qRT-PCR. Toename van 
expressie van CCL2 correleerde zeer sterk met een toename van het aantal TAM. 
Ook klinisch/pathologische parameters werden vergeleken met het expressie niveau 
van CCL2 waarbij er vooral een correlatie aanwezig was tussen CCL2 expressie en 
(ziektevrije) overleving. Patiënten die geen CCL2 tot expressie brachten bleken 
een betere overleving te hebben. Door middel van “loss of heterozygosity” (LOH) 
onderzoek van het gebied waarin het gen, verantwoordelijk voor de expressie van 
CCL2, is gelegen (chromosoom 17), werd duidelijk dat bij 5 van de 6 patiënten waar 
CCL2 in de coupes niet aantoonbaar was, er sprake was van verlies van (een deel) van 
dit gebied van chromosoom 17.
Behalve CCL2 zijn ook andere cytokines van invloed op de samenstelling van het 
ontstekingsinfiltraat dat vaak in het tumorstroma van baarmoederhalskanker 
aanwezig is. In Hoofdstuk 3 werd daarom de rol van een aantal relevante ontsteking 
bevorderende cytokines in baarmoederhalskanker onderzocht, te weten granulocyte-
monocyte colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-α en 
interleukine (IL)-12 waarbij ook in deze studie gebruik werd gemaakt van de RISH. 
Deze cytokines spelen een belangrijke rol in het activeren, differentiëren en migreren 
van antigeen-presenterende cellen (APC). Ook deze cytokines werden tot expressie 
gebracht door baarmoederhalskanker cellen en de mRNA expressie niveaus werden 
vergeleken met aan- dan wel afwezigheid en/of aantal APC in de tumor. APC is 




afweersysteem, waarbij fragmenten van micro-organismen of antigenen worden 
opgenomen en ter plaatse of in een lymfklier gepresenteerd worden aan helper 
T-cellen voor een effectieve immuunrespons. De APC fungeren als boodschappers 
tussen de natuurlijke en verworven immuniteit. In deze studie werd gekeken naar 
TAM, cellen van Langerhans (LHC) en volwassen dendritische cellen (DC). TAM 
kwamen zowel intra-epitheliaal als in het tumorstroma voor terwijl LHC in het 
bijzonder intra-epitheliaal en DC nagenoeg uitsluitend in het tumorstroma werden 
aangetoond. Er bleek een positieve correlatie te bestaan tussen de hoeveelheid 
TAM en de hoeveelheid DC. Beide soorten APC waren ook positief gecorreleerd met 
GM-CSF en TNF-α. IL-12 was positief gecorreleerd met het aantal TAM en TNF-α 
was juist negatief gecorreleerd met het aantal LHC. Een hoge expressie of juist 
afwezigheid van de functionele subunit van IL-12 (IL-12p40) bleek geassocieerd met 
een betere overleving. Deze studie suggereert een rol voor zowel GM-CSF als TNF-α 
in het rekruteren en mogelijk ook differentiëren van monocyten naar macrofagen of 
volwassen DC of zelfs LHC. De negatieve correlatie tussen TNF-α en LHC wijst juist op 
een rol van de TNF-α in de migratie van de LHC naar de regionale lymfklieren voor 
antigeen presentatie.
In hoofdstuk 3 is aangetoond dat afwezigheid of juist hoge IL-12p40 mRNA expressie 
geassocieerd is met een verbeterde overleving in baarmoederhalskanker. In Hoofstuk 
4 werd de rol van IL-12p40 (als subcomponent van IL-12 en IL-23) en IL-6 nader 
onderzocht. IL-12 is in staat om leukocyten als CD8+ T lymfocyten en NK cellen te 
activeren wat kan leiden tot een antitumor respons. IL-23 speelt een belangrijke rol in 
de IL-17/IL-23 route, resulterend in de aanmaak van T helper (TH)17 lymfocyten welke 
IL-17 kunnen produceren. De rol van IL-17 bij het ontstaan en de groei van kanker lijkt 
een tweeslachtige: IL-17 is in staat tot zowel tumorprogressie als tumorregressie, 
waarbij het netto effect mogelijk afhankelijk is van meerdere factoren. Uit onze data 
kan worden afgeleid dat, bij een lage hoeveelheid IL-12p40 het biologische effect van 
IL-23 dominant is, terwijl bij een hoge hoeveelheid IL-12p40 het effect van IL-12 juist 
de overhand heeft. Dit resulteert in respectievelijk een minder goede en een betere 
overleving. Naast IL-23 lijken ook IL-1 en IL-6 een belangrijke rol te spelen bij het 
stimuleren van de IL-17/IL-23 route. In onze studie is er geen relatie tussen IL-1 en 
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ziektevrije overleving. IL-6 producerende cellen werden voornamelijk aangetoond in 
het tumorstroma. Indien de groep baarmoederhalskanker patiënten werd verdeeld 
in patiënten met een hoog aantal IL-6 producerende cellen en patiënten met een 
laag aantal IL-6 producerende cellen, bleken patiënten met een laag aantal IL-6 
producerende cellen een betere prognose te hebben vergeleken met de patiënten 
met een hoog aantal IL-6 producerende cellen. Indien de groep patiënten met een 
hoog aantal IL-6 producerende cellen in het tumorstroma verder werd onderverdeeld 
in een groep met expressie van IL-12 en een groep met expressie van IL-23, dan 
liet de combinatie van hoog aantal IL-6 producerende cellen in het tumorstroma in 
combinatie met een lage expressie van IL-12p40 een duidelijk slechtere ziektevrije 
overleving zien. De IL-17/IL-23 route lijkt, naar aanleiding van deze resultaten, een 
immunosuppressieve rol te vervullen binnen stadium IB-IIA baarmoederhalskanker. 
De samenstelling van het tumorstroma is van grote invloed op het biologisch gedrag 
van kanker. Behalve ontstekingsinfiltraat is ook een balans nodig tussen aanvoer 
van zuurstof en voedingsstoffen en afvoer van afvalstoffen. Tumorgroei en het 
ontwikkelen van uitzaaiingen (metastasering) heeft vaatnieuwvorming (angiogenese) 
nodig om deze balans veilig te stellen. In Hoofdstuk 5 wordt de rol van angiogenese 
onderzocht in baarmoederhalskanker. De prikkel voor angiogenese kan liggen in 
zuurstoftekort (hypoxie) in de centra van (grotere) tumorvelden, maar zou ook al 
in een vroeg stadium door de tumor opgestart kunnen worden door productie van 
pro-angiogenetische factoren. Als een tumor een grootte van 1 mm3 overschrijdt is 
diffusie van voedingsstoffen en afvalstoffen onvoldoende en is vaatnieuwvorming 
nodig voor verdere groei. Angiogenese is een proces waarbij veel factoren een rol 
spelen. In deze studie werden immuunhistochemische kleuringen verricht om het 
aantal nieuwgevormde bloedvaten (CD105 positief) ten opzichte van het totaal 
aantal aanwezige bloedvaten (CD31 positief) te bepalen, waarbij niet alleen werd 
gelet op het aantal bloedvaten, maar ook de positie van deze vaten in de tumor. 
Eén van de belangrijkste factoren voor vaatnieuwvorming is vascular endothelial 
growth factor-A (VEGF-A) waarvoor zowel een RISH als een immuunhistochemische 
eiwitkleuring werd verricht. Daarnaast werden andere factoren betrokken bij de 




activator inhibitor-1 (PAI-1), matrix metalloproteinase-2 (MMP-2) en transforming 
growth factor (TGF)-β1. Het aantal CD31- en CD105 positieve bloedvaten bleek 
onderling positief gecorreleerd: hoe groter het aantal bloedvaten in de tumor, 
hoe meer CD105 positieve bloedvaten aanwezig waren. Zowel bFGF- als VEGF-A- 
producerende cellen werden voornamelijk gevonden in het tumorstroma en 
indien tumoren VEGF-A produceerden was dit vooral aanwezig op de grens tussen 
tumorepitheel en tumorstroma, de plaats waar ook de bFGF producerende cellen 
voornamelijk te vinden waren. Er was geen correlatie tussen het aantal CD105 
positieve bloedvaten en aantal bFGF- of VEGF-A- producerende cellen. Er was wel 
een correlatie tussen het aantal CD105 positieve bloedvaten en de VEGF-A expressie 
door tumorcellen. Verrassend bleek dat de productie van VEGF-A eiwit niet overeen 
kwam met VEGF-A mRNA in onze kleuringen. TAM staan bekend om de productie 
van angiogenese bevorderende signaalmoleculen. Er bleek een positieve correlatie 
tussen het aantal TAM en het aantal CD105 positieve bloedvaten te zijn waarbij 
opgemerkt dient te worden dat dit het totaal aantal TAM in de tumor betreft, dus 
zowel degene tussen de epitheliale tumorcellen als degene in het tumorstroma. 
Het aantal TAM correleerde tevens met de intensiteit van aankleuring van het 
integrine ανβ6, een receptor betrokken bij proliferatie en migratie van tumorcellen 
en activatie van TGF-β. Zowel CD31- als CD105 positieve vaten bleken een positieve 
relatie te hebben met lymfkliermetastasen, waarbij CD105 positieve vaten in het 
tumorstroma ook positief gecorreleerd waren met het aantal metastasen bevattende 
lymfklieren. De aanwezigheid van het aantal CD105 positieve vaten ín de epitheliale 
tumorvelden bleek negatief gecorreleerd met ziektevrije overleving. In deze studie 
werd geconcludeerd dat CD105 gebruikt kan worden als een (slechte) prognostische 
factor waarbij de positie van deze vaten in de tumor van belang is.
De grens tussen tumorepitheel en tumorstroma lijkt van groot belang in de expansie 
van baarmoederhalskanker. Dit is het gebied waar VEGF-A werd aangetroffen en bFGF 
producerende cellen voornamelijk werden aangetoond. Het is ook het gebied waar 
ruimte gemaakt dient te worden voor groei en angiogenese waarvoor herstructurering 
van het tumorstroma nodig is. Hoofdstuk 6 handelt over de expressie van matrix 
metalloproteinase (MMP)-7 in baarmoederhalskanker. MMP zijn eiwit afbrekende 
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enzymen, betrokken bij afbraak en herstructurering van extracellulaire matrix en 
basaal membranen. MMP kunnen daardoor invloed hebben op tumorprogressie 
door ruimte te creëren voor expansie van tumorcellen en vaatnieuwvorming, 
leidend tot groei en mogelijkheid tot metastasering. Zuurstoftekort in tumorweefsel 
en aanwezigheid van VEGF zijn signalen die kunnen leiden tot productie van MMP-
7, een MMP dat de mate waarin cellen aan elkaar gehecht zijn (cel-cel contact) 
beïnvloed en effect heeft op het activeren van andere MMP en het vrijmaken/
splitsen van andere bioactieve moleculen. Productie van MMP-7 werd aangetoond 
in de bekledende cellen van bloedvaten (endotheel) in verschillende soorten kanker 
waaronder baarmoederhalskanker. Ook werd aangetoond dat het voorkomen van 
MMP-7 in de endotheelcellen overeenkomt met vaatnieuwvorming door middel van 
een CD105 kleuring. In vitro onderzoek bevestigde dit: remming van MMP-7 leidde 
tot remming van angiogenese en expressie van MMP-7 werd bevorderd door de 
toevoeging van VEGF. MMP-7 bleek in deze studie een slechte prognostische factor: 
hoge aanwezigheid van MMP-7 in endotheelcellen correleerde met een slechtere 
overleving. 
Behalve MMP-7 is ook versican in staat tot het destabiliseren van cel-cel contacten. 
Hierdoor is ook versican in staat invloed uit te oefenen op tumorprogressie en 
angiogenese. In Hoofdstuk 7 werd de aanwezigheid van versican en de relatie 
tussen aanwezigheid van versican en de aanwezigheid van verschillende typen 
ontstekingscellen onderzocht. Versican is een onderdeel van de extracellulaire matrix 
en behoort tot de familie van de proteoglycanen. Naast cel-cel contact en migratie 
van cellen speelt versican ook een rol bij de ontstekingsreactie door interactie met 
chemokines die een rol spelen bij het aantrekken van ontstekingscellen. In deze studie 
werd de aanwezigheid, type en locatie van versican in baarmoederhalskanker bepaald, 
als ook de relatie met de aanwezigheid van verschillende ontstekingsceltypen. Bij 
baarmoederhalskanker blijkt versican voornamelijk in het tumorstroma aanwezig te 
zijn, met name op de grens van tumorcellen en tumorstroma, en rondom bloedvaten. 
Versican bleek vooral geproduceerd te worden door myofibroblasten (spiercellen) 
in het tumorstroma. Van de verschillende vormen waarin versican voor kan komen 




gecorreleerd te zijn met een lager aantal intra-epitheliale CD8+ T lymfocyten. Dit 
effect is mogelijk het gevolg van het binden (en daarmee inactiveren) van cytokines 
die normaal T lymfocyten aantrekken. Verder heeft versican een positieve relatie 
met een grotere invasiediepte (≥15 mm) en een hogere kans op de aanwezigheid 
van tumorcellen in de parametria, mogelijk door enerzijds het bevorderen van de 
mobiliteit van baarmoederhalskanker cellen en anderzijds verlaging van de binding 
van deze cellen aan andere tumorcellen en omgevende tumorstroma cellen. Er werd 
geen relatie tussen expressie van versican en overleving gevonden. 
In Hoofdstuk 8 wordt nader ingegaan op de mogelijkheden van diagnostiek naar 
(pre)maligne afwijkingen van de baarmoederhals (het afnemen van uitstrijkjes, 
self-sampling) en de toekomst van behandeling of voorkomen van baarmoederhals 
afwijkingen, waarin vaccinatie een grote rol zal spelen en uiteindelijk een afname 
van zowel baarmoederhalskanker als ook vulva-, vagina- en anuskanker zou kunnen 
bewerkstelligen. Momenteel zijn er 2 preventieve HPV vaccins op de markt, te weten 
Gardasil® en Cervarix®. Vaccinatie wordt in Nederland sinds 2009 aangeboden aan 
meisjes en jonge vrouwen van 12 t/m 16 jaar waarbij primaire preventie wordt 
nagestreefd. Het in Nederland momenteel gebruikte vaccin Cervarix® is werkzaam 
tegen type HPV 16 en 18. Nadat een HPV-infectie heeft plaatsgevonden is primaire 
preventie (het voorkómen van een infectie) niet meer mogelijk. Om het virus effectief 
te bestrijden wordt momenteel veel onderzoek gedaan naar het ontwikkelen van een 
therapeutisch vaccin. Deze onderzoeken richten zich met name op versterking van de 
T-cel reactie tegen specifieke eiwitten welke in een geïnfecteerde cel aanwezig zijn. 
Ook zijn er momenteel diverse studies waarin het immuun modulerende effect van 
(onder andere) anti-VEGF en anti-IL6 wordt onderzocht. Wellicht dat de incidentie 
van, door HPV-geïnduceerde, kanker en voorstadia hiervan verder af zal nemen door 
preventieve vaccinatie. In geval van baarmoederhalskanker kan in de toekomst door 
analyse van een biopt van de tumor mogelijk een specifiek op die tumor gerichte 











ANOVA  analysis of variance
APAAP  alkaline phosphatase anti-alkaline phosphatase
APC  antigen presenting cells
bFGF  basic fibroblast growth factor
BSA  bovine serum albumin
CAF  cancer-associated stromal fibroblasts
Caspase  cysteine-dependent aspartate-directed proteases 
CCL  chemokine (C-C motif) ligand
CCR   chemokine (C-C motif) recepor
CD  cluster of differentiation
CIN   cervical intraepithelial neoplasia
CRI   cancer-related inflammation
CSF-1  colony stimulating factor-1
CSPG  chondroitin sulphate proteoglycan
CTGF  connective tissue growth factor
CXC  chemokine CXC motif
DC   dendritic cells
DCreg  regulatory DC
DFS  disease-free survival
DIG  digoxigenin
E  early
E6AP   E6 associated protein
ECM  extracellular matrix
FIGO  Fédération Internationale de Gynécologie et d’Obstétrique
G-CSF  granulocyte colony-stimulating factor
GM-CSF  granulocyte-macrophage colony-stimulating factor
h  hour(s)
HPF  high-power field of view
HPV   human papilloma virus 
HRP  horseradish peroxidase
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HSIL  high-grade squamous intraepithelial lesion
IFN  interferon
IL  interleukin 
IL-6R  IL-6 receptor
IL-23R   IL-23 receptor
JAK  Janus kinase
L  late
lDC   lymphoid DC 
LHC   Langerhans’ cells 
LLETZ  large loop excision of the transformation zone
LOH  loss of heterozygosity
LPS  lipopolysaccharide
LSIL  low-grade squamous intraepithelial lesion
M-CSF  macrophage colony-stimulating factor
MAb  monoclonal antibody
MAPK  mitogen-associated protein kinase
MCP-1  monocyte chemotactic protein-1
mDC  myeloid DC
MHC   major histocompatibility complex
MMP  matrix metalloproteinases
NFAT  nuclear factor of activated T-cells
NF-κB  nuclear factor-κB
NK   natural killer cells
on  overnight
OS  overall survival
PAI-1  plasminogen activator inhibitor-1
Pap  Papanicolaou
PBA  phosphate-buffered saline containing 1% bovine serum albumin
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
PDGF  platelet derived growth factor
PGE  prostaglandin E
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PI  propidium iodide
PI3K  phosphatidyl inositol-3’-kinase
pRb   retinoblastoma protein
RISH  RNA-in situ hybridization
RORγt  related orphan receptor γt
RT-PCR  real-time quantitative polymerase chain reaction
qRT-PCR  quantitative RT-PCR
SD  standard deviation
SLP  synthetic long peptide
SSC  saline-sodium citrate
STAT   signal transducer and activator of transcription\
STS  sequence tagged site
TAM  tumor-associated macrophages
TGF-β  transforming growth factor-β
T
H  T helper lymphocyte 
TIMP-2  tissue inhibitor of metalloproteinase-2
TNF-α  tumor necrosis factor-α 
TNFR  tumor necrosis factor receptor
TNM  cancer staging system: tumor size, regional lymph node, distant 
  metastasis
TRAF  TNFR-associated factor
TRAIL-R1 TNF-related apoptosis-inducing ligand-receptor 1
Treg  regulatory T cells
VEGF  vascular endothelial growth factor 
VEGFR  VEGF receptor 
VIA  visual inspection with acetic acid
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onder leiding van dr. F.M. van den Berg onderzoek werd verricht naar detectie van C. 
pylori in paraffine coupes met behulp van DNA-in	situ hybridisatie. Na het vervullen 
van de militaire dienstplicht werkte hij van 1990 tot 1999 als research analist bij de 
afdeling Cytochemie & Cytometrie van het Sylvius Laboratorium te Leiden, waar 
hij onderzoek deed naar het gebruik van kleine anorganische fosfordeeltjes als 
immunocytochemische marker, onder leiding van prof. dr. H.J. Tanke. In 1991 koos 
hij alsnog voor de studie geneeskunde waar hij datzelfde jaar werd ingeloot. Dit 
werd omgezet in een schaduwplaats aangezien nog natuurkunde en scheikunde op 
VWO-niveau gehaald dienden te worden. In 1992 werd met de studie geneeskunde 
gestart aan de Rijksuniversiteit Leiden. In 1995 verrichtte hij een klinische stage bij 
de afdeling Traumatología van Hospital Obrero te La Paz, Bolivia. De co-schappen 
werden afgesloten met een keuze co-schap Anaesthesiologie in het Leids Universitair 
Medisch Centrum. 
In 1999 behaalde hij zijn artsenbul en startte hij als AGNIO (assistent geneeskundige 
niet in opleiding) op de afdeling Gynaecologie en Verloskunde van het Eemland 
Ziekenhuis, locatie St. Elisabeth te Amersfoort, gevolgd door een AGNIO positie 
op de afdeling Gynaecologie en Verloskunde van het Westeinde Ziekenhuis te Den 
Haag. In 2001 begon hij als AGIKO (assistent geneeskundige in opleiding tot klinisch 
onderzoeker) met promotie onderzoek bij de afdelingen Gynaecologie en Pathologie 
van het Leids Universitair Medisch Centrum, uitgevoerd onder leiding van prof. dr. 
G.J. Fleuren, prof. dr. G.G. Kenter en dr. A. Gorter. In 2004 begon hij met de opleiding 
tot gynaecoloog in het Leids Universitair Medisch Centrum (opleiders prof. dr. H.H.H. 
Kanhai en prof. dr. G.G. Kenter) en het Medisch Centrum Haaglanden te Den Haag 
(opleider dr. P.J. Dörr) wat in augustus 2009 werd afgerond. Van september 2009 tot 
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en met november 2011 was hij fellow Gynaecologische Oncologie in het Universitair 
Medisch Centrum Groningen, onder leiding van prof. dr. A.G.J. van der Zee. Sinds 
december 2011 is hij werkzaam als gynaecologisch oncoloog in het Centrum voor 
Gynaecologische Oncologie Amsterdam (CGOA), locatie Nederlands Kanker Instituut 




Een proefschrift is het resultaat van samenwerking. Ik wil graag de mensen bedanken 
die hebben bijgedragen aan de totstandkoming van dit proefschrift. Allereerst alle 
coauteurs, betrokken bij de hoofdstukken. Dank voor jullie discussies, kritische 
kanttekeningen, opbeurende kritiek en vooral ook het vertrouwen. 
Iedereen op de afdeling Pathologie bedankt voor alle hulp met fotografie, blokjes 
verzamelen, coupes snijden, kleuren en mede beoordelen, FACS proeven en wegwijs 
maken in de in	situ hybridisatie techniek. In het bijzonder Christa, Enno, Hans, Klaas, 
Lambert, Natalja, Sandra en Wim. Uiteraard ook de kamergenoten van de Joenit op 
P1-40: Antoinette, Cees, Christine, Jan Willem, Jessica, Judith, Katja, Kyra, Maaike en 
Marjon: goed overleg en goede sfeer. 
Stafleden, A(N)IOS, verpleegkundigen en (poli)assistenten van de verschillende 
ziekenhuizen waar ik in deze periode werkzaam ben geweest: LUMC (met name 
de wekelijkse AGIKO lunches waren altijd nuttig maar vooral ook een humorvol 
klankbord), Medisch Centrum Haaglanden (met name Joep en Marjolein, dank voor 
jullie betrokkenheid en grote steun voor deze coassistent/ANIOS/AIOS/gynaecoloog) 
en het UMCG (Ate, Hans, Henriëtte en Marjan: dank voor een geweldige tijd in 
Groningen en de mogelijkheid om de wetenschappelijke draad weer op te pakken). 
Ook kamergenoten uit het UMCG (Ayten, Maaike, Marinka, Maureen, Moira en 
Nathalie): geweldig om een kamer met mede fellows te delen.
Hans Tanke, jij hebt eigenlijk aan de basis gestaan van mijn opleiding tot gynaecologisch 
oncoloog, al wisten we dat toen nog niet. Door mijn baan als research analist naar 
50% te verlagen en werkbesprekingen af te stemmen op mijn diensten schema als 
coassistent was het voor mij mogelijk om de studie Geneeskunde te volgen. En ook 
al noemde je het een ‘win-win’ situatie, heel veel dank hiervoor. De collega’s van 
Vakgroep Cytochemie & Cytometrie van het Sylvius Laboratorium, in het bijzonder 
Annemarie, Berna, Frans, Irma, Joop, Karien, Richard en Rob: bedankt voor een 
fantastische leerschool gecombineerd met veel plezier.
Ook familie en vrienden bedankt voor steun door de jaren heen. Door mijn chronische 
drukte is er nogal eens geschoven met afspraken, bezoekjes en bijeenkomsten. Dank 
voor jullie begrip. 
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Beste Merryn en Onno, dat jullie bereid zijn om mijn paranimfen te zijn is voor mij 
ongelofelijk waardevol. Onno: één terrasje in Eindhoven in 1990 heeft geleid tot de 
studie Geneeskunde, specialisatie tot gynaecologisch oncoloog en dit proefschrift. 
Het lijkt me een goed idee als je nu ook bij de afronding bent. Merryn, door afstand 
en tijd zien en spreken we elkaar minder dan ik zou willen. Toch is iedere keer dat we 
elkaar treffen als vanouds.
En tenslotte Jaklien: we kennen elkaar nu meer dan 20 jaar waarbij ieder jaar drukker 
lijkt te worden. Zeker de laatste jaren waren erg druk met schrijven, diensten en 
opleiding. Je hebt mij vaak de ruimte gegeven om dit alles te kunnen doen naast je 
eigen drukke baan en ons gezin. Dank voor alles. We gaan wederom een avontuur 






Figure 1. CCL2 (RISH) and CD68 (immunohistochemical) staining of cervical 
carcinoma. 
figure 1. CCL2 (RISH) and CD68 (immunohistochemical) staining for monocytes/macrophages in cervical 
carcinoma. Panels (a), (b) and (c) represent strong, weak and no expression of CCL2 mRNA respectively. 
(d) Sense probe for CCL2 (negative control). Monocytes/macrophages are indicated by arrows. Panels (e) 
and (f) represent positive and negative immunohistochemical staining of monocytes/macrophages (anti-
CD68), respectively; sections are counterstained with Mayer’s haematoxylin. (a-f) Scale bar = 100 μm.
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figure 1. Immunohistochemical and RISH staining of paraffin sections of cervical carcinoma are shown. 
Carcinoma cells are indicated by a T, whereas S represents tumor stroma. (a-c) Immunohistochemical 
staining of cervical carcinoma. (a) Staining for monocytes and macrophages (anti-CD68). Staining is 
present intraepithelial as well as in the tumor stroma. (b) Staining for mature dendritic cells [DC (anti-DC-
Lamp)] seen as nests in the tumor stroma. (c) Staining for Langerhans’ cells [LHC (anti-CD1a)]. Staining can 
be seen intraepithelial. Positive cells are clearly visible by a dark-brown precipitation. Sections (a-c) are 
counterstained with Mayer haematoxylin. (d-h) RNA-in	situ hybridization (RISH) for cytokines in the same 
cervical carcinoma sample as shown in (a-c). (d) Negative control. (e) GM-CSF shows a weak expression in 
both cervical carcinoma cells and in inflammatory cells in the tumor stroma. (f)	TNF-α is strongly expressed 
in cervical carcinoma cells as well as in some of the cells in the tumor stroma. (g) IL-12p35 is strongly 
expressed in the cervical carcinoma cells as well as in inflammatory cells in the tumor stroma. (h) IL-12p40 
shows a moderate expression in the tumor cells and a strong expression in some of the cells in the tumor 
stroma. Positive signal in RISH is seen as a (dark) blue precipitation. Sections (d-h) are not counterstained. 
Original magnification, x80. 
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figure 1 The expression of IL-23p19, IL-12p40 and IL-6. The expression of IL-23p19 and IL-12p40 were 
determined using RNA-in	 situ hybridization (RISH) and the expression of IL-6 was determined using 
immunohistochemistry as described in the Materials and methods section (magnification, x250). (A) 
Cervical tumor, IL-23p19 RISH. Tumor cells stain positive (moderate) for IL-23p19; (b) Negative (sense) 
control of IL-23p19 RISH; (c) Cervical tumor, IL-12p40 RISH. Tumor cells stain positive (strong) for IL-12p40; 
and (d) Negative (sense) control of IL-12p40 RISH. (e) IL-6 staining of cervical cancer tissue. Both cells in 
the epithelial compartment (EC) as well as cells in the stroma express IL-6. Arrows indicate positive stromal 
cells. Detail (x400, magnification) of IL-6 positive cells in the stroma; and (f) Association between cells in 
the epithelial compartment with low (IL-6 EC low) and high IL-6 (IL-6 EC high) expression and disease-
specific survival. No significant association between low or high IL-6 expression of the epithelial cells with 





figure 1. Expression and location of CD105- and CD31- positive vessels, bFGF, VEGF-A fibronectin, αvβ6, 
PAI-1 and CD68-positive cells. 
Expression and location of CD105- and CD31- positive vessels, bFGF and VEGF-A were determined using 
immunohistochemistry as well as RNA-in	situ hybridization (RISH) as described in Materials and methods 
section (magnification, x125). (A) CD105 vascular staining, (A1) Detail (magnification, x400) of vessels 
present in the tumor stroma as well as in the epithelial cell clusters. (b) CD31 vascular staining, (b1) detail 
(magnification, x400) of vessels present in the tumor stroma as well as in the epithelial cell clusters. (c) 
bFGF, positive staining of the border of the epithelial cell clusters and cells in the stromal compartment. 
(d) VEGF-A immunohistochemical staining with increased positive staining of the borders of the epithelial 
cell clusters, (d1) detail (magnification, x400) of VEGF-A positive stromal cells. (e) VEGF-A RISH with weak 
cytoplasmic staining of the epithelial cell clusters. (f) Negative (sense) control of VEGF-A RISH. Expression 
and location of fibronectin, αvβ6, PAI-1 and CD68-positive cells (magnification, x400). (G) fibronectin, 
positive staining (>75%) of the stromal compartment. (H) αvβ6, positive staining (strong intensity; of the 
border) of the epithelial cell clusters. (i) PAI-1, positive staining of the epithelial cell clusters. (J) Positive 
staining of CD68-positive cells in the stromal compartment and in the epithelial cell clusters. 
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figure 7 Role of TGF-β1 in cervical cancer. 
Cervical tumors are composed of malignant epithelial cells, tumor stroma, comprising the tumor 
vasculature extra cellular matrix and (myo)fibroblasts, and an inflammatory infiltrate. Latent TGF-β1 is 
produced amongst others by cervical cancer cells, secreted and stored in the extracellular matrix. TGF-β1 
can be activated by the epithelial cell specific integrin ανβ6 or by matrix metalloproteinases (MMP), 
especially active MMP-2 in complex with MMP-14 and TIMP-2 on the cell membrane of cervical cancer 
cells at the epithelial cell-stroma border. Active TGF-β1 induces VEGF in the epithelial cancer cells and 
differentiates fibroblasts into myofibroblasts. Depending on the local concentration, active TGF-β1, 
promotes endothelial proliferation and migration or promotes cytostasis and vessel maturation. Active 
TGF-β1 acts as an immunosuppressor by blocking the activity of the inflammatory cells and inducing 




figure 1. Immunohistochemical staining of endothelial cells for MMP-7, indicated by arrows in gastric 
cancer (A), colonic cancer (b), breast cancer (c), cervical cancer (d), prostate cancer (e), and in in vitro 
sprouting HUVEC cells (f). Inserts I and II indicate respectively CD34 and CD105 staining in sequential 
section from the same tissue. The inserts in (f) show VEGF-induced endothelial cell sprouting in control 
and Marimastat-treated HUVEC spheroids. Arrowheads indicate epithelial cell staining. Bars correspond 
with 100 μm in (A-e) and with 300 μm in (f). 
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figure 1. The expression and location of versican. 
The expression and location of versican was determined using immunohistochemistry as well as RNA-in 
situ hybridization as described in Materials and methods (x250 magnification). (a) Cervical tumor, weak 
versican staining; (b) Cervical tumor, moderate stromal versican staining; (c) Cervical tumor, strong stromal 
versican staining; and (d) Cervical tumor, strong stromal versican staining (x400 magnification). The arrow 
indicates a positive tumor cell. (e) Subepithelial versican staining in normal cervical tissue and (f) RNA-in 
situ hybridization cervical tumor with weak cytoplasmic staining of stromal cell clusters (magnification, 
x400). Arrows indicate positive stromal cells. 
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figure 2. The expression and location of versican by stromal cells and tumor cells. 
The expression and location of versican and smooth muscle actin (SMA) was determined using fluorescent 
immunohistochemistry as described in Materials and methods (magnification, x250). (a) Cervical tumor, 
strong stromal versican staining (green) and strong stromal SMA staining (red); the arrow indicates positive 
tumor cells, colocalization of versican and SMA in stromal cells (yellow). (b) Cervical tumor, strong stromal 




figure 4. The expression of versican and location of CD8-positive T cells. 
The expression of versican (green) and location of CD8-positive T cells was determined using fluorescent 
immunohistochemistry as described in Materials and methods (magnification, x250). The tumor is 
visualized as a phase-contrast Nomarski image (grey). (a) Cervical tumor, weak versican staining in the 
peripheral stromal area (green) was associated with a high number of intraepithelial CD8-positive T cells 
(blue); (b) Cervical tumor, strong versican staining in the peripheral stromal area (green) was associated 
with a low number of intraepithelial CD8-positive T cells (blue). E, epithelial tumor cells; S, stroma. 
